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ABSTRACT 
 Both enantiomers of highly enantioenriched chiral allenylsilanes were prepared in 
high yields through a scalable synthetic sequence, employing a modified copper-
mediated SN2’ reaction. These reagents were utilized in the asymmetric three-component 
propargylation reactions to produce enantioenriched homopropargylic ethers. The 
generated ethers were then subjected to titanium alkoxide-mediated reductive coupling 
with acetylenic esters to produce (E,E)-dienes bearing α,β,γ,δ-unsaturated esters. NFAT-
68, a natural product isolated from the broth and mycelia of two Streptomyces sp. 
Fermentations, displayed potent in vitro immunosuppressive activity with an IC50 
concentration <1 μg/ mL and no cytotoxicity observed at that concentration. The 
sequential use of the two methodologies facilitated the convergent synthesis of the both 
enantiomers of NFAT-68 in five steps and allowed a quick access to its analogues for 
future SAR studies. 
 Stereodefined, highly functionalized (E,E)-dienes are common structural moiety 
embedded in natural products and pharmaceutically important agents. A titanium 
alkoxide-based alkyne-alkyne reductive coupling mediated by in situ generated 
 
 viii 
arylamidate was developed. Complete regioselectivity was achieved in 39 (out of 40) 
examples, where (E,E)-dienes were formed exclusively in preference to other 
regioisomers. Mechanistic studies pointed to the directing effects of arylacetamide and –
carbamate. 
 Muramyl dipeptide (MDP) and its analogues exhibit potent anti-inflammatory 
effect. To aid the biochemical evaluation of the role of MDP in porphyromonas 
gingivalis (P.g.)-induced TNF-α production, a convergent and scalable solution-phase 
synthesis of diastereomerically and enantiomerically pure MDP analogues was 
developed. The developed method allowed fast production of MDP analogues in useful 
quantities that ultimately led to the discovery of one analogue that further improved MDP 
function and inhibition of P.g.-induced pro-inflammatory activities. 
 Periodontal disease caused by bacterial accumulations or dental plaque on the 
teeth is highly prevalent in the United States. Six kava analogues of the structural type 3-
oxocyclohex-1-en-1-yl benzoates (and benzamides) were synthesized and evaluated for 
their affect on periodontal deconstruction in collagen anti-body primed oral gavage 
model of periodontitis. The benzoates showed promise in the prevention and treatment of 
inflammation and alveolar bone loss associated with periodontitis.  
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 Organosilane reagents including crotyl-, allyl-, and allenylsilanes have been 
versatile carbon nucleophiles and played privileged role in natural product and diversity-
oriented synthesis.
1
 In that context, chiral allenylsilanes
2
 have proven to be useful carbon 







 with complete transfer of axial chirality to point chirality and moderate to 
high syn selectivity. A number of methods have been developed to access 
enantioenriched allenylsilanes. 
 Transition metal-mediated reductive coupling reactions have proven to be 
powerful, atom- and step-economical in carbon-carbon bond forming reactions, owing to 
their diverse reactivity and selectivity without alkyne/alkene prefunctionalization. In that 
context, titanium-mediated alkyne−alkyne reductive coupling is emerging as a useful 
method for the construction of stereodefined conjugated (E,E)-dienes embedded in 
natural products and pharmaceutically important agents. This methodology will be 
discussed in detail in chapter two. 
 Immunosuppressant drugs such as cyclosporine A and fujimycin target the 
inhibition of T-cell activation by preventing the activation of the nuclear factor of 
activated T-cells (NFAT-68) transcription factor. NFAT-68, a new polyketide natural 
product isolated from the broth and mycelia of two Streptomyces sp. fermentations, 
displayed potent in vitro immunosuppressive activity with an IC50 concentration <1 μg/ 




the first synthesis of both enantiomers of NFAT-68 utilizing a chelation-controlled 
vinylogous Mukaiyama aldol reaction originally developed by the Kobayashi group. 
 In this chapter, a brief review of the methods including ours for the preparation 
and application of enantioenriched allenylsilanes and subsequent total synthesis of 
NFAT-68 will be reviewed. 
1.2 Selected Recent Approaches for the Preparation of Chiral Allenylsilanes 
 
 This section provides brief survey of methods for the synthesis of chiral 
allenylsilanes from early 1980s to late 2015 chronologically. 
1.2.1 Copper-Mediated SN2’ Reaction of Propargylic Alcohol (Racemix Allene) 
 The early report by Westmijze and Vermeer in 1979
4 
and later extended by 
Danheiser in 1985
5
 described the synthesis of 1-substituted (trimethylsilyl) allenes D2 
and D3 (Scheme 1.2.1). Since then, the synthesis of allenylsilanes based on copper-
mediated SN2’ reaction has been the most widely used method. Treatment of the mesylate 
derivative (generated in situ) of 3-(trimethylsilyl)-2-propyn-l-ol D1 with 
methylmagnesium chloride, cuprous bromide, and lithium bromide in THF (-70 to 25 °C) 
produced 1-methyl- 1- (trimethylsilyl)allene D1 in 83% yield on a 25 gram scale. The 
preparation of the isopropyl derivative D3 was carried out in a similar fashion. 





1.2.2 CuCl-Catalyzed Synthesis of Allenylsilane 
 Marshall also reported
6
 an in situ preparation of chiral trichlorosilanes through 
CuCl-catalyzed addition of trichlorosilane to chiral propargylic mesylates (Scheme 
1.2.2). Treatment of mesylate M1 of (R)-3-butyn-2-ol with CuCl, HSiCl3, and Hunig’s 
base afforded in situ chiral allenylsilane M2 with excellent diastereo- and 
enantioselectivity.  
Scheme 1.2.2 CuCl-Catalyzed Synthesis of Allenylsilane 
 
 The possible reaction mechanism for the in situ formation of M2 was proposed 
(Scheme 1.2.3). Accordingly, the starting propargylic mesylate may undergo SN2 or SN2’ 
displacement by a tricholorosilyl cuprate to form the intermediate chlorocuprates M3 or 
M4 that are likely in equilibrium. Subsequent reductive elimination then occurs with 
retention of configuration to afford allene M2. Chlorosilanes M5 and M2 and the 
chlorosilylcuprate precursors may exist as an equilibrating mixture. 






1.2.3 Rh-Catalyzed Coupling between Propargylic Carbonates and a Silylboronate 
 A rhodium-catalyzed coupling between propargylic carbonates and a 
silylboronate that had broad functional group compatibility was reported by Sawamura.
7
 
Specifically, propargylic carbonate and PhMe2SiB(pin) (1.5 equiv) were treated with 
catalytic amount of [Rh(cod)2][BF4] (5 mol %) and Et3N (2.5 equiv) in acetone at 50 °C 
(18 h), affording allenylsilane in 81% yield (Scheme 1.2.4). Assuming silyl anion 
PhMe2Si- as a nucleophile, the allenylsilane was believed to be a formal SN2′ product. 
Indeed, no SN2 product was observed. Importantly, the rhodium-catalyzed coupling could 
be performed “open flask” with comparable product yield. 
Scheme 1.2.4 Rh(I)-Catalyzed Coupling between Carbonate S1 and Silylboronate S2 
 
 To demonstrate the scope of the reaction, various propargylic carbonates were 
surveyed (Table 1.2.1). Secondary propargylic carbonate S4a bearing bulky cyclohexyl 
groups at both the α- and γ-positions, phenyl substituted carbonate S4b, tertiary 
propargylic carbonates S4c and S4d, tertiary propargylic carbonates bearing a bulky 
cyclohexyl group at the γ-position S4e, quaternary propargylic carbamate S4f and even 
S4g bearing a free hydroxyl group were all well tolerated. 
 They further investigated and extended the method to the synthesis of 




propargylic carbonate (S)-6 (97% ee) and S2 in the presence of catalytic amount of 
[Rh(cod)2][BF4] (10 mol %) and Et3N in DMF/CH3CN (100:1) at 25 
o
C afforded 
allenylsilane (R)-7 in 77% yield and greater than 95% ee.  
Table 1.2.1 Carbonate Scope in Rh-Catalyzed Allenylsilane Formation 
 





1.2.4 Rh-Catalyzed Enantioselective 1,6-Addition of Arylboronic Acids to 
Enynamides 
 
  While the previous synthetic methods to access enantioenriched allenylsilanes 
take advantage of chiral starting materials (chiral propargylic mesylates and carbonates), 
the present method developed by Hayashi
8
 and coworkers provided direct access to chiral 
allenylsilanes uitilizing achiral starting materials and marked a significant advance in this 
area. Highly enantioenriched allenylsilane H3a was obtained as a 1,6-adduct in 85% 
yield and 98% ee with a small amount of 1,4-adduct H4 (17% yield), when enynamide 
H1 and phenylboronic acid H2 were treated with the rhodium/chiral diene catalyst 
[RhCl((S,S)-Fc-tfb*(L1))]2 (Fc= ferrocenyl) (5 mol % Rh) and K3PO4 (20 mol %) in 1,4-
dioxane and H2O at 50 °C for 3 h (Scheme 1.2.6). 
Scheme 1.2.6 Synthesis of Chiral Allenylsilane by Rh-Catalyzed Asymmetric 1,6-
Addition of Phenylboronic Acid H1 to Enynamide H1 
 
 During the development of this reaction, they surveyed different types of ligands 
and found their profound effects on the reactivity and selectivity of the reaction (Table 
1.2.2). While complete consumption (entry 1) of starting material with high product yield 
and ee was observed using diene ligand L1 substituted with ferrocenyl groups, significant 
lower conversion and yield were obtained with the use of diene ligands substituted with 




recovery of a significant amount of unreacted H1a (entries 2 and 3). Importantly, 
prolonged reaction time (9 h) did not give noticeable improvement in either conversion or 
yield with the use of [RhCl(L3)]2, presumably due to the lost of catalyst activity during 
the reaction course (entry 4). Ligand L4 also showed low reactivity, affording H3a in 
only 18% yield (entry 5). Moreover, no product formation was observed with the use of 
binap L5 or phosphoramidite L6 (entries 6-8). 







 After the optimal reaction condition was found, the substrate scope (both the 
enynamide and arylboronic acid) were then evaluated. Differentially functionalized 
arylboronic acids (H2) were successfully reacted with enynamide (H1a), affording the 
corresponding addition products (H3a-h) in constantly high yield and with 
enantioselectivities ranging from 95 to 98% ee (entries 1-8). Enynamides substituted with 
tertbutyldimethylsilyl (H1b) and triethylsilyl (H1c) groups on the alkyne produced H3i 
and  





H3j with excellent yield and enantioselectivities (entries 9 and 10). Variations on the 
amide, namely diisoproplyl, dibenzyl, and diphenyl substitution, did not affect the 
reaction efficiency and still gave the addition products in good yields and 94-99% ee 
(entries 11-13). 
Scheme 1.2.7 Proposed Catalytic Cycle 
 
 A catalytic cycle has been proposed to account for the formation of allenylsilane. 
Phenylrhodium species B is formed by transmetalation of a phenyl group from the boron 
to the rhodium center, followed by alkyne H1a insertion into the phenyl-rhodium bond to 
generate alkenylrhodium C. The insertion happens such that the phenyl is placed 
proximal to a silyl group on H1a, where the regiochemical course favors the formation of 
thermodynamically more stable intermediate C. A subsequent isomerization by 
coordination of an alkene moiety to the rhodium center gives benzylidene-π-allylrhodium 
D, which is in equilibrium with allenyl rhodium complex E. H3a and hydroxorhodium 




 The stereochemical course of this reaction for the formation of S configuration 
was rationalized by the model shown in Scheme 1.2.8. Through the coordination with the 
(S,S)-L1 ligand, an effective C2-symmetric environment is created with the ferrocenyl 
substituents located at upper-left and lower-right positions. When isomerization occurs 
that converts alkenyl species C into the benzylidene- π-allylrhodium D, the either face of 
the double bond intramolecularly could coordinate to the rhodium center leading to the 
two different rhodium complex D-1 and D-2. D-1 that leads to final product with an S 
configuration is favored over D-2 because the unfavorable steric repulsions between the 
substituent on the diene ligand and the benzylidene moiety (and/or the amide Z) are 
avoided in D-1. 









1.2.5 Copper-Catalyzed Hydrosilylation of (Z)-2-Alken-4-ynoates with Silylboronate 




While traditional methods to synthesize chiral allenylsilane utilizes chirality transfer form 
chiral propargylic mesylate or carbonate, recent advance in the transition-metal catalyzed 
asymmetric synthesis has allowed the synthesis of chiral allenylsilanes using achiral 
starting materials. In that context, Loh and coworkers
9
 reported the synthesis of highly 
substituted racemic and enantioenriched allenylsilanes through the use of inexpensive 
copper-catalyst and silylboronate for the 1,6-silyl addition to enynoates. Their initial 




additive in MeOH solution at room temperature as the optimal condition. With the 
optimized reaction condition established, they then surveyed various enynoates 
substituted with aryl that had different electronic and steric environment, heteroaryl, 
cyclopropyl, alkyl, or ester. Moderate to good yields were obtained. Furthermore, di- and 
tetrasubstituted allenylsilanes could be generated with good yields. With the successful 
synthesis of racemix allenylsilane, they then moved to the development of the 
enantioselective synthesis (Table 1.2.4). 








 After a screening of the copper catalysts, solvents, and a collection of chiral 
ligands, the optimized condition was found to be 5 mol % CuTC (copper(I) thiophene-2-




Am = tert-amyl) 
solution at 0 °C with stirring for 48 h, producing L*3a in 80% yield and with 92% 
enantiomeric excess (entry 10). With the optimal condition, enynoates substituted with a 
variety of aryl groups, heterocylce, and alkyl groups were examined for the scope of this 
reaction (Table 1.2.5). In general, aryl substituted enynoates were good substrates that 
delivered allenylsilanes with constantly good yield and high ee (L*3a-i), regardless of the 
electronic and steric environment present on the aryl ring. Due to the possible 
coordination with the copper catalyst, thiophene substituted enynoate (L*3j) only gave 
moderate yield with recovery of unreacted starting material. However, aliphatic 
substituent (L*3k) was not well tolerated, leading to eroded enantioselectivity but in 
good yields. Tetra-substituted allenylsilane (L*3l) could be generated albeit with only 
36% ee and in 74% yield.  In addition, the effect of ester group was also examined and 
showed it had no effect on either yield or enantiopurity of the products. 
 A plausible catalytic cycle was proposed for the CuTC and chiral bisoxazoline 
ligand system catalyzed asymmetric hydrosilylation reaction of enynoates. The reaction 
of silylboronate L*2 with CuTC generated Cu-Si species I, which coordinated with the 
enynoate L*1a to form the intermediate II. Subsequent silylation led to the formation of 






Scheme 1.2.9 Proposed Plausible Mechanism for the Copper- Catalyzed 
Asymmetric Hydrosilylation of Enynaoate 
 
1.2.6 Previous Approach to the Preparation of Allenylsilanes from the Panek 
Laboratory 
 Through the years, our laboratory has been actively involved in the development 
and application of chiral organosilane reagents in the past three decades. In that context, 
chiral allenylsilane has received considerable interest. Dr. Ryan Brawn from our 
laboratory has reported the scalable preparation of highly enantioenriched allenylsilane 
(Ra)-3 (also (Sa)-3) and the subsequent application in the asymmetric synthesis of 




 takes advantage of Johnson orthoester Claisen rearrangement 
to transfer the chirality from enantioenriched 1-silyl propargylic alcohol to allenylsilane. 




that involves deprotonation of commercially available 3-butyn-2-ol to generate a dianion 
using n-butyllithium and selective C-silylation facilitated by the addition of lithium 
chloride. Racemic propargylic alcohol B1 was subjected to a kinetic resolution using 
Amano lipase AK that produced alcohol (S)-11 in 49% yield and >95 ee and acetate (R)-
B2 in 48% yield. Acetate (R)-B2 was hydrolyzed in the presence of lipase in pH 7 butter 
to afford alcohol (R)-11in 77% yield and >99% ee. The subsequent orthoester Claisen 
rearrangement of respective alcohols (R)-11 and (S)-11delivered enantioenriched 
allenylsilanes (Sa)-3 in 81% yield and 98% ee and (Ra)-3 in 79% yield and 98% ee. 





1.2.7 Copper-Mediated SN2’ Reaction of 1-Silyl Propargylic Alcohol to Access New 
Allenylsilane from the Panek Laboratory 
 Taking advantage of our previous synthesis of allenylsilane and a modified SN2’ 
addition reaction, we were able to obtain multigram quantities (>30 g prepared in one 
synthetic sequence) of (Sa)-4 and (Ra)-4 in a four-step sequence with high yield and >98% 
ee (Scheme 1.2.11)
11
. The individual propargylic alcohols (R)-11 and (S)-11 were 
subjected to mesylation to afford methanesulfonate (R)-12 and (S)-12 in 86% and 85% 
yield, respectively. Subsequent copper-mediated SN2’ reaction of (R)-12 and (S)-12 in the 
presence of methyl magnesium bromide, copper(I) bromide, and lithium bromide 
delivered allenylsilanes (Ra)-4 and (Sa)-4 in 86% and 90% yield, respectively. The 
enantiomeric excess of both allenylsilanes were determined to be >98%, deduced from 
their respective propargylation products. 





1.3 Asymmetric Three-Component Propargylation Reactions 
 Chiral homopropargylic alcohols are important synthons in diversity-oriented- 
and natural product synthesis. The development of diastereo- and enantioselective 
synthesis of them has been an ongoing interest in the synthetic community. This section 
covers the methodology development in the context of allenylsilanes, -boronates, -
stannanes, and -zinc. The diastereofacial- and enantioselectivity of the reaction is 
controlled either by the reagent or the chiral ligand. 
1.3.1 Marshall’s Propargylation with Allenylstannane ,-zinc, and -silane 
 Marshall and coworkers have made significant contributions to the 
enantioselective propargylation of carbonyls. A range of allenylmetal reagents including 
allenylstannane, -zinc, and -silane have been prepared, employing an anti-SN2’ process 
that uses chiral propargylic mesylate and the corresponding metal reagents. These chiral 
allenylmetal reagents participate in the Lewis acid-catalyzed propargylation reactions that 
deliver homopropargylic alcohols with multiple stereogenic centers with good to 
excellent enantio- and diastereoselectivities. Notably, the diastereoselectivity (syn/anti) 
and the configuration (R/S) of the resulted homopropargylic alcohols could be controlled 
by tailoring the structures of the allenylmetals and carbonyls or the Lewis acids.  
 In their early studies on propargylation reactions between allenylstannane (S)-M1 
and α-chiral aldehyde (S)-M2 or (R)-M2,
12
 they were able to access the four 
diastereomers of the so-called stereotriads (M3, M4, M5, and M6) in a highly efficient 
and diastereoselective manner (Scheme 1.3.1). Through the careful choice of Lewis acid 




diastereomers. When (S)-M1 was reacted with (S)-M2, boron trifluoride diethyl etherate 
was chosen as Lewis acid that enabled the reaction to favor the acyclic Cram’s transition 
state, affording the syn,syn-isomer M3. Magnesium bromide ethyl etherate was chosen as 
the Lewis acid to catalyze the reaction, when the addition was taking place between (S)-
M1 and (R)-M2 under the acyclic chelation controlled transition state, delivering the 
syn,anti-isomer M4. Interestingly, when SnBu3 group was substituted with SnCl3 group 
to generate the tricholorotin allene in situ, the anti,anti-isomer M5 resulting from a cyclic 
chelation transition state (Scheme 1.3.2 A) was obtained combing (S)-M1, (S)-M2 and 
Lewis acid SnCl4. Lastly, the anti,syn-isomer M6 was generated when propargylation 
was undertaken between the in situ generated tricholorotin allene and (R)-M2 going 
through a cyclic Cram transition state (Scheme 1.3.2 C).  







Scheme 1.3.2 Transition state arrangements for additions of the (R)-
(trichlorostannyl)allene derived from stannanes (S)-M1a/M1c to aldehydes M2. 
 





 In their related study trying to reproduce the above results, they found that the 
results were not constant. To develop a more reliable method, they finally used BuSnCl3 




 Later on, based on the work by Tamaru and co-workers, they proposed a Pd(0) 
catalyzed zincation of propargylic mesylates that would generate a allenylzinc species IV 
in situ (Scheme 1.3.4).
14
 The presumed allenylzinc species IV was found to participate in 
propargylation reaction with aldehyde to give anti homopropargylic alcohols. 
Scheme 1.3.4 Possible catalytic cycle for Pd(0)-catalyzed zincationof propargylic 
mesylates 
 
 To further expand the scope of the propargylation reaction, they went on 
optimization of the reaction conditions. Through the screen of catalyst, temperature, and 




substrate scope. Good to excellent diastereoselectivities were achieved though the 
chirality transfer was lost a little bit from chiral mesylate to the product (Table 1.3.1). 
Table 1.3.1 Additions of the Allenylzinc Reagent to Achiral Aldehydes 
 
 With the general reactivity established, they went on to examine the addition of 
M12 to the α-chiral aldehydes (S)-M7 and (R)-M7. The propargylation proceeded well to 
produce the chiral homopropargylic alcohols in good yields and excellent 
diastereoselectivities, regardless of the stereochemistry of the α-methyl group (Scheme 
1.3.5). 





 A cyclic transition state was proposed to explain the formation of anti products 
(Scheme 1.3.6). For the addition between M12 and (S)-M7, a chelation controlled Felkin-
Ahn orientation was employed to explain the formation of the anti,syn-isomer M13, 
whereas a chelation controlled anti- Felkin-Ahn transition state between the allenylzinc 
species and aldehyde (R)-M7 was adopted to rationalize the anti adduct M14. 
Scheme 1.3.6 Transition States Analysis for the Formation of Anti Adducts 
 
 With the established reactivity and selectivity of propargylation reactions between 
chiral allenylmetal reagents (allenylstannane, -zinc, and –indium (not shown)) and 
chiral/achiral carbonyls, they next moved their attention to allenylsilane reagents
15 
complementary to the transition-metal based allenes. Prior to Marshall’s study, Danheiser 
and Fleming had independently investigated the allenylsilane additions to achiral 
aldehyde to generate homopropargylic alcohols. However, the corresponding additions to 
chiral aldehyde were not reported. In that context, building on the early success on the 
synthesis of highly enantioenriched allenylsilanes by Fleming, Marshall and coworkers 
explored the propargylation between allenysilane (Ra)-M15 and aldehyde M7 or M2 




Scheme 1.3.7 Propargylation between Allenylsilane M15 and aldehyde M7 or M2 
 
 The TiCl4-catalysted syn additions of allenylsilane (Ra)-M15 to ODPS aldehydes 
(R)-M7 and (S)-M7 followed the acyclic Felkin-Anh (matched) and anti-Felkin-Anh 
(mismatched) transition states to give sole syn,syn-isomer M16a and an 80:20 mixture of 
syn,anti-isomer M17a and anti,syn-isomer M17b (anti addition product) respectively, 
closely paralleled to the BF3-promoted additions of the analogous allenylstannanes. In 
comparison, when the ether of the aldehydes was benzyl ether, striking results that 
differed from the tert-butyldiphenyl silyl ether were obtained. As opposed to the addition 
to aldehyde (R)-M7 producing a syn adduct M16a, the propargylation between 
allenylsilane (Ra)-M15 and (R)-M2 afforded an anti adduct M16b. Besides, the addition 
to (S)-M2 delivered an analogous syn,anti-isomer M17c but with complete selectivity. 




ether to benzyl ether could be rationalized by the following transition states analysis 
(Scheme 1.3.8) as proposed by Marshall and coworkers. 
Scheme 1.3.8 Proposed Transition States for TiCl4-Promoted Additions of 
Allenylsilanes to α-Methyl β-Oxygenated Aldehydes 
 
 The “matched” addition of allenylsilane (Ra)-M15 to β-ODPS aldehyde (R)-M7 
proceeded through the acyclic antiperiplanar Felkin-Anh transition state A, producing 
M16a. On the other hand, the “mismatched” syn addition to (S)-M7 to afford M17a was 
expected to favor the anti-Felkin-Anh antiperiplanar arrangement B, where the reagent 




thought to arise from synclinal Felkin-Anh arrangement C, where the substrate control 
overrode the reagent control. In contrast to the mainly reagent control in the acyclic 
transition states, the additions to -OBn aldehydes M2 went through substrate (aldehyde) -
controlled cyclic transition states D and E. In these two additions, the aldehyde strongly 
directed the approach of the allenylsilane reagent delivering the syn,anti-isomer M17c 
and anti,anti-isomer M16b. 
1.3.2 Copper Catalyzed Asymmetric Propargylation of Aldehydes 
 The traditional approach for asymmetric propargylation of aldehydes relies on the 
chirality transfer from enantioenriched allenes. Recently, the emergence of transition 
metal-mediated asymmetric catalysis has prompted the development of asymmetric 
synthesis of homopropargylic alcohols with the use of achiral starting materials combined 
with chiral ligand and catalytic amount of transition metal. In that context, Fandrich
16
 and 
coworkers at Boehringer Ingelheim Pharmaceuticals, Inc in connecticut have developed a 
highly enantioselective and site selective copper alkoxide-catalyzed propargylation of 
aldehydes with a propargyl borolane. 
 Building on the reported success with an analogous B/Cu exchange with an allyl 
borolane reagent and propargylation with an allenylcopper species, they proposed a 
catalytic cycle that rested on a Cu-alkoxide mediated B/Cu exchange with the propargyl 
borolane I to generate an allenylcopper intermediate III. The in situ generated 
allenylcopper species III then added to aldehyde via a SN2’pathway to give 




borolane I to afford borolane alkoxide V and regenerate allenylcopper species III 
(Scheme 1.3.9). 
Scheme 1.3.9 Proposed Mechanism for a Cu-Catalyzed Propargylation of Aldehydes 
with a Propargyl Borolane 
 







 Conforming to the model, an allenylalcohol product F3 was obtained presumably 
resulting from a slow background reaction SN2 addition of allenylcopper to aldehyde with 
or without a catalytic copper halide catalyst. Building on the previous study on B/Cu 
exchange with a Cu(I) alkoxide complex, replacement of CuCl with Cu(I)-tert-butoxide 
rapidly promoted the propargylation of p-anisaldehyde with moderate site selectivity for 
the alkynyl over the allenyl product and improvement of enantiomeric excess. In terms of 
Ligand effect, the reaction displayed favored formation of homopropargylic alcohol with 
phosphine ligands, and an enantioselective reaction was achieved by employing their 
previously developed air stable BIBOP ligands (Table 1.3.2). 







 With the highly enantioselective conditions established, the scope of the reaction 
was then explored. In general, compared with a slight decrease in enantioselectivity (90% 
ee) for the aliphatic aldehyde (F5j), high enantioselectivities (93-99% ee) and yields were 
achieved for aromatic and alkenyl aldehydes. Moreover, good functional group tolerance 
was also attained, including esters, nitriles, an aryl fluoride, a carbamate, Lewis basic 
substrates bearing Lewis basic functional group, and heterocycles. 
1.3.3 Allenylboration Reactions to Access Chiral Homopropargyl Alcohols 
 A significant breakthrough in the field of allenylboronate additions to chiral or 
achiral aldehyde to access chiral homopropargylic alcohol type stereotriads with excellent 
diastereochemical control and chirality transfer of the axial chirality of the allene into the 
propargyl center of the products has been reported by Chen of the Roush group.
18
 By 
employing an external chirality source, a chiral phosphoric acid catalyst (S)-R4, to 
override the reagent or substrate control and for control of the configuration of the 
hydroxyl group, highly diastereoselective propargylation reactions to give anti-, syn-, 
anti,anti-, anti,syn-products were achieved.  
 In the reaction optimization process, syn isomer R3a was produced as the major 
diastereomer without the chiral phosphoric acid, consistent with the established cyclic 
transition state involved in carbonyl addition reactions using allenylboron reagents. 
Dramatic change in diastereoselectivity with improved yield was observed, when 20 mol% 
of (S)-R4 was employed in the reaction, delivering anti isomer R2a as a single 




the best condition as 5 mol% of (S)-R4 stirring for 24 hours warming from 0 
o
C to room 
temperature (Table 1.3.4).  
Table 1.3.4 Optimization of Matched Allenylboration Reactions Using 








 With the optimized condition developed for matched pair between allenylsilane 




allenylboration. The anti-homopropargyl alcohols were obtained as the only isomers with 
good to excellent yields and excellent enantioselectivities in all cases (Table 1.3.5).  
 Table 1.3.6 Optimization of Mismatched Allenylboration Reactions Using 








 For the mismatched case between allenylsilane (Ra)-R1 and acid catalyst (R)-R4, 
reaction optimization revealed that use of 5 mol% of (R)-R4 and stirring at -30 
o




hours gave the best yield of 98% and 10:1 diastereoselectivity favoring the syn-isomer. 
These reaction conditions were applied to a variety of aldehydes. In general, compared 
with the matched case the obtained diastereoselectivity was lower in the present case. 
Specifically, syn-isomers were generated in 90-98% yield with ≥9:1 diastereoselectivity 
and >98% ee for aromatic aldehydes (Table 1.3.7, R3a-f), while the selectivity was much 
lower with unsaturated or aliphatic aldehydes (Table 1.3.7, R3g). A reversal of selectivity 
was obtained that favored the production of anti-isomers when the aliphatic aldehydes 
were sterically large (Table 1.3.7, R3h-i).  
Table 1.3.8 Diastereoselective Syntheses of anti,anti-Stereotriads R6 via Triple 
Asymmetric Allenylboration Reactions 
 
 More significantly, a triple asymmetric allenylboration reaction was achieved 
with a α-chiral aldehyde, where complete diastereoselectivity was obtained (Table 1.38). 
 An interesting chiral Brønsted acid catalyzed enantioselective synthesis of anti-




allenylboronates was also reported by the Roush group.
18
 Realizing that the reaction of 
the matched case proceeded faster than the mismatched case, a basis for a possible kinetic 
resolution of a racemic allenylboronate in reactions catalyzed by chiral phophoric acid 
(R)-R4, racemic R1 was reacted with aldehydes under a lower temperature, producing 
anti homopropargylic alcohols ent-R2 with diastereoselectivities and enatiomeric excess 
ranging from 9:1 to 20:1 and 73% to 95% respectively (Scheme 1.3.10). 
Scheme 1.3.10 Kinetic Resolution/Allenylboration of Racemic Allenylboronates with 
Aldehydes 
 
 Related Chiral biphenols catalyzed asymmetric propargylation of ketones using 
allenylboronates was reported by Schaus from our department.
19
 The reaction was 
catalyzed by 10 mol% of 3,3’-Br2-BINOL S3 and used allenyldioxoborolane S1 as the 
nucleophile to produce chiral homopropargylic alcohols S2 under microwave irridation. 
Under the optimal condition, good to excellent yields (60-98%) and enantiomeric ratios 
(3:1-99:1) were obtained. Importantly, this study expanded the scope of asymmetric 
propargylation that allowed addition to ketones complementary to the well-established 








Scheme 1.3.11 Propargylation of Ketones Catalyzed by Chiral Biphenols 
 
1.3.4 Previous Approach for Asymmetric Three-Component Propargylation from the 
Panek Laboratory  
 In addition to the development and application of organosilane-based crotylation 
chemistry, the Panek laboratory is also interested in exploring the field of allenylsilanes 
as versatile carbon nucleophiles in addition to various electrophiles and subsequent 
diversification. As previously discussed, Brawn and Panek have established a scalable 
method for the multigram preparation of highly enantioenriched allenylsilane (Sa)-3 and 
(Ra)-3 based on the Johnson orthoester Claisen rearangement. In view of the well-
established reactivity of allenylmetal reagents in the propargylation reactions and the 
ability to transfer axial chirality into central chirality in the resulting products, a Lewis 
acid-mediated three-component asymmetric propargylation reaction between 
allenylsilane (Ra)-3, trimethylsily ether, and aldehyde was developed to provide access to 
a range of structurally diverse homopropargylic ethers.
10
 
 A screening of reaction conditions identified boron trifluoride diethyl etherate as 
the Lewis acid to effect the reaction. Aromatic aldehydes were well tolerated with greater 
than 10:1 diastereoselectivities (Table 1.3.9, B3a-e). However, heteroaromatic 




aliphatic systems gave low yields and selectivities (Table 1.3.9, B3h-i), while a branched 
aliphatic aldehyde displayed improved selectivity. 
Table 1.3.9 Three-Component Reactions with TMSOMe 
 
 In further experiments, Brawn extended this propargylation to the synthesis of 
homopropargylic sulfonamides
20
 by a three component reaction of aldehyde, 
sulfonamides, and allenylsilane (Ra)-3 through the in situ generation of N-sulfonylimines 
(Scheme 1.3.11). Interestingly, in his initial exploration of [3+2] annulation of (Ra)-3 
with N-acyliminium ions, it was discovered that the acyclic propargylation product was 
obtained as a byproduct under certain conditions. This discovery led to the pursuit for the 
selective formation of homopropargylic amines.  When the condition for the formation of 
dihydrooxazines was applied to the reaction between (Ra)-3 and 2-bromobenzaldehyde in 
the presence of TMSOTf in propionitrile at -50 
o




45% yield with 35% of annulation product. To further improve the formation of 
propargylic product and suppress the annulation pathway, solvent and amine source 
screen were performed. While solvent screen did not enhance the selectivity, promising 
result was found that the use of sulfonamides exclusively favored the propargylation 
pathway. Under the optimal condition, enantioselective propargylation with 
methanesulfonamide was performed with a library of aldehydes. Complete 
diastereoselectivity was obtained with aliphatic aldehydes bearing α-tertiary branch, 
while primary aliphatic aldehydes gave moderate but useful levels of selectivity. Besides, 
the reaction with aliphatic aldehydes was also tolerant to a number of sulfonamides. In 
comparison, propargylation with aromatic aldehydes were sluggish, leading to 
diminished yields and selectivities.  
Scheme 1.3.11 Three Component Propargylation to Generate Homopropargylic 
Sulfonamides 
 
 The observed syn selectivity in the formation of homopropargylic ethers or 
sulfonamides can be rationalized by the open transition states using antiperiplanar or 
synclinal orientations of reaction partners, where allenylsilane (Ra)-3 was added to the Re 







Scheme 1.3.12 Transition State Models 
 
1.3.5 Asymmetric Three-Component Propargylation with New Allenylsilane 
 During our program directed toward the synthesis of natural product NFAT-68, 
we wanted to establish a propargylation reaction that could provide access to the 
stereochemistry of the C6 methyl group and the C7 hydroxyl group. As discussed earlier, 
we have had a longstanding interest in developing and utilizing organosilane reagents as 
versatile carbon nucleophiles in natural product and diversity-oriented synthesis. In that 
context, chiral allenylsilanes have proven to be useful carbon nucleophiles in acyclic 
stereocontrol to produce homopropargylic alcohols, ethers, and sulfonamides with 
complete transfer of axial chirality to point chirality and moderate to high syn selectivity.  
 The study was initiated by establishing the reactivity and selectivity of chiral 
allenylsilane (Sa)-4 in asymmetric three-component propargylation reactions. Taking 
advantage of our previous synthesis of (Ra)-3 and a modified SN2 addition reaction, we 
were able to obtain multigram quantities (>30 g prepared in one synthetic sequence) of 
(Sa)-4 and (Ra)-4 in a four-step sequence with high yield and >98% ee. With multigram 
quantities of (Sa)-4 in hand, we proceeded to evaluate the asymmetric three-component 
propargylation reactions between (Sa)-4, aldehydes, and (benzyloxy)trimethylsilane. A 




identified 0.5 equiv of TMSOTf and propionitrile as the optimal combination of reagents. 
Once the conditions were determined, a range of aldehydes were evaluated to probe the 
reaction scope (Table 1.3.10). As anticipated, syn products were produced as the major 
diastereomer with moderate to high levels of diastereoselectivities and yields, consistent 
with the well-documented antiperiplanar transition state, where the destabilizing 
interaction between the R group on the oxonium ion and the methylene groups of the 
allene is minimized.  
Table 1.3.10 Asymmetric Three-Component Propargylation with (Sa)-4 
 







1 benzaldehyde 5a 75 3.5:1 
2 3-bromobenzaldehyde 5b 85 3.3:1 









5e 78 3.0:1 
6 o-tolualdehyde 5f 51
d
 >20:1 
7 cyclohexanecarbaldehyde 5g 86 >20:1 
8 isobutyraldehyde 5h 75 >20:1 
9 isovaleraldehyde 5i 66 3.0:1 
10 n-pentanal 5j 65 2.0:1 
a
Isolated yields after chromatographic purification over silica gel. 
b
Diastereomeric ratios (dr) were 
determined by 
1
H NMR analysis on crude material. 
c
Diastereomeric ratio after column chromatography 
purification over silica gel. 
d







 In general, aromatic aldehydes with either activating or deactivating substituents 
afforded products with good yields but moderate diastereoselectivities (Table 1.3.10, 
entries 1-5), with the exception for o-tolualdehyde, with which syn product 5f was 
obtained as the single diastereomer. On the other hand, reactions with aliphatic aldehydes 
afforded products with good yields and more predictable diastereoselectivies (Table 
1.3.10, entries 7-10). Tertiary aliphatic aldehydes delivered 5g with good yields and 
complete diastereoselectivity (Table 1.3.10, entries 7 and 8). As the tertiary center moved 
one carbon away, the diastereoselectivity dropped significantly with slightly lower yield 
(Table 1.3.10, entry 9). When the substrate was a straight chain aliphatic aldehyde, the 
diastereoselectivity decreased further (Table 1.3.10, entry 10). 
1.4 Alkyne-Alkyne Reductive Coupling 






 As the three-component propargylation reaction with (Sa)-4 was established, we 
next sought to investigate the titanium-mediated reductive coupling between the 
propargylation products and acetylenic esters with the anticipation that it would be used 
in a successful synthesis of NFAT-68. At the outset, we anticipated that the reductive 
coupling with electronically activated acetylenic esters would exhibit very different 
reactivity than that with electronically neutral terminal alkynes. Indeed, after extensive 
reaction optimization, it was found that lower reaction temperature and prolonged 
reaction time (a modification of Micalizio’s conditions for alkyne-alkyne reductive 
coupling) were essential for efficient generation of the presumed titanocyclopropene 
complex and subsequent coupling with acetylenic ester. With the optimized conditions, 
we then explored the internal alkyne substrate scope. Generally, moderate yields and 
moderate to excellent regioselectivities were achieved with slightly higher yields and 
cleaner reactions for internal alkynes bearing aliphatic substituents (Scheme 1.4.1, entries 
6-9). The yields were moderate presumably due to the instability and/or incomplete 
formation of the metallacycle intermediate. Interestingly, the observed regioselectivity 
with aromatic and aliphatic terminal alkynes exhibited an interesting dependence on the 
substitution patterns of the aromatic reaction partners (Scheme 1.4.1, entries 1-5) and the 
steric bulk near the reacting centers for aliphatic reaction partners (Scheme 1.4.1, entries 
6-9). Notably, the para-fluoro substrate afforded homopropargylic ether 6e with high 
regioselectivity (Scheme 1.4.1, entry 5), which was only observed for Ti-based alkyne-
alkyne reductive coupling reactions employing alkoxide as a directing group or TMS as a 




bearing tertiary carbons rendered products 6h and 6i with complete regioselectivity 
(Scheme 1.4.1, entries 8 and 9). Lastly, variation on the steric bulk of the ester group on 
the terminal alkyne was also explored, and the regioselectivity also appeared to depend 
on the steric environment of the terminal alkyne. Changing from a methyl ester to an 
ethyl ester group exhibited a two-fold enhancement of selectivity, while the substitution 
with a t-butyl group led to complete conversion to a single regioisomer (Scheme 1.4.1, 
entries 10 and 11). 
Figure 1.4.1 Empirical Transition State Models for Regiochemical Course of 
Reductive Coupling 
 
 The observed steric effects on the regiochemical course of Ti-based reductive 
coupling reactions may be rationalized by the empirical models depicted in Figure 1.4.1. 




ClTi(OiPr)3 by cC5H9MgCl, leads to the presumed titanocyclopropene complex I. A 
classic Newman projection maybe utilized to aid in analysis by sighting down the C4-C5 
bond of metallacycle I, where the A
1,3 
strain is minimized and the lowest energy 
conformation is presented by minimizing gauche interactions between the C4 and C5 
substituents. Importantly, this open transition state analysis results in the position of the R 
group from internal alkyne in proximity to the titanium reacting center, and thus the steric 
bulk or the position of substituent on the aryl ring of the R group could potentially affect 
the steric environment of the titanium reaction center. Subsequent intermolecular 
carbometalation between metallacycle I and acetylenic ester is anticipated to proceed 
through three distinct pathways (Figure 1.4.1, a, b, and c) resulting in three transition 
states (Figure 1.4.1, II, III, and IV), and deliver three titanocyclopentene complexes (not 
shown), which upon hydrolytic quench form three regioisomers. In the present case, 
regiosiomer A is formed as the major isomer, since transition state III has the fewest 
destabilizing steric interactions and thus is energetically favored. 
1.5 Total Synthesis of Nuclear Factor of Activated T-Cells-68 (NFAT-68) 
 Immunosuppressant drugs such as cyclosporine A and fujimycin target the 
inhibition of T-cell activation by preventing the activation of the nuclear factor of 
activated T-cells (NFAT-68) transcription factor.
22
 In 1995, the New Lead Discovery 
group from AbbVie (formally Abbott Laboratories) isolated a new polyketide natural 
product NFAT-68 (Figure 1.5.1) from the broth and mycelia of two Streptomyces sp. 
fermentations.
23
 That molecule displayed potent in vitro immunosuppressive activity with 




original isolation paper, neither the absolute nor the relative stereochemistry of the C6 
methyl group and the C7 hydroxyl group was established. Recently, the Yang group 
reported the first synthesis of both enantiomers of NFAT-68 utilizing a chelation-
controlled vinylogous Mukaiyama aldol reaction originally developed by the Kobayashi 
group,
24
 which resulted in the elucidation of a syn stereochemical relationship between 
the C6 methyl group and the C7 hydroxyl group. This chapter will review two synthetic 
efforts toward the total synthesis of both enantiomers of NFAT-68, one by the Yang 
group from Peking University and the other by us. 
Figure 1.5.1 Enantiomers of NFAT-68 
 
1.5.1 Yang’s Total Synthesis of NFAT-68 
 The first reported total synthesis of NFAT-68 was disclosed in 2010 by the Yang 
group from the Peking University via the chelation-controlled vinylogous Mukaiyama 
aldol reaction (VMAR) as a key step. Through their total synthesis, the structures of 
NFAT-68 were also elucidated. 
 Their retrosynthetic analysis was outlined in Figure 1.5.2. NFAT-68 was 







Figure 1.5.2. Retrosynthetic Analysis 
 
 Their synthesis commenced with VMAR of aldehyde Y3 and the chiral 
vinylketene silyl N,O-acetal Y2 to give the aldol adducts Y1 and Y4 in a 85% combined 
yield with greater than 20:1 diastereoselectivity. Subsequent MOM protection and 
DIBAL-H readuction afforded aldehyde Y5 in 73% yield over two steps, which 
underwent a wittig olefination to form diene Y6. An arylnitro reduction of Y6 followed 
by acetylaiton delivered Y7 in 74% yield over two steps. NFAT-68 was obtained in a 50% 
yield after a global deprotection by treatment of Y7 with AlCl3/t-BuSH. Ent-NFAT-68 
was synthesized following the same synthetic steps starting with ent-Y2 (Scheme 1.5.1).  





1.5.2 Panek’s Total Synthesis of NFAT-68 
 Our synthesis commenced with a three-component propargylation between 
aldehyde 7, (benzyloxy)trimethylsilane, and chiral allenylsilane (Sa)-4 produced internal 
alkyne 8 with good yield and diastereoselectivity. The ee of alkyne 8 was determined to 
be 98% by chiral HPLC analysis. The arylnitro group of alkyne 8 was reduced by in situ 
generated sulfurated borohydride NaBH2S3 to afford alkynyl aniline 8a (not shown here), 
which was subsequently N-acylated to yield alkyne 9. Originally, we adopted the above 
optimized condition for reductive coupling between 9 and methyl propiolate. However, to 
our surprise, we did not obtain the desired coupled product. After considerable effort, we 
learned that excess of Grignard reagent (6 equiv) was essential for the efficient 
generation of titanocyclopropene complex and elevated temperature (room temperature) 
was required to drive the intermolecular carbometalation process to completion. Thus, a 
solution of alkyne 9, ClTi(OiPr)3 (2 equiv), and cC5H9MgCl (6 equiv) in toluene was 
subjected to -40 
o
C for 5 hours to generate the metallacycle complex, after which methyl 
propiolate was added, and the mixture was warmed to room temperature, at which time 
the reaction proceeded for another two hours before being stopped. This experiment 
showed that the coupled product 10 was formed as a single regioisomer with moderate 
yield. Subsequent global deprotection of diene 10 afforded ent-NFAT-68 cleanly with a 
51% isolated yield. NFAT-68 was synthesized starting from chiral allenylsilane (Ra)-4 in 
the same manner. In summary, both enantiomers of NFAT-68 were synthesized in five 
steps with a 14% overall yield starting from chiral allenylsilanes (Sa)-4 (Scheme 1.5.2). 






 In conclusion, highly enantioenriched chiral allenylsilanes (Sa)-4 and (Ra)-4, 
generated in scalable four-step and five-step sequences, respectively, have been applied 
in the asymmetric three-component propargylation to give access to syn homopropargylic 
ethers 5. The reactivity and selectivity of the titanium-mediated alkyne−alkyne reductive 
coupling between these internal alkynes and electronically activated acetylenic esters 
were studied to expand the scope of this bond construction. Accordingly, the convergent 
total synthesis of both enantiomers of NFAT-68 was achieved in five steps with a 14% 
overall yield. In addition, the diene products maybe suitable for a future SAR study of 
NFAT-68 with respect to its immunosuppressive activity. Future studies on generating a 
library of differentially functionalized diene products and subsequent biological 




1.7 Experimental Section 
1.7.1 Experimental Procedures 
 
 All reactions were carried out in oven or flame-dried glassware under argon 
atmosphere unless otherwise specified. Triethylamine was distilled over calcium hydride 
and stored over potassium hydroxide. Dichloromethane, tetrahydrofuran, and toluene 
were obtained from a dry solvent system (alumina) and used without further drying. 
Propionitrile was distilled over calcium hydride and stored over 4 Å molecular sieves. 
Cyclopentylmagnesium chloride was purchased from Sigma-Aldrich, and was titrated by 
the Watson–Eastham method using 1,10-phenanthroline and sec-butanol. Aldehydes were 
freshly distilled before use and stored under nitrogen at 4 
o
C. Lithium chloride was 
purchased from Alfa Aesar and vacuum dried at 120 
o
C for 12 hours before use. All other 
reagents were used as supplied. Unless otherwise noted, reactions were magnetically 
stirred and monitored by thin layer chromatography with Macherey Nagel Polygram 0.20 
mm silica gel 60 Å plates. Flash chromatography was performed on Sorbent 
Technologies 32-63 μm 60 Å silica gel. Yields referred to chromatographically and 




C NMR spectra 
were taken in CDCl3, C6D6, and CD3OD at 400 or 500 MHz (as indicated), respectively. 
Chemical shifts are reported as major diastereomer and/or regioisomer in parts per 
million using the solvent internal standard (chloroform, 7.24 and 77.0 ppm, benzene, 7.16 
and 128.06 ppm, and methanol, 3.30 and 47.58 ppm respectively). Data are reported as 




multiplet, br = broad), coupling constant, integration. Infrared resonance spectra were 
recorded on a Nexus 670 FT-IR spectrometer. Optical rotations were recorded on a 
Rudolph Autopol II digital polarimeter at 589 nm and reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), 
coupling constant, integration. Infrared resonance spectra were recorded on a Nexus 670 
FT-IR spectrometer. Optical rotations were recorded on a Rudolph Autopol II digital 
polarimeter at 589 nm and reported as follows:     
   (concentration in g/100 mL solvent 
and solvent). High resolution mass-spectra were obtained on a Waters Q-TOF Mass 
Spectrometer at Boston University Chemical Instrumentation Center (CIC). 
Preparation of Chiral Allenylsilanes 
 
(S)-4-(dimethyl(phenyl)silyl)but-3-yn-2-yl methanesulfonate ((S)-12): A solution of 
(S)-11 (39.6 g, 193.7 mmol, 1 equiv) and methanesulfonyl chloride (19.6 mL, 253.33 
mmol, 1.3 equiv) in 774 mL dry dichloromethane was cooled to -78 
o
C. Triethylamine 
(34.3 mL, 220.9 mmol, 1.2 equiv) was added in dropwise. The resulting mixture was 
stirred for 12 hours, gradually warming to room temperature. The reaction was quenched 
with 400 mL DI water. It was then extract with dichloromethane (3 x 300 mL), and the 
combined organic layers were dried over MgSO4, filtered, and concentrated. Purification 
over silica gel chromatography (11.4% EtOAc/Hexanes) afforded product (S)-12 as a 
colorless oil (46.4g, 85% yield).     





H NMR (500 MHz, CDCl3): δ7.61-7.59 (m, 2H), 7.44-7.38 (m, 3H), 5.31 (q, J = 6.75 
Hz, 1H), 3.04 (s, 3H), 1.67 (d, J = 6.75 Hz, 3H), 0.46 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ135.61, 133.57, 129.83, 128.06, 102.89, 91.85, 68.44, 
39.07, 22.45, -1.36; 
IR (neat/cm
-1
) υmax : 3001, 2176, 1429, 1362, 1252, 1177, 1117, 1091, 1024, 974, 921, 
890, 839, 815, 783, 734, 700, 664; 
HRMS (ESI) m/z calcd for C13H18O3SSi [M+Na]
 + 
305.0644, found 305.0652. 
 
 
(S)-dimethyl(penta-2,3-dien-2-yl)(phenyl)silane (Sa)-4: CuBr was purified before use 
according to the following procedure: CuBr (68.3 g, 475.8 mmol) was dissolved in 113.3 
mL HBr (33% w/w in acetic acid) and stirred until it was fully dissolved. The resulting 
thick mixture was pour into cold DI water (2.32 L). Solids formed was filtered, collected, 
and washed with DI water, MeOH, and Et2O sequentially. It was then dried with LiBr 
under vacuum at 120 
o
C for 12 hours. A solution of CuBr (~47.8 g, 328.7 mmol, 2 equiv) 
and LiBr (28.5 g, 328.7 mmol, 2 equiv) in 580 mL THF was cooled to 0 
o
C. 
Methylmagnesium bromide (110.6 mL, 3M solution in diethyl ether, 328.7 mmol, 2 
equiv) was added into above solution slowly. The resulting mixture was stirred for 30 
min at 0 
o
C. (S)-12 (46.4g, 164.3 mmol, 1 equiv) in 7 mL THF was added in. The 
reaction mixture was stirred for 36 hours, gradually warming to room temperature. The 




300 mL), and the combined organic layers were dried over MgSO4, filtered, and 
concentrated. Purification over silica gel chromatography (5% CH2Cl2/Hexanes) afforded 
product (Sa)-4 as a colorless oil (30 g, 90% yield).     
  = +2.8 (c 7.0, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.55-7.53 (m, 2H), 7.37-7.35 (m, 3H), 4.79-4.73 (m, 1H), 
1.65 (d, J = 2.8 Hz, 3H), 1.62 (d, J = 6.9 Hz, 3H), 0.35 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ207.97, 138.30, 133.81, 128.98, 127.73, 89.09, 79.01, 
15.99, 13.82, -3.15, -3.25; 
IR (neat/cm
-1
) υmax : 3088, 2961, 1934, 1428, 1363, 1248, 1113, 1066, 976, 872, 832, 811, 
778, 699, 660; 
LCMS (ES+) m/z calcd for C13H18Si [M+Na]
 + 
225.11, found 225.12. 
 
 
(R)-4-(dimethyl(phenyl)silyl)but-3-yn-2-yl methanesulfonate ((R)-12): Made by the 
same procedure as (S)-12, using (R)-11 Purification over silica gel chromatography (11.4% 
EtOAc/Hexanes) afforded product (R)-12 as a colorless oil (46.9g, 86% yield).     
  = 
+8.8 (c 2.5, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.61-7.59 (m, 2H), 7.44-7.38 (m, 3H), 5.31 (q, J = 6.75 
Hz, 1H), 3.04 (s, 3H), 1.67 (d, J = 6.75 Hz, 3H), 0.46 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ135.61, 133.57, 129.83, 128.06, 102.89, 91.85, 68.44, 






) υmax : 3001, 2176, 1429, 1362, 1252, 1177, 1117, 1091, 1024, 974, 921, 
890, 839, 815, 783, 734, 700, 664; 
HRMS (ESI) m/z calcd for C13H18O3SSi [M+Na]
 + 
305.0644, found 305.0649. 
 
 
(R)-dimethyl(penta-2,3-dien-2-yl)(phenyl)silane (Ra)-4: Made by the same procedure 
as (Sa)-4, using (R)-12. Purification over silica gel chromatography (5% CH2Cl2/Hexanes) 
afforded product (Ra)-4 as a colorless oil (46.9g, 86% yield).     
  = -2.8 (c 7.0, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.55-7.53 (m, 2H), 7.37-7.35 (m, 3H), 4.79-4.73 (m, 1H), 
1.65 (d, J = 2.8 Hz, 3H), 1.62 (d, J = 6.9 Hz, 3H), 0.35 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ207.97, 138.30, 133.81, 128.98, 127.73, 89.09, 79.01, 
15.99, 13.82, -3.15, -3.25; 
IR (neat/cm
-1
) υmax : 3088, 2961, 1934, 1428, 1363, 1248, 1113, 1066, 976, 872, 832, 811, 
778, 699, 660; 
LCMS (ES+) m/z calcd for C13H18Si [M+Na]
 + 
225.11, found 225.12. 
 
Ee analysis of (S)-11 and (R)-11: (S)-11 ,and (R)-11 were run on chiral HPLC using a 
ChiralCel OD-H column, isocratic 1% ispropanol/hexanes at a flow rate of 1mL/min. (S)-
11 was found to have 96% ee (however, we believe within system error, the ee would 






















Asymmetric Three-Component Propargylation 
General procedure for asymmetric three-component propargylation between (Sa)-4, 
(benzyloxy)trimethylsilane, and aldehydes: A solution of allenylsilane (S)-4 (417mg, 2.06 
mmol, 1 equiv), (benzyloxy)trimethylsilane (0.49 mL, 2.47 mmol, 1.2 equiv), and 
aldehyde (2.47 mmol, 1.2 equiv) in 10 mL propionitrile (EtCN) was cooled to -78 
o
C. 
Trimethylsilyl trifluoromethanesulfonate (TMSOTf) (0.19 mL, 1.03 mmol, 0.5 equiv) 
was added to above mixture dropwise. The resulting mixture was placed into -50 
o
C 
chiller and stirred for 24 hours. The reaction was quenched by adding 10 mL DI water. It 




dried over MgSO4, filtered, and concentrated. Purification over silica gel chromatography 
(CH2Cl2/Hexanes) afforded product 5 as an oil. 
((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)benzene (5a): Prepared 
by the general procedure using benzaldehyde, alkyne 5a (407 mg, 75% yield, dr: 3.5:1) 
was obtained as a pale yellow oil.     
  = -2.9 (c 1.9, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.30-7.17 (m, 10H), 4.43 (ABq, J = 12.0 Hz, 1H), 4.18 
(ABq, J = 12.0 Hz, 1H), 4.09 (d, J = 7.2 Hz, 1H), 2.73-2.67 (m, 1H), 1.60 (d, J = 2.4 Hz, 
3H), 1.13 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ136.67, 134.93, 124.78, 124.43, 124.29, 124.24, 124.27, 
123.98, 80.67, 77.24, 74.32, 67.13, 30.28, 14.33, 0.00; 
IR (neat/cm
-1
) υmax : 3086, 3064, 3030, 2970, 2933, 2929, 2888, 1496, 1454, 1071, 1028, 
735, 699; 
LCMS (ES+) m/z calcd for C19H20O [M+Na]
 + 
287.14, found 287.13. 
 
 1-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-3-bromobenzene 
(5b): Prepared by the general procedure using 3-bromobenzaldehyde, alkyne 5b (598 
mg, 85% yield, dr: 3.3:1) was obtained as a pale yellow oil.     





H NMR (500 MHz, CDCl3): δ7.47 (s, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.27-7.13 (m, 9H), 
4.44 (ABq, J = 12.0 Hz, 1H), 4.18 (ABq, J = 12.0 Hz, 1H), 4.03 (d, J = 7.3 Hz, 1H), 
2.68-2.63 (m, 1H), 1.62 (d, J = 2.4 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ139.24, 134.57, 127.41, 127.39, 126.06, 124.91, 124.37, 
124.21, 122.89, 118.73, 80.15, 76.80, 67.46, 30.34, 14.44, 0.00; 
IR (neat/cm
-1
) υmax : 3088, 3065, 3034, 2975, 2917, 2875, 1595, 1570, 1497, 1475, 1454, 
1429, 1203, 1070, 784, 734, 696; 
LCMS(ES+) m/z calcd for C19H19BrO [M+Na]
 +
 365.05, found 365.13. 
 
 1-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-2-bromobenzene 
(5c): Prepared by the general procedure using 3-bromobenzaldehyde, alkyne 5c (570 mg, 
81% yield, dr: 4.0:1) was obtained as a pale yellow oil.     
  = -4.9 (c 1, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.57 (dd, J = 7.8, 1.7 Hz, 1H), 7.54 (dd, J = 8.0, 1.2 Hz, 
1H), 7.37-7.28 (m, 6H), 7.16 (ddd, J = 8.0, 7.3, 1.8 Hz, 1H), 4.80 (d, J = 6.4 Hz, 1H), 
4.47 (ABq, J = 11.9 Hz, 1H), 4.31 (ABq, J = 11.9 Hz, 1H), 2.86-2.79 (m, 1H), 1.72 (d, J 
= 2.4 Hz, 3H), 1.20 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ139.61, 138.16, 132.48, 129.05, 128.92, 128.25, 127.88, 
127.56, 127.39, 124.43, 81.89, 80.41, 77.39, 71.11, 32.71, 16.83, 3.60; 
IR (neat/cm
-1
) υmax : 3088, 3065, 3034, 2975, 2917, 2875, 1595, 1570, 1497, 1475, 1454, 
1429, 1203, 1070, 784, 734, 696; 
LCMS(ES+) m/z calcd for C19H19BrO [M+Na]
 +





(5d): Prepared by the general procedure using 2,5-dimethoxybenzaldehyde, alkyne 5d 
(301 mg, 52% yield, 4.0:1) was obtained as a pale yellow oil.     
  = -3.8 (c 3.2, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.38-7.27 (m, 7H), 7.07-7.04 (m, 2H), 4.50 (ABq, J = 
12.0 Hz, 1H), 4.25 (ABq, J = 12.0 Hz, 1H), 4.14 (d, J = 7.4 Hz, 1H), 2.79-2.72 (m, 1H), 
1.69 (dd, J = 2.4, 0.6 Hz, 3H), 1.22 (dd, J = 6.9, 0.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ163.37, 161.42, 138.16, 135.87, 129.29, 129.23, 128.31, 
127.78, 127.56, 114.87, 114.70, 83.51,80.42, 78.11, 70.60, 33.83, 17.96, 3.44; 
IR (neat/cm
-1
) υmax : 3034, 2972, 2880, 1606, 1454, 1223, 1157, 1074, 835, 737, 698; 
HRMS (ESI) m/z calcd for C19H19FO [M+H]
 + 
283.1498, found 283.1499. 
 
 2-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-1,4-
dimethoxybenzene (5e): Prepared by the general procedure using 2,5-
dimethoxybenzaldehyde, alkyne 5e (521 mg, 78% yield, dr: 3.0:1) was obtained as a pale 
yellow oil.     
  = -0.2 (c 0.9, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.29-7.17 (m, 5H), 7.03 (d, J = 1.7 Hz, 1H), 6.74-6.70 (m, 
2H), 4.75 (d, J = 5.6 Hz, 1H), 4.45 (ABq, J = 12.1 Hz, 1H), 4.26 (ABq, J = 12.1 Hz, 1H), 





C NMR (125 MHz, CDCl3): δ149.97, 148.24, 135.12, 125.94, 124.52, 124.12, 123.69, 
109.89, 109.66, 107.83, 77.82, 73.46, 72.96, 67.38, 52.36, 52.01, 28.53, 12.91, 0.00; 
IR (neat/cm
-1
) υmax : 2937, 2833, 1497, 1454, 1276, 1215, 1048, 1028, 810, 735, 699; 
HRMS (ESI) m/z calcd for C21H24O3 [M+Na]
 + 
347.1623, found 347.1627. 
 
 1-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-2-methylbenzene 
(5f): Prepared by the general procedure using o-tolualdehyde and 1 equivelant TMSOTf, 
alkyne 5f (286 mg, 51% yield, dr: >20:1) was obtained as a colorless oil.     
  = -7.2 (c 
2.5, CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ7.52 (d, J = 7.6 Hz, 1H), 7.40-7.16 (m, 8H), 4.54 (d, J = 
7.6 Hz, 1H), 4.49 (ABq, J = 12.0 Hz, 1H), 4.23 (ABq, J = 12.0 Hz, 1H), 2.82-2.74 (m, 
1H), 2.34 (s, 3H), 1.68 (d, J = 2.4 Hz, 3H), 1.31 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ135.36, 135.06, 133.09, 126.55, 124.78, 124.31, 123.99, 
123.79, 123.41, 122.47, 77.39, 76.43, 73.34, 66.96, 29.87, 16.01, 14.28, 0.00; 
IR (neat/cm
-1
) υmax : 3066, 3029, 2968, 2930, 1495, 1454, 1110, 1064, 757, 726, 697; 
LCMS(ES+) m/z calcd for C20H22O [M+H]
 +






(5g): Prepared by the general procedure using cyclohexanecarbaldehyde, alkyne 5g (479 
mg, 86% yield, dr: >20:1) was obtained as a colorless oil.     
  = -0.5 (c 1.6, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.31-7.17 (m, 5H), 4.66 (ABq, J = 11.0 Hz, 1H), 4.51 
(ABq, J = 11.0 Hz, 1H), 3.06 (dd, J = 11.6, 6 Hz, 1H), 2.62-2.55 (m, 1H), 1.81 (d, J = 
12.7 Hz, 1H), 1.71 (d, J = 2.4 Hz, 3H), 1.67-1.52 (m, 5H), 1.12 (d, J = 6.9 Hz, 3H), 1.21-
1.00 (m, 5H); 
13
C NMR (125 MHz, CDCl3): δ135.45, 124.66, 124.14, 123.80, 83.74, 78.93, 73.03, 
71.64, 37.44, 27.02, 24.96, 24.28, 22.98, 22.95, 22.72, 13.31, 0.00; 
IR (neat/cm
-1
) υmax : 2929, 2852, 1497, 1452, 1110, 1091, 1057, 732, 696; 
HRMS (ESI) m/z calcd for C19H26O [M+H]
 + 
271.2062, found 271.2053. 
 
 ((((3R,4R)-2,4-dimethylhept-5-yn-3-yl)oxy)methyl)benzene (5h): 
Prepared by the general procedure using isobutyraldehyde, alkyne 5h (356 mg, 75% 
yield, dr: >20:1) was obtained as a colorless oil.  α  
  = -2.8 (c 1.2, CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ7.40-7.27 (m, 5H), 4.76 (ABq, J = 11.1 Hz, 1H), 4.63 
(ABq, J = 11.1 Hz, 1H), 3.17-3.14 (m, 1H), 2.68-2.60 (m, 1H), 2.15-2.06 (m, 1H), 1.81-
1.80 (m, 3H), 1.25 – 1.23 (m, 3H), 1.01-0.98 (m, 6H); 
13
C NMR (100 MHz, CDCl3): δ135.39, 124.69, 124.14, 123.85, 84.35, 78.67, 73.19, 






) υmax : 2966, 2874, 1454, 1135, 1094, 1068, 969, 733, 696; 
HRMS (ESI) m/z calcd for C16H22O [M+H]
 + 
231.1749, found 231.1745. 
 
 ((((4R,5R)-2,5-dimethyloct-6-yn-4-yl)oxy)methyl)benzene (5i): 
Prepared by the general procedure using isovaleraldehyde, alkyne 5i (332 mg, 66% yield, 
dr: 3.0:1) was obtained as a colorless oil.  α  
  = -3.1 (c 0.9, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.38-7.28 (m, 5H), 4.70 (ABq, J = 11.4 Hz, 1H), 4.52 
(ABq, J = 11.4 Hz, 1H), 3.38 (ddd, J = 8.6, 5.0, 3.2 Hz, 1H), 2.77-2.70 (m, 1H), 1.88-
1.76 (m, 1H), 1.81 (d, J = 2.4 Hz, 3H), 1.66 (ddd, J = 13.9, 9.3, 4.4 Hz, 1H), 1.31 (ddd, J 
= 14.2, 9.5, 3.2 Hz, 1H), 1.17 (d, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ138.75, 128.28, 127.97, 127.88, 127.49, 81.32, 80.23, 
76.99, 71.87, 41.09, 30.16, 24.43, 23.84, 21.91, 17.31, 3.64; 
IR (neat/cm
-1
) υmax : 2956, 2933, 2920, 2869, 1497, 1454, 1368, 1349, 1098, 734, 697; 
HRMS (ESI) m/z calcd for C17H24O [M+H]
 + 
245.1905, found 245.1900. 
 
 ((((4R,5R)-4-methylnon-2-yn-5-yl)oxy)methyl)benzene (5j): Prepared 
by the general procedure using pentanal, alkyne 5j (327 mg, 65% yield, dr: 2.0:1) was 
obtained as a colorless oil.  α  





H NMR (400 MHz, CDCl3): δ7.38-7.26 (m, 5H), 4.63 (ABq, J = 11.5 Hz, 1H), 4.55 
(ABq, J = 11.5 Hz, 1H), 3.31-3.26 (m, 1H), 2.72-2.64 (m, 1H), 1.81 (d, J = 2.4 Hz, 3H), 
1.72-1.62 (m, 2H), 1.37-1.27 (m, 4H), 1.19 (d, J = 7.0 Hz, 2H), 0.91 (t, J = 7.1 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ135.14, 124.66, 124.29, 123.86, 78.66, 77.76, 73.28, 
68.39, 27.71, 26.52, 23.86, 19.23, 13.96, 10.48, 0.00; 
IR (neat/cm
-1
) υmax : 2957, 2933, 2858, 1497, 1454, 1375, 1347, 1302, 1205, 1096, 734, 
697; 
HRMS (ESI) m/z calcd for C17H24O [M+H]
 + 
245.1905, found 245.1911. 
 
Supplementary Table S2: Titanocyclopropene Complex Generation Optimization 
 
 The efficient generation of titanocyclopropene complex is crucial to the success 
of alkyne-alkyne reductive coupling. Reaction condition evaluation (Table S2) identified 




isolated yield, when the reaction was conducted at -50 
o
C for 4 hours. Upon hydrolytic 
quench, (Z)-alkene was cleanly formed. 
 
Supplementary Table S3: Optimization for Alkyne-Alkyne Reductive Coupling 
between 5b and Methyl Propiolate 
 
 The initial trial employed Micalizio’s condition for non-directed alkyne-alkyne 
reductive coupling (Table S3, entry 6), which resulted in significant decomposition. A 
screen of temperature, stoichiometry of methyl propiolate, and reaction time identified -
50 
o








Alkyne-Alkyne Reductive Coupling 
General procedure for alkyne-alkyne reductive coupling between internal alkyne 5 and 
acetylenic esters: To a solution of internal alkyne 5 (0.14mmol, 1 equiv) in Et2O (2.4 mL) 
at -78 
o
C was added sequentially ClTi(OiPr)3 (1.0 M in hexanes, 0.28 mL, 0.28 mmol, 2 
equiv) and c-C5H9MgCl (2.0 M in Et2O, 0.28 mL, 0.56 mmol, 4 equiv) dropwise. The 
resulting yellow solution turned brown while warming slowly to -50 
o
C over 45 min. The 
reaction mixture was placed in -50 
o
C chiller and stirred for 4 hours, while solution 
turned to be black and heterogenous. It was then cooled to -78 
o
C, to which acetylenic 
ester (0.11 mmol, 0.8 equiv) was added dropwise. The resulting mixture was again 
warmed to -50 
o
C over 45 min, which was subsequently placed into -50 
o
C chiller and 
stirred for 12 hours. The reaction was quenched with saturated aqueous NH4Cl solution 
(3 mL). The mixture was warmed to r.t. before extractive isolation with diethyl ether (3 x 
3 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated. 
Purification over silica gel chromatography (EtOAc/Hexanes, or CH2Cl2/Hexanes) 
afforded coupled product 6. 
 Methyl (2E,4E,6R,7S)-7-(benzyloxy)-4,6-dimethyl-7-
phenylhepta-2,4-dienoate 6a: Prepared by the general procedure using internal alkyne 
5a, diene 6a (17 mg, 45%) was obtained as a pale yellow oil in a 3:1.2:1 mixture of 
regioisomers.  α  
  = +2.8 (c 0.4, CH2Cl2); 
1
H NMR (500 MHz, C6D6): δ7.41 (d, J = 15.7 Hz, 1H), 7.23-6.99 (m, 10H), 5.73 (d, J = 




1H), 3.87 (d, J = 7.2 Hz, 1H), 3.40 (s, 3H), 2.79-2.71 (m, 1H), 1.19 (d, J = 1.2 Hz, 3H), 
1.02 (d, J = 6.6 Hz, 3H); 
13
C NMR (125 MHz, C6D6): δ166.97, 149.25, 143.11, 140.51, 138.68, 132.69, 128.17, 
128.00, 127.50, 127.34, 127.22, 115.98, 84.29, 70.36, 50.60, 40.68, 16.34, 11.67; 
IR (neat/cm
-1
) υmax : 3032, 2951, 2869, 1720, 1625, 1494, 1454, 1313, 1275, 1171, 1069, 
761, 700; 
HRMS (ESI) m/z calcd for C23H26O 3[M+Na]
 + 
373.1780, found 373.1770. 
 
 Methyl (2E,4E,6R,7S)-7-(benzyloxy)-7-(3-bromophenyl)-
4,6-dimethylhepta-2,4-dienoate (6b): Prepared by the general procedure using internal 
alkyne 5b, diene 6b (22 mg, 46%) was obtained as a pale yellow oil in a 2.2:0:1 mixture 
of regioisomers.  α  
  = +0.3 (c 0.5, CH2Cl2); 
1
H NMR (500 MHz, C6D6): δ7.40-7.37 (m, 2H), 7.19-7.04 (m, 8H), 5.74 (d, J = 15.7 Hz, 
1H), 5.26 (d, J = 10.0 Hz, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.91 (d, J = 12.0 Hz, 1H), 3.70 
(d, J = 7.1 Hz, 1H), 3.40 (s, 3H), 2.62-2.55 (m, 1H), 1.13 (s, 3H), 0.93 (d, J = 6.6 Hz, 3H),  
13
C NMR (125 MHz, C6D6): δ166.92, 148.97, 143.24, 142.30, 138.21, 132.92, 130.54, 
130.21, 129.56, 128.22, 127.94, 127.58, 125.76, 122.45, 116.28, 83.42, 70.58, 50.62, 
40.47, 16.07, 11.64; 
IR (neat/cm
-1
) υmax : 3065, 3028, 2949, 2927, 2871, 1719, 1625, 1571, 1454, 1433, 1311, 
1270, 1192, 1171, 1070, 846, 785, 736, 699; 
HRMS (ESI) m/z calcd for C23H25BrO 3[M+H]
 + 





tolyl)hepta-2,4-dienoate (6c): Prepared by the general procedure using internal alkyne 
5c, diene 6c (18 mg, 46%) was obtained as a pale yellow oil in a 4.7:1.7:1 mixture of 
regioisomers.  α  
  = +0.75 (c 0.7, CH2Cl2); 
1
H NMR (500 MHz, C6D6): δ7.43 (dd, J = 15.65, 0.75 Hz, 1H), 7.41 (dd, J = 7.6, 1.3 Hz), 
7.18-7.14 (m, 2H), 7.08-6.95 (m, 4H), 6.88-6.87 (m, 1H), 5.74 (dd, J = 15.7, 0.6 Hz, 1H), 
4.32 (d, J = 11.9 Hz, 1H), 4.20 (d, J = 7.0 Hz, 1H), 3.96 (d, J = 12.0 Hz, 1H), 3.40 (s, 3H), 
2.80-2.73 (m, 1H), 1.96 (s, 3H), 1.15 (d, J = 1.2 Hz, 3H), 1.08 (dd, J = 6.8, 1.0 Hz, 3H); 
13
C NMR (125 MHz, C6D6): δ166.92, 149.18, 143.16, 138.69, 135.60, 132.31, 130.26, 




) υmax : 2947, 1718, 1622, 1454, 1311, 1170, 1067; 
HRMS (ESI) m/z calcd for C24H28O 3[M+Na]
 + 
387.1936, found 387.1921. 
 
 Methyl (2E,4E,6R,7S)-7-(benzyloxy)-7-(2-bromophenyl)-4,6-
dimethylhepta-2,4-dienoate (6d): Prepared by the general procedure using internal 
alkyne 5d, diene 6d (22 mg, 46%) was obtained as a pale yellow oil in a 4.7:1.7:1 
mixture of regioisomers.  α  





H NMR (500 MHz, C6D6): δ7.53 (d, J = 16.3 Hz, 1H), 7.38 (d, J = 9.4 Hz, 1H), 7.24 (dd, 
J = 8.0, 1.2 Hz, 1H), 7.17-7.11 (m, 4H), 7.07-7.03 (m, 1H), 6.89 (td, J = 7.4, 0.9 Hz, 1H), 
5.84 (d, J = 10 Hz, 1H), 5.82 (d, J = 15.6 Hz, 1H), 4.65 (d, J = 5.6 Hz, 1H), 4.20 (ABq, J 
= 11.8 Hz, 1H), 3.95 (ABq, J = 11.8 Hz, 1H), 3.41 (s, 3H), 2.89-2.82 (m, 1H), 1.35 – 
1.33 (m, 3H), 0.98 (d, J = 6.7 Hz, 3H); 
13
C NMR (125 MHz, C6D6): δ166.87, 149.27, 142.97, 139.87, 138.18, 132.61, 128.75, 




) υmax : 3064, 3032, 2949, 2872, 1720, 1624, 1436, 1311, 1270, 1170, 1027, 
983, 849, 756, 699; 
HRMS (ESI) m/z calcd for C23H25BrO 3[M+H]
 + 
429.1065, found 429.1062. 
 
Methyl (2E,4E,6R,7S)-7-(benzyloxy)-7-(4-fluorophenyl)-4,6-
dimethylhepta-2,4-dienoate (6e): Prepared by the general procedure using internal 
alkyne 5e, diene 6e (20 mg, 50%) was obtained as a pale yellow oil in a 10:1:0 mixture of 
regioisomers.  α  
  = +2.8 (c 0.7, CH2Cl2); 
1
H NMR (500 MHz, C6D6): δ7.41 (dd, J = 15.7, 0.7 Hz, 1H), 7.18-7.13 (m, 4H), 7.09-
7.06 (m, 1H), 6.86-6.82 (m, 2H), 6.74-6.68 (m, 2H), 5.75 (dd, J = 15.7, 0.5 Hz, 1H), 4.26 
(ABq, J = 12.0 Hz, 1H), 3.95 (ABq, J = 12.0 Hz, 1H), 3.75 (d, J = 7.4 Hz, 1H), 3.41 (s, 





C NMR (125 MHz, C6D6): δ166.95, 163.22, 161.27, 149.05, 142.58, 138.45, 136.17, 
136.14, 132.81, 128.78, 128.72, 128.21, 127.50, 116.20, 114.90, 114.73, 83.56, 70.32, 
50.62, 40.62, 16.35, 11.66; 
IR (neat/cm
-1
) υmax : 3063, 3032, 2951, 2867, 1719, 1622, 1605, 1508, 1454, 1434, 1312, 
1274, 1221, 1193, 1169, 1071, 1015, 983, 833, 736, 698; 
HRMS (ESI) m/z calcd for C23H25FO 3[M+H]
 +
369.1866, found 369.1855. 
 
 Methyl (2E,4E,6R,7R)-7-(benzyloxy)-4,6-dimethylundeca-
2,4-dienoate (6f): Prepared by the general procedure using internal alkyne 5f, diene 6f 
(17 mg, 49%) was obtained as a colorless oil in a 10.5:1:2.5 mixture of regioisomers. 
 α  
  = +1.6 (c 0.3, CH2Cl2); 
1
H NMR (500 MHz, C6D6): δ7.53 (dd, J = 15.7, 0.8 Hz, 1H), 7.28-7.24 (m, 2H), 7.17-
7.13 (m, 2H), 7.09-7.06 (m, 1H), 5.87 (dd, J = 15.7, 0.6 Hz, 1H), 5.50-5.48 (m, 1H), 4.34 
(ABq, J = 11.6 Hz, 1H), 4.26 (ABq, J = 11.6 Hz, 1H), 3.45 (s, 3H), 3.00-2.97 (m, 1H), 
2.63-2.55 (m, 1H), 1.46 (s, 3H), 0.91 (d, J = 6.8 Hz, 3H), 0.82 (t, J = 7.2 Hz, 3H); 
13
C NMR (125 MHz, C6D6): δ167.02, 149.48, 144.33, 139.14, 131.98, 128.14, 127.40, 
127.26, 115.95, 82.58, 71.73, 50.63, 36.91, 31.22, 27.44, 22.87, 15.91, 13.91, 11.92; 
IR (neat/cm
-1
) υmax : 2956, 2935, 2873, 1720, 1625, 1255, 1435, 1312, 1272, 1170, 1069, 
984, 848, 736, 699; 
HRMS (ESI) m/z calcd for C21H30O 3[M+H]
 +





dienoate (6g): Prepared by the general procedure using internal alkyne 5g, diene 6g (15 
mg, 43%) was obtained as a colorless oil in a 4.6:1:0 mixture of regioisomers.  α  
  = 
+1.3 (c 0.3, CH2Cl2); 
1
H NMR (400 MHz, C6D6): δ7.15 (d, J = 15.7 Hz, 1H), 6.87 (d, J = 7.0 Hz, 2H), 6.88-
6.65 (m, 3H), 5.49 (d, J = 15.7 Hz, 1H), 5.16 (d, J = 10.0 Hz, 1H), 3.90 (d, J = 2.0 Hz, 
2H), 3.05 (s, 3H), 2.77-2.72 (m, 1H), 2.25-2.15 (m, 1H), 1.35-1.25 (m, 1H), 1.07 (d, J = 
1.2 Hz, 3H), 1.02-0.99 (m, 1H), 0.74-0.68 (m, 1H), 0.48 (d, J = 6.8 Hz, 3H), 0.41 (d, J = 
6.7 Hz, 3H), 0.39 (d, J = 6.6 Hz, 3H); 
13
C NMR (100 MHz, C6D6): δ167.05, 149.50, 144.32, 139.07, 132.19, 128.15, 127.54, 
127.28, 115.96, 80.96, 71.65, 50.66, 40.96, 36.87, 24.61, 23.41, 22.05, 15.69, 11.99; 
IR (neat/cm
-1
) υmax : 2956, 2870, 1721, 1625, 1454, 1435, 1311, 1273, 1169, 1094, 1028, 
983, 848, 736, 698; 
HRMS (ESI) m/z calcd for C21H30O 3[M+H]
 +
331.2273, found 331.2273. 
 
 Methyl (2E,4E,6R,7R)-7-(benzyloxy)-4,6,8-trimethylnona-2,4-
dienoate (6h): Prepared by the general procedure using internal alkyne 5h, diene 6h (24 
mg, 62%) was obtained as a colorless oil in a 20:0:0 mixture of regioisomers.  α  
  = +2.1 





H NMR (500 MHz, C6D6): δ7.51 (dd, J = 15.7, 0.7 Hz, 1H), 7.29 (dd, J = 7.9, 1.0 Hz, 
2H), 7.18-7.15 (m, 2H), 7.10-7.07 (m, 1H), 5.88 (d, J = 15.3 Hz, 1H), 5.40 (d, J = 10.1 
Hz, 2H), 4.37 (ABq, J = 11.4 Hz, 1H), 4.34 (ABq, J = 11.4 Hz, 1H), 3.46 (s, 3H), 2.70 
(dd, J = 7.2, 4.2 Hz, 1H), 2.65-2.57 (m, 1H), 1.62-1.56 (m, 1H), 1.44 (d, J = 1.2 Hz, 1H), 
0.92 (d, J = 6.6 Hz, 3H), 0.85 (d, J = 5.9 Hz, 3H), 0.84 (d, J = 6.0 Hz, 3H); 
13
C NMR (125 MHz, C6D6): δ167.04, 149.47, 144.82, 139.17, 131.30, 128.15, 127.93, 
127.26, 115.96, 88.06, 75.25, 50.66, 36.73, 31.34, 20.26, 16.70, 16.13, 11.75; 
IR (neat/cm
-1
) υmax : 2965, 2871, 1720, 1623, 1497, 1454, 1434, 1311, 1270, 1169, 1067, 
1028, 985, 848, 734, 697; 
HRMS (ESI) m/z calcd for C20H28O 3[M+H]
 +
317.2117, found 317.2111. 
 
 Methyl (2E,4E,6R,7R)-7-(benzyloxy)-7-cyclohexyl-4,6-
dimethylhepta-2,4-dienoate (6i): Prepared by the general procedure using internal 
alkyne 5i, diene 6i (26 mg, 67%) was obtained as a colorless oil in a 20:0:0 mixture of 
regioisomers.  α  
  = +0.45 (c 0.3, CH2Cl2); 
1
H NMR (500 MHz, C6D6): δ7.52 (dd, J = 15.7, 0.6 Hz, 1H), 7.31-7.29 (m, 2H), 7.18-
7.15 (m, 2H), 7.10-7.07 (m, 1H), 5.89 (d, J = 15.6 Hz, 1H), 5.51 (d, J = 9.9 Hz, 1H), 4.39 
(ABq, J = 11.4 Hz, 1H), 4.34 (ABq, J = 11.4 Hz, 1H), 3.45 (s, 3H), 2.75 (dd, J = 6.4, 4.9 
Hz, 1H), 2.71-2.64 (m, 1H), 1.78-1.47 (m, 5H), 1.47 (d, J = 1.2 Hz, 3H), 1.40-1.33 (m, 





C NMR (125 MHz, C6D6): δ167.00, 149.44, 145.21, 139.20, 131.30, 128.16, 127.23, 
115.98, 87.72, 75.23, 50.65, 41.56, 35.91, 30.72, 27.75, 26.51, 26.30, 15.63, 11.81; 
IR (neat/cm
-1
) υmax : 2929, 2855, 1743, 1721, 1624, 1451, 1312, 1269, 1170, 1110, 984, 
737, 700; 
HRMS (ESI) m/z calcd for C23H32O 3[M+H]
 +
357.2430, found 357.2440. 
 
 Ethyl (2E,4E,6R,7S)-7-(benzyloxy)-7-(3-bromophenyl)-4,6-
dimethylhepta-2,4-dienoate (6j): Prepared by the general procedure using internal 
alkyne 5b, diene 6j (21 mg, 44%) was obtained as a pale yellow oil in a 5:0:1 mixture of 
regioisomers.  α  
  = +2.2 (c 0.4, CH2Cl2); 
1
H NMR (500 MHz, C6D6): δ7.42 (dd, J = 15.7, 0.6 Hz, 1H), 7.39 (t, J = 1.8 Hz, 1H), 
7.17-7.04 (m, 6H), 6.82 (d, J = 7.7 Hz, 1H), 6.66 (t, J = 7.8 Hz, 1H), 5.77 (d, J = 15.4 Hz, 
1H), 5.26 (d, J = 10.0 Hz, 1H), 4.03 (qd, J = 7.1, 2.4 Hz, 2H), 3.91 (d, J = 12.0 Hz, 1H), 
3.70 (d, J = 7.2 Hz, 1H), 2.63-2.56 (m, 1H), 1.14 (d, J = 1.2 Hz, 3H), 0.96 (t, J = 7.1 Hz, 
3H), 0.93 (d, J = 6.6 Hz, 3H); 
13
C NMR (125 MHz, C6D6): δ166.61, 148.82, 143.35, 142.21, 138.32, 133.05, 130.62, 
130.28, 129.64, 128.31, 128.03, 127.67, 125.88, 122.54, 116.87, 83.53, 70.66, 59.76, 
40.58, 16.20, 14.09, 11.77; 
IR (neat/cm
-1
) υmax : 2978, 2866, 1713, 1625, 1455, 1367, 1308, 1268, 1176, 1115, 1070, 
982, 786, 698; 
HRMS (ESI) m/z calcd for C24H27BrO 3 [M+H]
 +





bromophenyl)-4,6-dimethylhepta-2,4-dienoate (6k): Prepared by the general 
procedure using internal alkyne 5b, diene 6k (28 mg, 54%) was obtained as a pale yellow 
oil in a 20:0:0 mixture of regioisomers.  α  
  = +1.8 (c 1.0, CH2Cl2); 
1
H NMR (500 MHz, C6D6): δ7.40-7.37 (m, 2H), 7.13-7.03 (m, 6H), 6.80 (d, J = 7.7 Hz, 
1H), 6.65 (t, J = 7.8 Hz, 1H), 5.76 (d, J = 15.3 Hz, 1H), 5.25 (d, J = 10.1 Hz, 1H), 4.24 
(ABq, J = 12.0 Hz, 1H), 3.90 (ABq, J = 12.0 Hz, 1H), 3.69 (d, J = 7.2 Hz, 1H), 2.64-2.56 
(m, 1H), 1.40 (s, 9H), 1.15 (d, J = 1.2 Hz, 3H), 0.93 (d, J = 6.6 Hz, 1H); 
13
C NMR (125 MHz, C6D6): δ166.03, 147.90, 143.30, 141.56, 138.26, 132.97, 130.51, 




) υmax : 2994, 1709, 1624, 1455, 1392, 1368, 1314, 1152, 1068, 983, 700; 
HRMS (ESI) m/z calcd for C26H31BrO 3[M+Na]
 +
493.1354, found 493.1367. 
 
Total Synthesis of ent-NFAT-68 and NFAT-68 
a) Total Synthesis of ent-NFAT-68 
 
1-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-2,5-dimethoxy-3-nitrobenzene (8): 




mmol, 1.08 equiv), and (benzyloxy)trimethylsilane (6.4 mL, 32.7 mmol, 1.1 equiv) in 
propionitrile (300 mL, c=0.1) at -78 
o
C was added trimethylsilyl 
trifluoromethanesulfonate (2.6 mL, 14.2 mmol, 0.5 equiv) dropwise. The resulting 
reaction mixture was stirred at -60 
o
C for 24 hours. The reaction was quenched with 50 
mL saturated NaHCO3 aqueous solution. It was then extract with ethyl acetate (3 x 300 
mL), and the combined organic layers were dried over MgSO4, filtered, and concentrated. 
Purification over silica gel chromatography (60% CH2Cl2/Hexanes) afforded product 8 (8 
g, 76% yield, dr: 5:1) as a yellow oil.  α  
  = -3.9 (c 2.9, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.35-7.28 (m, 7H), 4.69 (d, J = 7.3 Hz, 1H), 4.46 (ABq, J 
= 11.9 Hz, 1H), 4.35 (ABq, J = 11.9 Hz, 1H), 3.84 (s, 3H), 3.80 (s, 3H), 2.90-2.83 (m, 
1H), 1.68 (d, J = 2.4 Hz, 3H), 1.23 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ155.16, 145.81, 143.51, 138.17, 137.79, 128.34, 127.76, 
127.74, 118.99, 109.64, 80.29, 78.18, 77.08, 71.20, 63.07, 55.95, 32.89, 17.75, 3.51; 
IR (neat/cm
-1
) υmax : 2942, 2918, 1532, 1482, 1454, 1429, 1348, 1307, 1227, 1051, 996, 
737, 699; 
HRMS (ESI) m/z calcd for C21H23NO5[M+Na]
 +
392.1474, found 392.1464. 
 
Ee analysis of 8: Racemic propargylation product and 8 were run on chiral HPLC using a 
ChiralCel AD-H column, isocratic 1% ispropanol/hexanes at a flow rate of 1mL/min. 8 











3-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-2,5-dimethoxyaniline (8a): Sulfur 
powder (3.2 g, 100 mmol, 4.6 equiv) and sodium borohydride (1.28 g, 33.7 mmol, 1.56 
equiv) were suspended in 460 mL THF and stirred for 30 min, giving a yellow, 




mixture was heated at 70 
o
C for 4 hours until the complete consumption of 8 indicated by 
TLC. The reaction was cooled to room temperature and quenched with 160mL 8% (w/v) 
NaOH aqueous solution. It was then extract with ethyl acetate (3 x 400 mL), and the 
combined organic layers were dried over MgSO4, filtered, and concentrated. Purification 
over silica gel chromatography (24% EtOAc/Hexanes) afforded 8a (6.29 g, 82%) as a 
brown oil.  α  
  = -3.9 (c 2.5, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.41-7.24 (m, 5H), 6.45 (d, J = 3.0 Hz, 1H), 6.28 (d, J = 
3.0 Hz, 1H), 4.62 (d, J = 7.0 Hz, 1H), 4.49 (ABq, J = 12.0 Hz, 1H), 4.33 (ABq, J = 12.0 
Hz, 1H), 3.78 (s, 2H), 3.75 (d, J = 1.7 Hz, 3H), 3.68 (s, 3H), 2.92-2.86 (m, 1H), 1.70 (d, J 
= 2.4 Hz, 3H), 1.24 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ156.41, 140.43, 140.18, 138.63, 133.95, 128.20, 127.72, 
127.38, 101.65, 81.41, 77.86, 77.15, 70.64, 60.13, 55.35, 32.56, 17.59, 3.64; 
IR (neat/cm
-1
) υmax : 3459, 3365, 2937, 2836, 1615, 1495, 1453, 1350, 1240, 1197, 1170, 
1045, 1000, 837, 738, 699; 
HRMS (ESI) m/z calcd for C21H25NO3[M+H]
 +




dimethoxyphenyl)acetamide (9): To a solution of 8a (6.29 g, 18.54 mmol, 1 equiv), 




equiv) in CH2Cl2 (463 mL) at 0 
o
C was added triethylamine (8.95 mL, 55.62 mmol, 3 
equiv) dropwise. The resulting mixture was stirred for 12 hours, gradually warming to 
room temperature. The reaction was quenched with 400 mL DI water. It was then extract 
with CH2Cl2 (3 x 200 mL), and the combined organic layers were dried over MgSO4, 
filtered, and concentrated. Purification over silica gel chromatography (38% 
EtOAc/Hexanes) afforded 9 (6.99 g, 99% yield) as a viscous, brown oil (became solid 
after stored at 4 
o
C for several days).  α  
  = -16 (c 1.6, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.94 (d, J = 3.0 Hz, 1H), 7.64 (s, 1H), 7.34-7.24 (m, 5H), 
6.76 (d, J = 3.0 Hz, 1H), 4.55 (d, J = 7.4 Hz, 1H), 4.45 (ABq, J = 12.0 Hz, 1H), 4.30 
(ABq, J = 12.0 Hz, 1H), 3.80 (s, 3H), 3.68 (s, 3H), 2.94-2.88 (m, 1H), 2.23 (s, 3H), 1.67 
(d, J = 2.4 Hz, 3H), 1.24 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ168.25, 156.24, 141.35, 138.25, 133.53, 131.63, 128.38, 
128.26, 127.99, 127.78, 127.71, 127.52, 108.11, 105.98, 80.97, 77.79, 77.55, 70.63, 61.66, 
55.59, 32.47, 24.96, 17.81, 3.58; 
IR (neat/cm
-1
) υmax : 3303, 2941, 1674, 1597, 1525, 1462, 1419, 1348, 1244, 1210, 1150, 
1052, 997, 856, 737, 699; 
HRMS (ESI) m/z calcd for C23H27NO4[M+Na]
 +







dimethylhepta-2,4-dienoate (10): To a solution of 9 (100 mg, 0.262 mmol, 1 equiv) in 
toluene (8 mL) at -78 
o
C was added sequentially ClTi(OiPr)3 (1.0 M in hexanes, 0.61 mL, 
0.61 mmol, 2.3 equiv) and c-C5H9MgCl (2.0 M in Et2O, 0.77 mL, 1.68 mmol, 6.4 equiv) 
dropwise. The resulting yellow solution turned dark brown while warming slowly to -40 
o
C over 50 min. The reaction mixture was placed in -40 
o
C chiller and stirred for 5 hours, 
while solution turned to be black and heterogenous. It was then cooled to -78 
o
C, to 
which methyl propiolate (48 μL, 0.55 mmol, 2.1 equiv) was added dropwise. The 
resulting mixture was warmed to room temperature over 2 hours and stirred for another 2 
hours at room temperature. The reaction was quenched with saturated aqueous NH4Cl (8 
mL) solution. It was then extract with EtOAc (3 x 10 mL), and the combined organic 
layers were dried over MgSO4, filtered, and concentrated. Purification over silica gel 
chromatography (16% EtOAc/CH2Cl2, then 15% acetone/Hexanes) afforded 10 (54 mg, 
45%) as a colorless, viscous oil and single regioisomer.  α  
  = -1.7 (c 3.3, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.87 (d, J = 3.1 Hz, 1H), 7.57 (s, 1H), 7.34-7.27 (m, 5H), 
6.72 (d, J = 3.0 Hz, 1H), 5.79 (d, J = 9.9 Hz, 1H), 5.71 (d, J = 15.6 Hz, 1H), 4.52 (d, J = 
11.8 Hz, 1H), 4.28 (d, J = 11.8 Hz, 1H), 3.78 (s, 3H), 3.73 (s, 3H), 3.61 (s, 3H), 2.94-2.87 
(m, 1H), 2.21 (s, 3H), 1.57 (d, J = 1.2 Hz, 3H), 1.11 (d, J = 6.7 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ168.28, 168.00, 156.31, 149.88, 143.93, 140.85, 138.10, 
133.78, 132.34, 131.85, 128.35, 128.31, 127.62, 115.50, 107.84, 105.65, 78.51, 70.92, 
61.19, 55.63, 51.44, 40.08, 24.92, 16.13, 12.06; 
IR (neat/cm
-1




HRMS (ESI) m/z calcd for C27H33NO6[M+Na]
 +




dimethylhepta-2,4-dienoate (ent-NFAT-68): To a solution of aluminium chloride (114 
mg, 0.86 mmol, 20 equiv) in dichloromethane (3 mL) at 0 
o
C was added 10 (20 mg, 0.043 
mmol, 1 equiv) in dichloromethane (1.4 mL) and tert-butylthiol (1.65 mL, 14.55 mmol, 
340 equiv) sequentially. The resulting solution was stirred at 0 
o
C for 30 min. The 
reaction was quenched with 6 mL aqueous NaH2PO4. It was then extract with EtOAc (3 x 
4 mL), and the combined organic layers were dried over MgSO4, filtered, and 
concentrated. Purification over silica gel chromatography (60% EtOAc/CH2Cl2) afforded 
ent-NFAT-68 (6 mg, 41%) as a colorless, viscous oil.  α  
  = +11.3 (c 0.3, CHCl3); 
1
H NMR (500 MHz, CD3OD): δ7.24 (dd, J = 15.7, 0.6 Hz, 1H), 6.79 (d, J = 2.9 Hz, 1H), 
6.57 (d, J = 2.7 Hz, 1H), 5.86 (d, J = 10.0 Hz, 1H), 5.74 (d, J = 15.4 Hz, 1H), 4.79 (d, J = 
6.3 Hz, 1H), 3.70 (s, 3H), 3.01 (dq, J = 10.0, 6.6 Hz, 1H), 2.16 (s, 3H), 1.66 (d, J = 1.2 
Hz, 3H), 1.06 (d, J = 6.6 Hz, 3H); 
13
C NMR (125 MHz, CD3OD): δ171.08, 168.26, 150.04, 149.55, 144.85, 138.97, 132.26, 
131.99, 126.39, 114.71, 111.11, 107.92, 73.55, 50.49, 39.42, 21.78, 14.42, 10.92; 
IR (neat/cm
-1





HRMS (ESI) m/z calcd for C18H23NO6[M+H]
 +
350.1604, found 350.1602. 
 
b)  Total Synthesis of NFAT-68 
 1-((1R,2S)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-2,5-dimethoxy-
3-nitrobenzene (ent-8): Prepared by the same procedure as 8. Purification over silica gel 
chromatography (50% CH2Cl2/Hexanes) afforded product ent-8 (8 g, 75% yield, dr: 5:1) 
as a yellow oil.  α  
  = +4.7 (c 1.4, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.36-7.26 (m, 7H), 4.70 (d, J = 7.3 Hz, 1H), 4.47 (ABq, J 
= 11.9 Hz, 1H), 4.36 (ABq, J = 11.9 Hz, 1H), 3.84 (s, 3H), 3.81 (s, 3H), 2.91-2.84 (m, 
1H), 1.68 (d, J = 2.4 Hz, 3H), 1.24 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ151.64, 142.29, 139.97, 134.62, 134.25, 124.83, 124.25, 
124.22, 115.47, 106.11, 76.77, 74.67, 73.51, 67.65, 59.57, 52.42, 29.37, 14.23, 0.00; 
IR (neat/cm
-1
) υmax : 2937, 2836, 1533, 1483, 1455, 1429, 1351, 1307, 1229, 1051, 998, 
737, 699; 
HRMS (ESI) m/z calcd for C21H23NO5[M+Na]
 +
392.1474, found 392.1467. 
 
Ee analysis of ent-8: Racemic propargylation product and ent-8 were run on chiral 
HPLC using a ChiralCel AD-H column, isocratic 1% ispropanol/hexanes at a flow rate of 













dimethoxyaniline (ent-8a): Prepared by the same procedure as 8a. Purification over 
silica gel chromatography (24% EtOAc/Hexanes) afforded product ent-8a (6.13 g, 80%)) 
as a viscous, brown oil.  α  
  = +3.7 (c 2.7, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.35-7.24 (m, 5H), 6.48 (d, J = 3.0 Hz, 1H), 6.32 (d, J = 
3.0 Hz, 1H), 4.62 (d, J = 7.1 Hz, 1H), 4.49 (ABq, J = 12.0 Hz, 1H), 4.34 (ABq, J = 12.0 
Hz, 1H), 3.75 (s, 3H), 3.69 (s, 3H), 2.93-2.86 (m, 1H), 1.70 (dd, J = 2.4, 0.5 Hz, 3H), 
1.24 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ156.40, 140.67, 139.45, 138.60, 134.07, 128.19, 127.71, 
127.38, 102.23, 102.01, 81.37, 77.87, 77.17, 70.67, 60.28, 55.37, 32.56, 17.58, 3.18; 
IR (neat/cm
-1
) υmax : 3457, 3367, 2938, 1614, 1495, 1454, 1349, 1240, 1197, 1170, 1045, 
1001, 838, 736, 698; 
HRMS (ESI) m/z calcd for C21H25NO3[M+H]
 +
340.1913, found 340.1904. 
 
 N-(3-((1R,2S)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-2,5-
dimethoxyphenyl)acetamide (ent-9): Prepared by the same procedure as 9. Purification 
over silica gel chromatography (38% EtOAc/Hexanes) afforded product ent-9 (6.87 g, 99% 
yield) as a viscous, brown oil (became solid after stored at 4 
o
C for several days).  α  
  = 





H NMR (500 MHz, CDCl3): 7.93 (d, J = 2.9 Hz, 1H), 7.67 (s, 1H), δ7.36-7.24 (m, 5H), 
6.76 (d, J = 3.0 Hz, 1H), 4.56 (d, J = 7.4 Hz, 1H), 4.45 (ABq, J = 12.0 Hz, 1H), 4.30 
(ABq, J = 12.0 Hz, 1H), 3.79 (s, 3H), 3.68 (s, 3H), 2.94-2.87 (m, 1H), 2.22 (s, 3H), 1.66 
(d, J = 2.4 Hz, 3H), 1.24 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ168.27, 156.24, 141.38, 138.26, 133.54, 131.63, 128.24, 




) υmax : 3278, 2939, 1675, 1595, 1524, 1463, 1419, 1348, 1244, 1209, 1150, 
1053, 997, 856, 737, 698; 
HRMS (ESI) m/z calcd for C23H27NO4[M+Na]
 +
404.1838, found 404.1836. 
 
Methyl (2E,4E,6S,7R)-7-(3-acetamido-2,5-
dimethoxyphenyl)-7-(benzyloxy)-4,6-dimethylhepta-2,4-dienoate (ent-10): Prepared 
by the same procedure as 10. Purification over silica gel chromatography (16% 
EtOAc/CH2Cl2, then 15% acetone/Hexanes) afforded product ent-10 (53 mg, 44% yield) 
as a viscous, colorless oil and single regioisomer.  α  
  = -1.7 (c 3.3, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.87 (d, J = 3.1 Hz, 1H), 7.56 (s, 1H), 7.25-7.28 (m, 5H), 
7.22 (d, J = 15.7 Hz, 1H), 5.79 (d, J = 9.9 Hz, 1H), 5.71 (d, J = 15.7 Hz, 1H), 4.52 (ABq, 




3.73 (s, 3H), 3.61 (s, 3H), 2.94-2.87 (m, 1H), 2.22 (s, 3H), 1.57 (d, J = 1.1 Hz, 3H), 1.11 
(d, J = 6.7 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ168.26, 168.00, 156.32, 149.88, 143.93, 140.85, 138.10, 
133.78, 132.34, 131.84, 128.35, 128.31, 127.62, 115.50, 107.85, 105.65, 78.51, 70.92, 
61.20, 55.63, 51.45, 40.08, 24.93, 16.14, 12.06; 
IR (neat/cm
-1
) υmax : 3332, 2941, 1695, 1621, 1526, 1459, 1418, 1170, 997, 848, 738, 699; 
HRMS (ESI) m/z calcd for C27H33NO6[M+H]
 +
468.2386, found 468.2379. 
 
Methyl (2E,4E,6S,7R)-7-(3-acetamido-2,5-dihydroxyphenyl)-
7-hydroxy-4,6-dimethylhepta-2,4-dienoate (NFAT-68): Prepared by the same procedure 
as ent-NFAT-68. Purification over silica gel chromatography (60% EtOAc/CH2Cl2) 
afforded product NFAT-68 (4 mg, 41% yield) as a viscous, colorless oil.  α  
  = -11.4 (c 
0.3, CHCl3); 
1
H NMR (500 MHz, CD3OD): δ7.24 (dd, J = 15.7, 0.6 Hz, 1H), 6.79 (d, J = 2.9 Hz, 1H), 
6.57 (d, J = 2.9 Hz, 1H), 5.86 (d, J = 9.9 Hz, 1H), 5.74 (d, J = 15.4 Hz, 1H), 4.79 (d, J = 
6.3 Hz, 1H), 3.70 (s, 3H), 3.01 (dq, J = 10.1, 6.6 Hz, 1H), 2.16 (s, 3H), 1.66 (d, J = 1.2 
Hz, 3H), 1.06 (d, J = 6.7 Hz, 3H); 
13
C NMR (125 MHz, CD3OD): δ171.06, 168.26, 150.04, 149.55, 144.85, 138.97, 132.26, 
131.99, 126.39, 114.71, 111.11, 107.92, 73.55, 50.49, 39.42, 21.78, 14.42, 10.92; 
IR (neat/cm
-1




HRMS (ESI) m/z calcd for C18H23NO6[M+H]
 +
350.1604, found 350.1604. 
 




H NMR (mult, J in Hz, CD3OD) 
Panek δ Cai 
(500 MHz, ref. 
3.30ppm) 
Mcalpine Δδ (ppm) 
1-OCH3 3.70 (s, 3H) 3.70 (s, 3H) 0 
2 5.74 (d, J = 15.4 Hz, 
1H) 
5.72 (d, 1H, J = 15.7 
Hz) 
+0.02 
3 7.24 (dd, J = 15.7, 0.6 
Hz, 1H) 
7.22 (br d, 1H, J = 
15.7 Hz) 
+0.02 
5 5.86 (d, J = 9.9 Hz, 1H) 5.84 (brd, 1H, J = 
9.9 Hz) 
+0.02 
6 3.01 (dq, J = 10.1, 6.6 
Hz, 1H) 
3.01 (mult, 1H) 0 
7 4.79 (d, J = 6.3 Hz, 1H) 4.80 (d, 1H, J = 7.2 
Hz) 
-0.01 
10-NAc 2.16 (s, 3H) 2.15 (s, 3H) +0.01 
11 6.79 (d, J = 2.9 Hz, 1H) 6.80 (d, 1H, J = 2.9 
Hz) 
-0.01 
13 6.57 (d, J = 2.9 Hz, 1H) 6.57 (d, 1H, J = 2.9 
Hz) 
0 
14 1.66 (d, J = 1.2 Hz, 3H) 1.63 (br s, 3H) +0.03 






C NMR (CD3OD) 
Panek δ Cai 
(125 MHz, ref. 47.58 
ppm) 
Mcalpine Δδ (ppm) 
1 168.26 169.7 -1.44 
1-OCH3 50.49 51.9 -1.41 




3 150.04 151.4 -1.36 
4 132.26 133.7 -1.44 
5 114.71 116.1 -1.39 
6 39.42 40.8 -1.38 
7 73.55 75.1 -1.55 
8 131.99 133.2 -1.21 
9 138.97 140.3 -1.33 
10 126.39 127.8 -1.41 
10-NAc 171.06 172.5 -1.44 
 21.78 23.3 -1.52 
11 107.92 109.3 -1.38 
12 149.55 150.9 -1.35 
13 111.11 112.5 -1.39 
14 14.42 15.9 -1.48 
15 10.92 12.4 -1.48 
 
Confirmation of Relative Stereochemistry of ent-8 and Absolute Stereochemistry of 
9 and ent-9 
a) Confirmation of Relative Stereochemistry of ent-8 by Converting ent-8 to 
Acetonide 15   and Measuring Three-Bond Coupling Constants 
 
Ent-8 was reduced to Z-alkene 13 by hydrogenation using Lindar’s catalyst, while the 
arylnitro group was simultaneously reduced to amino group. Subsequent N-acylation of 
13 produced arylacetamide 14. A three-step sequence involving dihydroxylation, 
oxidation, and reduction obtained primary alcohol 15. Deprotection of benzyl ether of 17 




catalyzed ketalization. Three-bond coupling constant between H1 and H2 is 2.5 Hz, 
indicating the syn relationship between C1 methyl group and C2 oxygen.  
 
N-(2,5-dimethoxy-3-((4R,5S)-2,2,5-trimethyl-1,3-dioxan-4-
yl)phenyl)acetamide (17): 17 was isolated as a light brown solid.  α  
  = +2.4 (c 1.9, 
CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.87 (s, 1H), 7.55 (s, 1H), 6.76 (s, 1H), 5.32 (d, J = 2.2 Hz, 
1H), 4.30 (dd, J = 11.5, 2.4 Hz, 1H), 3.79 (s, 3H), 3.72 (s, 3H), 3.66 (d, J = 11.5 Hz, 1H), 
2.21 (s, 3H), 1.90-1.82 (m, 1H), 1.56 (s, 3H), 1.51 (s, 3H), 0.83 (d, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ168.133, 156.08, 138.89, 134.17, 131.52, 108.82, 104.61, 
99.10, 68.77, 66.36, 61.03, 55.59, 32.55, 29.64, 18.98, 11.43; 
IR (neat/cm
-1
) υmax : 3263, 3006, 2945, 1664, 1619, 1594, 1541, 1461, 1421, 1379, 1358, 
1254, 1225, 1243, 1194, 1172, 1150, 1135, 1108, 1059, 1002, 877, 865, 845, 800, 760, 
744, 707; 
HRMS (ESI) m/z calcd for C17H25NO5[M+Na]
 +
346.1630, found 346.1615. 




 The absolute stereochemistry of 9 and ent-9 was determined by converting them 




1-yl (S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate ((S)-19): (S)-19 was obtained 
as a colorless, viscous oil.  α  
  = -3.8 (c 1.5, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.96 (d, J = 2.8 Hz, 1H), 7.66 (s, 1H), 7.44-7.26 (m, 5H), 
6.58 (d, J = 2.9 Hz, 1H), 6.19 (d, J = 7.1 Hz, 1H), 3.86 (s, 3H), 3.73 (s, 3H), 3.47 (s, 3H), 





C NMR (100 MHz, CDCl3): δ165.02, 162.50, 152.75, 136.98, 128.64, 127.40, 126.47, 
126.09, 125.19, 124.79, 124.38, 124.02, 121.41, 118.54, 104.26, 103.36, 81.38, 81.10, 
75.66, 75.10, 71.44, 71.18, 58.47, 58.23, 52.30, 52.04, 28.37, 28.05, 21.65, 21.54, 13.55, 
13.37, 0.20, 0.00; 
IR (neat/cm
-1
) υmax : 3305, 2988, 2945, 2844, 1751, 1681, 1599, 1529, 1466, 1422, 1367, 
1248, 1172, 1123, 1054, 1019, 996, 723; 
HRMS (ESI) m/z calcd for C26H28F3NO6[M+Na]
 +
530.1766, found 530.1782. 
 
 (1S,2R)-1-(3-acetamido-2,5-dimethoxyphenyl)-2-methylpent-3-yn-
1-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate ((R)-19): (R)-19 was obtained 
as a colorless, viscous oil.  α  
  = +2.0 (c 2.1, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.91 (d, J = 2.8 Hz, 1H), 7.64 (s, 1H), 7.48-7.32 (m, 5H), 
6.31 (d, J = 2.9 Hz, 1H), 6.20 (d, J = 5.6 Hz, 1H), 3.87 (s, 3H), 3.61 (s, 3H), 3.60 (d, J = 
1.1 Hz, 3H), 2.99-2.92 (m, 1H), 2.21 (s, 3H), 1.72 (d, J = 2.4 Hz, 3H), 1.14 (d, J = 7.0 Hz, 
3H); 
13
C NMR (125 MHz, CDCl3): δ168.27, 165.73, 155.93, 139.97, 132.03, 131.89, 130.48, 
129.54, 128.29, 127.68, 127.32, 124.46, 122.17, 107.12, 106.87, 79.57, 78.35, 74.97, 






) υmax : 3334, 2943, 2848, 1750, 1681, 1602, 1527, 1465, 1421, 1366, 1247, 
1168, 1124, 1081, 1054, 1018, 993, 723, 698; 
HRMS (ESI) m/z calcd for C26H28F3NO6[M+Na]
 +
530.1766, found 530.1747. 
 
(1R,2S)-1-(3-acetamido-2,5-dimethoxyphenyl)-2-methylpent-3-yn-
1-yl (S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (ent-(S)-19): Ent-(S)-19 was 
obtained as a colorless, viscous oil.  α  
  = -8.6 (c 4.1, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.92 (d, J = 2.7 Hz, 1H), 7.61 (s, 1H), 7.48-7.33 (m, 5H), 
6.31 (d, J = 2.7 Hz, 1H), 6.19 (d, J = 5.6 Hz, 1H), 3.87 (s, 3H), 3.61 (s, 3H), 3.60 (s, 3H), 
2.99-2.92 (m, 1H), 2.22 (s, 3H), 1.73 (d, J = 2.3 Hz, 3H), 1.15 (d, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ168.26, 165.74, 155.93, 139.93, 132.02, 131.88, 130.48, 
129.55, 128.30, 127.32, 124.43, 122.15, 107.09, 106.81, 79.57, 78.35, 74.98, 61.44, 55.76, 
55.35, 31.40, 24.93, 16.18, 3.49; 
IR (neat/cm
-1
) υmax : 3321, 2988, 2949, 2844, 1751, 1680, 1602, 1527, 1466, 1421, 1369, 
1247, 1170, 1124, 1054, 1019, 994, 723; 
HRMS (ESI) m/z calcd for C26H28F3NO6[M+H]
 +






1-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (ent-(R)-19): Ent-(R)-19 was 
obtained as a colorless, viscous oil.  α  
  = +3.4 (c 4.8, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.97 (d, J = 2.8 Hz, 1H), 7.65 (s, 1H), 7.44-7.29 (m, 1H), 
6.57 (d, J = 2.8 Hz, 1H), 6.19 (d, J = 7.1 Hz, 1H), 3.87 (s, 3H), 3.73 (s, 3H), 3.47 (s, 3H), 
2.99-2.93 (m, 1H), 2.22 (s, 3H), 1.65 (d, J = 2.3 Hz, 1H), 1.07 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ168.33, 165.82, 156.09, 140.31, 131.98, 130.73, 129.61, 
129.49, 128.33, 128.23, 127.54, 127.26, 124.46, 122.17, 107.65, 106.69, 78.99, 78.44, 
74.65, 61.68, 55.52, 55.42, 31.55, 24.93, 16.79, 3.43; 
IR (neat/cm
-1
) υmax : 3320, 2987, 2948, 2845, 1749, 1677, 1601, 1526, 1465, 1421, 1366, 
1246, 1170, 1122, 1081, 1054, 1017, 995, 915, 734, 698; 
HRMS (ESI) m/z calcd for C26H28F3NO6[M+Na]
 +




















































































































































Titanium Alkoxide-Based Highly Regioselective Alkyne-Alkyne Reductive Coupling 







 Stereodefined, highly functionalized (E,E)-dienes are common structural moiety 
embedded in natural products and pharmaceutically important agents.
23
 Transition metal-
mediated reductive coupling reactions have recently emerged as step- and atom-
economical carbon-carbon bond formation reactions to access structural motifs such as 
(E,E)-dienes by avoiding alkene prefunctionalizaiton. The principle challenges that lie 
within all the metal-mediated reductive coupling reactions are the control of reactivity 
and selectivity. In response to these challenges in the context of reductive coupling 
between internal alkynes and carbonyl-based π-systems or alkynes, useful strategies to 
control regioselectivity, including steric differentiation (Scheme 2.1.1A), π conjugation, 





























Scheme 2.1.1 Background of Reductive Coupling 
 
 In this chapter, reductive coupling reactions mediated by Zr, Ni, Ir, Ru, and Rh 
will be discussed. In particular, a review of the discovery and development of titanium 
alkoxide-mediated reductive coupling will be detailed with the emphasis on Micalizo’s 
alkoxide-directed titanium alkoxide-mediated reductive coupling. In that context, the full 
account of our development of hetero-atom (arylacetamide and arylcarbamates) effect on 
titanium alkoxide-mediated reductive coupling will be disclosed. The proposed extension 
of this methodology to alkyne-alkene reductive coupling and application to the total 




2.2 Previous Approaches to Metal-Mediated Reductive Coupling 
 This section provides a cursory survey of metal-mediated reductive coupling by 
other groups and our hetero-atom directing effect in titanium-mediated coupling 
methodology. 
2.2.1 Zirconium-Mediated Coupling of Alkynes 
 Recent advances in organopalladium and organonickel chemistry have led to the 
development of several preparatively useful methods for the synthesis of isomerically 
pure 1,3-dienes.
25
 Although these methods have the advantage that they are often 
catalytic in palladium or nickel, a major drawback to this route is the need for the 
preparation and isolation of geometrically pure vinyl halides. In this study, Buchwald and 
coworkers
26
 developed an efficient and selective synthesis of 1,3-dienes and dihalo 
dienes from alkyne precursors via the generation of metallacyclopentadienes. 
Accordingly, hydrozirconation of the first alkyne with Schwartz’s reagent produced the 
chlorovinylzirconocene B1, which was converted to the methylvinylzirconocene B2 with 
either methyllithium in tetrahydrofuran or methylmagnesium bromide in CH2Cl2. B2 lost 
methane at room temperature to form an intermediate alkyne complex B3, which coupled 
with the second alkyne to form the metallacyclopentadiene B4. The metallacycle B4 was 
converted to the diene B5 after treatment with aqueous acid, or to the diiodide B6 upon 
treatment with ~2.5 equiv of solid I2 in CH2C12 at 0 °C (Scheme 2.2.1). In some cases 
where mixtures were initially formed, equilibration of the mixture to one isomer could be 
accomplished by heating the reaction mixture to 80 °C. The regiochemical outcome of 




the larger substituent (TMS) in the case of unsynmmetrical terminal alkyne coupled with 
terminal alkyne. 
Scheme 2.2.1 Stepwise Zirconium-Mediated Alkyne-Alkyne Reductive Coupling 
 
2.2.2 Nickel-Catalyzed Reductive Coupling between Aldehydes and Alkynes by 
Montgomery 
 Allylic alcohols are organic substructures that are exceptionally valuable in many 
synthetic applications. In this report, Montgomery and coworkers
27
 developed a 
procedure for the intermolecular reductive coupling of alkynes, aldehydes, and 
trialkylsilanes catalyzed by the combination of Ni(COD)2 and carbene M1. The scope of 
this optimized procedure was broad, and good to excellent yields and regioselectivities 
were observed across a broad range of substrates (Table 2.2.1). Highly regioselective 
alkyne insertion was noted in all cases with the exception of an internal aliphatic alkyne 












 Crossover experiments led to the following proposed mechanism which pointed to 
the formation of a nickel species M4 (Scheme 2.2.2). 
Scheme 2.2.2 Proposed Mechanism 
 
 While the broad scope of aldehydes and alkynes coupling has been demonstrated, 
the control of regiochemistry is consistently a major hurdle. Alkynes that possess either a 
strong electronic or steric bias often participate with good to excellent regiocontrol. 
These alkynes with sterically biased groups include aromatic alkynes, terminal alkynes, 
silyl alkynes, ynamides, and conjugated diynes and enynes and participate in highly 




outcome. Additionally, remote directing functionality such as alkenes and alcohols has 
proven to be effective in Ni-catalyzed and Ti-promoted variants. In this report, 
Montgomery
28
 described a ligand-controlled regioselective process that by switching the 
Ligand, either regiochemical outcome of the alkyne addition maybe selectively accessed.  
Table 2.2.2 Ligand-Controlled Regioselectivity Reversal 
 
 After ligand optimization, they went to evaluate the reaction scope. A range of 
biased and unbiased alkynes were well tolerated including electronic and steric biases 
(Table 2.2.2). 
 A simple steric model was employed to explain the ligand control in this coupling 
reaction wherein reorientation of the alkyne in π-complexes M7 and M8 ultimately 







Figure 2.2.1 Ligand Steric Control of Regiochemistry 
 
 A significant breakthrough was made by the same group where newly designed 
NHC ligands enabled regio- and enantiocontrol in nickel-catalyzed reductive couplings 
between aldehydes and alkynes.
29
 It was known that the ability to tune regioselectivity 
through catalyst control while obtaining high levels of enantioselectivity remained as an 
unsolved problem in this class of reactions. In this study, initial efforts were directed 
toward to the design of a ligand class to exert regio- and enantiocontrol. While ligand L1 
was widely used for steric control, ligand L2 was utilized in asymmetric catalysis. A 
couple of literature survey inspired them to incorporate the features of ligand type L1 and 




Scheme 2.2.3 NHC Templates for Steric Control and Asymmetric Catalysis 
 
 A series of ligand synthesis and optimization was carried out to obtain four types 
of ligands M9a, M9b, M9c, and M9d. The realization that the control of regiochemistry 
in additions of internal alkynes that bear aliphatic substituents of similar size are 
exceptionally challenging in virtually all classes of catalytic reactions, their initial 
exploration focused on alkyne M10. With this substrate, the catalyst must be able to 
distinguish a secondary from a tertiary propargylic substitution pattern in order to exert 
regiocontrol in the formation of product M11. After considerable experimentation, the 









Table 2.2.3 Optimization of the Reductive Coupling Reaction with Bulky NHC 
Ligands 
 
 With the optimized condition, the scope of the alkyne was explored in the 
enantioselective alkyne-aldehyde reductive coupling. To first focus on enantioselectivity, 
the reactions of symmetrical alkynes were examined to probe the influence of the length 
of the alkyl chain on the enantioselectivity. The removal of the propargylic branched 
substituent of the alkyne produced the silyl protected allylic alcohols in high yield with 
slightly decreased enantioselectivity. Compared to the results of the reaction with 
unbranched alkynes, improved enantioselectivity was observed for the reaction of the 
alkyne having homopropargylic branched substituent. Alkynes with phenyl, silyloxy, and 




that the reaction of a terminal alkyne afforded the terminal methylene product with low 
enantioselectivity and consequently not synthetically useful. 
2.2.3 Krische’s Reductive Coupling between Conjugated Alkynes and Carbonyls 
 The Krische group has been active in the field of hydrogen-mediated catalytic 
carbon-carbon bond forming coupling reactions. Recently, a catalytic reductive coupling 
of enones with aldehyde or ketone partners under hydrogenation conditions was disclosed 
from their laboratory.
30
 A key feature related to such reductive C-C bond formations was 





       Rh-H + HX. The catalytic reductive coupling of enones and dienes to 
carbonyl partners under hydrogenation conditions suggests the feasibility of activating 
other π-unsaturated systems as nucleophiles, thereby enabling a family of catalytic C-C 
bond forming hydrogenations. In this study, they disclosed such a reaction type, where 
upon exposure of diynes and glyoxals to cationic Rh(I) catalyst under 1 atm of hydrogen 
gas, regioselective coupling occurred to give unsaturated enyne products without over-
reduction. Importantly, in the presence of chiral phosphine ligand, reductive coupling 
products were obtained in high enantiomeric excess at ambient temperature and pressure 
(Scheme 2.2.4). 
Scheme 2.2.4 Enantioselective Catalytic Reductive Condensation of 





 In a later publication, they extended this methodology to reductive coupling 
between α-keto aldehydes and 1,3-enynes (Scheme 2.2.5).
31
 Exposure of 1,3-enynes to α-
keto aldehydes under the conditions of hydrogenation at ambient temperature and 
pressure results in regio- and stereoselective reductive coupling to afford (E)-2-hydroxy-
3,5-dien-1-one products. The significant outcome of this work demonstrates that 
unsaturated products are formed under hydrogenation conditions without over-reduction. 
Scheme 2.2.5 Reductive Condensation of Enyne with Assorted Glyoxals 
 
 An interesting highly regio- and stereoselective reductive coupling between 
conjugated alkynes and ethyl (N-sulfinyl)iminoacetates via rhodium-catalyzed C-C bond 
forming hydrogenation was reported by the same group to synthesize unnatural α-amino 
acids using the same catalytic system (Scheme 2.2.6).
32
 
Scheme 2.2.6 Hydrogen-Mediated Reductive Coupling of Conjugated Alkynes with 
Ethyl (N-Sulfinyl)iminoacetates 
 
 Their initial efforts were focused on the identification of the R3 group that gave 
the best regio- and stereoselection with the 1,3-enyne system. A survey of R3 groups 
found that use of ethyl (N-tert-butanesulfinyl)iminoacetate produced the best results. In 




Boc protecting group, and N- and O- heterocycles including indole and furan were all 
tolerated. With the success with the 1,3-enyne system, they moved to evaluate the 
coupling with 1,3-diyne system. A change of the R3 group from tert-butyl to (2,4,6-
triisopropyl)benzene allowed the efficient coupling of various 1,3-diynes with ethyl N-
(2,4,6- triisopropylbenzenesulfinyl)iminoacetate, delivering enyne-containing α-amino 
acid esters as single regio- and stereoisomers in good to excellent yield. It was 
noteworthy that the high enantioselectivity was controlled by the chiral iminoacetate. The 
model for asymmetric induction was proposed (Scheme 2.2.7). 
Scheme 2.2.7 Proposed Models for Asymmetric Induction 
 
 Base on the observed sense of stereoinduction, two stereochemical models A and 
B were proposed. In each case, the iminoacetate was bound to rhodium(I) in a five-
membered chelate. This mode of coordination has been established for late transition 
metal complexes of α-iminoketones and α -iminoesters. Upon oxidative coupling, the 
alkyne was delivered to the less encumbered π-face of the imine, as dictated by the 




C possessed an unoccupied coordinate site L, which should facilitate subsequent 
hydrogen activation. 
2.2.4 Jamison’s Nickel-Catalyzed Alkyne Reductive Coupling 
 The Jamison group at the Massachusetts Institute of Technology has been active 
in the field of Nickel-catalyzed reductive coupling. As allylic amines are key structural 
elements in a variety of important naturally occurring molecules and pharmaceuticals and 
are among the most versatile intermediates in the synthesis of other important molecules, 
their efforts resulted in a Ni-catalyzed assembly of allylic amines from three simple 
precursors-alkynes, imines, and organoboron reagents (Scheme 2.2.8).
33
 Catalyzed by 5 
mol% [Ni(cod)2] and (c-C5H9)3P, this reaction tolerated a range of alkynes with aliphatic 
and/or aromatic substitution, imines, ester and ketoness functionalities  and delivered 
coupled products with ≥9:1 regioselectivities and moderate to good yields. 
Scheme 2.2.8 Catalytic Assembly of Allylic Amines from Alkynes, Imines, and 
Organoboron Reagents 
 
 Mechanistic pathway was proposed to account for the observed regioselectivity 
(Scheme 2.2.9). This proposed mechanism well explained the high selectivity for 
alkylative coupling (1) imparted by methanol: occupation of coordination sites required 




Scheme 2.2.9 A Mechanistic Framework for a Novel Ni-Catalyzed Three-
Component Coupling Reaction that Accounts for the Selectivities Observed 
 
 The controlled addition of two groups across an alkyne triple bond is an important 
strategy for the synthesis of highly substituted alkenes. Low-valent nickel complexes 
catalyze several of these transformations. In intermolecular cases, regioselectivity is 
generally governed by electronic and/or steric differences between the two alkyne 
substituents. In this study, Jamison and coworkers reported that a transient interaction 
between a conjugated alkene and a transition metal dramatically enhanced reactivity and 
uniformly directed regioselectivity (Scheme 2.2.10).
33
  
Scheme 2.2.10 Alkene-Directed, Nickel-Catalyzed Coupling Reactions of Alkynes 
with Aldehydes and Epoxides 
 
 In Ni-catalyzed coupling reactions of alkynes of the general form Ar   C   C  alkyl 




formation distal to the aromatic group. However, in the present case an electronically 
similar and smaller vinyl group resulted in a complete reversal in regioselectivity, 
favoring C-C bond formation distal to the alkene (J3-6). The directing ability of the 
alkene depends neither on the nature or size of the other alkyne substituent (aryl, alkyl 
(1°, 2°, 3°)) nor on the degree of alkene substitution (Table 2.2.4, J5 and J6). 
Table 2.2.4 Effects of Alkene Directing Groups on Regioselectivity and Reactivity in 
Nickel-Catalyzed Alkyne Coupling Reactions 
 
 In a following study, they discovered the ligand-switchable directing effects of 
tethered alkenes in Nickel-catalyzed reductive couplings of aldehydes with alkynes.
34
 
They found that the degree of regioselectivity was due entirely to a directing effect of an 
appropriately placed alkene, and the sense of the regioselectivity was due entirely to the 
presence (or absence) of a phosphine ligand. When the alkyne and alkene were separated 
by four bonds, very high (>95:5) regioselectivities were observed. Importantly, the use of 
a monodentate phosphine as an additive led to formation of the opposite regioisomer in 
equal and opposite selectivity (5: >95). For alkyne scope, this reaction tolerated bulky 




tosyl protected amines. For the aldehyde scope, a range of aldehydes were tolerated 
including acetaldehyde, 2-((tert-butyldimethylsilyl)oxy)acetaldehyde, and 
isobutyraldehyde.  
Scheme 2.2.11 Mechanism for Ligand-Switchable Directing Effects of Tethered 
Alkenes 
 
 Mechanism accounting for the ligand effect was proposed (Scheme 2.2.11). 
Intermediate A was consistent with the studies of Pörschke, who showed that 1,6-
heptadiene and 1,6-heptadiyne chelate nickel in three-coordinate, approximately trigonal 
planar complexes in the solid state and in solution. The exclusive formation of 
regioisomer J9 when Cyp3P was employed can be explained by installation of the alkenyl 
H prior to carbon-carbon bond formation. Oxidative addition of a Ni-ligand complex into 
a carbon-boron bond of Et3B and directed hydrometalation would give alkenyl-nickel 
species B that underwent carbonyl addition. 
 Conversely, in the absence of Cyp3P, the formation of regioisomer J8 was best 
accounted for by reversing the order of events (C-C bond formation prior to alkenyl H 





Scheme 2.4.12 Nickel-Catalyzed Reductive Coupling of Alkynes and Epoxides 
 
 The most straightforward way to prepare homoallylic alcohol is probably the 
reductive coupling between an alkyne and an epoxide. In this context, Jamison and 
coworkers reported a Nickel-catalyzed, intramolecular and intermolecular reductive 
coupling of alkynes and enantioenriched epoxides to synthesize stereodefined 
homoallylic alcohols (Scheme 2.4.5, J10).
35
 Very high regioselectivity was generally 
observed, and cyclizations proceeded with complete selectivity for endo epoxide opening 
to produce cyclohexanes, tetrahydropyranyl, and piperidinyl heterocycles possessing a 
stereogenic center and an exocyclic, trisubstituted olefin of defined geometry, regardless 
of the nature of the linking group or ring size (Scheme 2.4.12, J11).  
 Mechanism for the formation of exclusive “endo” products was proposed 
(Scheme 2.2.13). A possible explanation involves the intermediacy of A, a 
metallaoxetane (oxametallacyclobutane) corresponding to a regioselective oxidative 
addition of a phosphine-nickel(0) complex into the less hindered C-O bond of the 
epoxide, followed by exo-dig cyclization onto the alkyne. Installation of the vinylic 
hydrogen atom could arise from transfer of Et to Ni from Et3B, β-H elimination, and 





Scheme 2.2.13 Reductive Cyclization via a Proposed Nickella(II)oxetane 
 
 An elegant application of this methodology was demonstrated in the total 
synthesis of (-)-gloeosporone, where the macrocyclization was achieved employing a 
Nickel-catalyzed, ester-promoted, epoxide-alkyne reductive coupling (Scheme 2.2.14). 
36
The key step for the simultaneous macrocyclization and formation of the chiral 
homopropargylic alcohol was accomplished by their Nickel-catalyzed alkyne-epoxide 
reductive coupling. 
Scheme 2.2.14 Macrocyclization by Nickel-Catalyzed, Ester-Promoted, Epoxide-
Alkyne Reductive Coupling: Total Synthesis of (-)-Gloeosporone 
 
2.2.5 Titanium Alkoxide-Based Alkyne Reductive Coupling 
 The earliest example of titanium-based reductive coupling was demonstrated in 
the reductive dimerization of diphenylacetylene, later studied by Bercaw, and 




on, the pioneering studies of Kulinkovich and Rothwell
37
 demonstrated that titanium 
aryloxides and titanium alkoxides could be employed to access similar reactivity seen 
with Cp2Ti-π complexes. Building on the work by Kulinkovich and Rothwell, the Sato 
group at Tokyo Institute of Technology and the Cha group at Wayne State University 
have independently developed a wide range of novel reactions utilizing Ti-alkoxides in 
metallacycle-mediated C–C bond forming processes.  Although the previous studies have 
established a firm foundation for Ti-mediated metallacycle-based bond constructions, the 
control of reactivity and selectivity in this process still remained as unconquered barriers. 
I. Titanium Alkoxide-Based Reductive Coupling by Sato and Coworkers 
 In their study, they reported that a low-valent titanium reagent, (η
2
-propene)Ti(O-
i-Pr)2 (S1) readily prepared from the in situ reaction of Ti(O-i-Pr)4 and i-PrMgCl, could 
cross couple two different functionalized alkynes to give dienes.
38
 Accordingly, treatment 
of an internal acetylene such as 5-decyne (S2) or 1-silyl-1-octyne (S3) with the above 
titanium complex S1 generated the acetylene-titanium complex (S4), which was allowed 
to react with a terminal acetylene, 4-(benzyloxy)-1-butyne (S5) to form S6. The 
intermediate titanacyclopentadiene (S6) was hydrolyzed, or intercepted with D
+
 or I2, to 
give the diene S7 or S8, or its bis-deuterated (J9) or bis-iodinated counterpart (J10) in 
good yields. If an excess amount of J5 was used, the yield of J8 (based on J3) decreased. 
Importantly, the carbon-carbon bond formation occurred exclusively at the carbon β to 
the silyl group of J3 and at the terminal carbon of J5. Other regio- and stereoisomers 
were not identified. In addition, under these reaction conditions, the amount of 




Regarding the regiocontrolling ability, the ester and amide groups also displayed such an 
effect as rendering the coupling β to the functional group. 
Scheme 2.2.15 Titanium Alkoxide-Based Method for Stereoselective Synthesis of 
Functionalized Conjugated Dienes 
 
II. Titanium Alkoxide-Based Reductive Coupling by Micalizio and Coworkers 
 The Micalizio group has made significant contribution to the titanium alkoxide-
based alkyne reductive coupling, where a variety of alkyne coupling with different π-
systems (alkynes, alkenes, aldehydes, and imines) were realized and highly regiocontrol 
was achieve through use of in situ generated alkoxide as a directing group. The strategic 
use of alkoxide as a directing group that renders the directed carbometalation remarkably 
increases (1) the reactivity that allows an efficient coupling of internal alkynes with 
terminal or internal alkynes and alkenes previously proved to be sluggish and (2) the 
regioselectivity favoring the production of (E,E)-dienes when unsymmetrical internal 
alkynes are coupled with unsymmetrical π-systems. The broad utility of this methodology 
has been demonstrated in several elegant total synthesis of biologically active natural 
















 (-)-virginiamycin M2, and more recently 
neurotrophic seco-prezizaane sesquiterpenes (1R,10S)-2-oxo-3,4-dehydroneomajucin, 
(2S)-hydroxy-3,4-dehydroneomajucin, and (–)-jiadifenin. 
Table 2.2.4 Construction of Complex Polyketides by Regioselective Coupling 
Reactions of Branched Homopropargylic Alcohols and Terminal Alkynes 
 
  In this study,
44
 deprotonation of the syn-anti homopropargylic alcohol M1, 
followed by exposure to the combination of ClTi(Oi-Pr)3 and cyclopentylmagnesium 
chloride, and addition of the terminal alkyne M2 provided, after aqueous workup, the 




diastereomeric homopropargylic alcohols M4, M6 and M8 with terminal alkyne M2 
provided the 1,3-diene products M5, M7 and M9 (Table 2.2.4). Overall, this study (1) 
expanded the role of titanium alkoxide in a new regioselective carbon-carbon bond-
forming process for the synthesis of unsaturated polypropionates (2) defined the impact 
of stereochemistry and the homopropargylic functional group on the regioselection of this 
type of reaction. 
Figure 2.2.2 Micalizio’s Directed Carbometalation Reaction for 1,3-Diene Synthesis 
 
 Following this result, they speculated that the participation of a tethered alkoxide 
on the second π-electrophile in a titanium alkoxide-mediated coupling reaction could 
provide a unique means to control regioselection in carbometalation processes across 
internal alkynes (design of an alkoxide-directed coupling reaction).
45
 Specifically, 
titanacyclopropene complex M13 was preformed by exposing the corresponding 
symmetrical alkyne to the combination of a titanium(IV) alkoxide and Grignard reagent. 
M13 was then exposed to an unsaturated alkoxide M12, resulting in rapid 
transesterification and transiently providing the mixed titanate ester M14. Subsequent 




titanacyclopentadiene M15, which after protonation would deliver 1,3-diene M16 as a 
single regioisomer (Figure 2.2.2). 
Table 2.2.5 Alkoxide-Directed Titanium-Mediated Alkyne-Alkyne Reductive 
Coupling 
 
 The scope of this alkoxide-directed reductive coupling was then examined. 
Significantly, the ethyl-, isopropyl-, and t-Bu-substituted alkynes M23, M26, and M28 
were all viable substrates for this reaction and provided the stereodefined tetrasubstituted 
1,3-dienes M25, M27, and M29 as single regioisomers, where the new carbon-carbon 
bond was formed at the site distal to the free hydroxyl, independent of substitution on the 




stereochemical relationships) present on the chain and even two unsymmetrical alkynes 
(Table 2.2.5, entries 6-8) did not impact the selectivity and were all well tolerated in the 
coupling reaction. Compared with coupling with terminal alkyne, the titanium alkoxide-
mediated reductive coupling between two internal alkynes directed by an alkoxide 
showed a much higher selectivity. 
Figure 2.2.3 Presence of a Tethered Alkoxide and the Length of the Tether Influence 
Reactivity as well as Regioselectivity 
 
 On the basis of the proposed directed carbometalation, the role of the tethered 
alkoxide was examined. As illustrated in Figure 2.2.3, deprotonation of the 
homopropargylic alcohol M18, followed by exposure to the preformed 
metallacyclopropene M37 (formed by treatment of diphenylacetylene with Ti(Oi-Pr)4 and 
C5H9MgCl, PhMe, -78 to -50 
o
C) and aqueous workup, provided the stereodefined diene 
M39 with high regioselection (rs ≥ 42:1). In comparison, exposure of an internal alkyne 




a complex mixture of products. In addition, the impact of the tether length was then 
explored. While the bis-homopropargylic alcohol M41 provided similarly high levels of 
regioselection, alkynl alcohols M44 and M45 did not display any productive reactivity, 
each leading to a complex mixture of products. 
Figure 2.2.4 Rationale for the Favored formation of (E,E)-Dienes in the Alkoxide-
Directed Reductive Coupling 
 
 An empirical model was proposed to account for the preferred formation of (E,E)-
dienes.
46
 As illustrated in Figure 2.2.4, the formation of M48 and M50 were strongly 
disfavored as significant unfavorable steric interactions between R
2
 and the allylic 
substituent of M51 would be incurred in the intermediates. Regarding isomers M47 and 
M49, the transition state leading to the metallacyclic precursor of M49 (B or C) would be 
destabilized due to the significant strain associated with the formation of a bridgehead 
alkene (via a carbometalation process that engaged bond “a” of M51; see B) or require 




led to the formation of M47 was most stable and (E,E)-dienes were generally the major 
isomers. 
Scheme 2.2.16 Intermolecular Alkene–Alkyne Coupling 
 
 With the success of alkyne-alkyne coupling, it is not surprising to explore the 
reactivity of reductive coupling between alkyne and alkene. Indeed, a site and 
stereoselective intermolecular alkyne-alkene coupling directed by an alkoxide was 
reported by the Micalizio group, where the C-C bond formation occurred exclusively 
distal to a pendent hydroxy group (Scheme 2.2.16).
47
 





 The subsequent application of the alkoxide-directed alkyne-alkyne reductive 
coupling was demonstrated by the highly convergent total synthesis of virginamycin M2 
from the Panek group
48
 and callystatin A
49
 by the Micalizio group (Scheme 2.2.17). 
Whereas complete regioselectivity was achieved in reductive coupling between 
propargylic alcohol M52 and M53 in the synthesis of virginiamycin M2, a 3:1 
regioselectivity was obtained when the alkoxide was at the homopropargylic position 
(M55) in the synthesis of callystatin A. These two examples pointed out the combined 
effects of substitution patterns and tether length had significant impact on the selectivity 
of the alkoxide-directed reductive coupling in a complex setting. 
 With a firm foundation of preliminary data that confirmed the ability to employ a 
hydroxy-group directing strategy to enable intermolecular metallacycle-mediated union 
of preformed metal-alkyne complexes with internal alkynes or substituted alkenes, they 
questioned whether the inherent reactivity of substrates could react by a process that 
engaged all three π-systems in an annulation process. Indeed, by careful design of 
substrates, they were able to achieve a bimolecular [2+2+2] annulation process that 
engaged in a stepwise alkyne-alkyne reductive coupling and metal-centered [4 + 2] 












Table 2.2.6 Asymmetric Synthesis of Dihydroindanes 
 
 Remarkably, this annulation process was very effective at generating 17-β-aryl 
substituted hydroindanes as essentially single regio and stereoisomers (Table 2.2.6, 
entries 1-3). It is noteworthy to mention that the process was sensitive to the relative 











Figure 2.2.5 Proposed Mechanistic Pathway for the Ti-mediated [2+2+2] Annulation 
 
 In order to distinguish between two possible mechanistic pathways, they have 
cleverly designed a substrate M70 after the reaction process to give such a product as to 
provide evidence for the support of a sequential [4+2]/cycloreversion in preference to 
alkene insertion/reductive elimination. The product M71 formation is constant with the 
empirical model depicted in Figure 2.2.5. Initial alkoxide-directed alkyne-alkyne 
coupling produced metallacyclopentadiene M72 in a regioselective fashion. Subsequent 
stereoselective annulation was then proposed to occur through a sequence of steps that 
could involve alkoxide-promoted cleavage of the oxa-metallacyclopentane (M72 → 
M73), followed by stereoselective intramolecular [4 + 2] (M73 → M74), a highly 




of the pendant alkoxide to a ligand on Ti. The intermediate M74 was suitably 
functionalized to undergo vinylogous elimination of the PMB ether to generate an 
unstable tertiary allyltitanium species M75. Finally, 1,3-metallotropic shift generated 
allyltitanium species M76 which, on protonolysis with allylic transposition, delivered the 
observed product M71. Alternatively, if annulation proceeded by a sequence defined by 
alkene insertion and reductive elimination (Figures 2.2.5 C), a suitable intermediate was 
not readily apparent to support the facile elimination of the PMB ether. 
Figure 2.2.6 Total Syntheses of (1R,10S)-2-oxo-3,4-dehydroneomajucin, (-)-
Jiadifenin, and (2S)-3,4-Dehydroneomajucin 
 
 An elegant demonstration of the powerful synthetic utility of this alkoxide-
directed [2+2+2] annulation methodology was showcased in the total synthesis of a 
family of neurotrophic seco-prezizaane sesquiterpenes (1R,10S)-2-oxo-3,4-




cowokers (Figure 2.2.6), where the bicyclic core of the common intermediate was 
established in a single operation.
51
 A suitably functionalized intermediate enyne M79 was 
accessed through a series of expoxide opening, desilylation, expoxide formation, and 
nucleophilic addition of propynyl lithium. With M79 in hand, exposure of stannyl-
substituted TMS-acetylene M80 to the combination of Ti(Oi-Pr)4 and n-BuLi (-78 to 50 
o
C), followed by addition of the Li-alkoxide of enyne M79 (-78 
o
C to rt), generated 
hydrindane M81 in 73% yield (rs ≥20:1), where the C9 quaternary center was established 
with high levels of stereoselectivity (ds ≥20:1). Subsequent radical cyclization and 
functional group manipulations afforded advanced intermediate M82, which after another 
sequence of functional group manipulations delivered the three natural products. 
2.3 Alkyne-Alkyne Reductive Coupling Mediated by in situ-Generated Arylamidates 
from the Panek Laboratory 
 Among the aforementioned strategies, substrate-directed transformations
52
 
including carbometalation have been demonstrated to be a powerful method in the sense 
that highly regio- and/or stereoselective bond formation can be rendered. The highly 
organized transition states or intermediates that are formed during the carbometalation 
processes can often create discrimination toward undesired reacting sites, thus delivering 
good to excellent regioselectivity while creating new reactivity profiles. The atom-
economy and remarkable convergency provided by this method was demonstrated by 
application in several elegant total synthesis of natural products and complex molecules. 
53








 In line with our previous studies on reductive coupling and inspired by Micalizio 
and Schafer’s work,
55
 herein we have disclosed a highly regiocontrolled synthesis of 
(E,E)-dienes in the context of polypropionate synthesis mediated by in situ generated 
arylamidate. This strategy takes advantage of the commonly used amine protecting 
groups, namely acetyl (Ac), tert-butyloxycarbonyl (Boc), and carboxybenzyl (Cbz) 
groups to render the directing effects and achieves exquisite levels of regioselectivity 
independent of the relative stereochemical and steric environment present on the coupling 
partners, which represent the first example of amide and carbamate directing effect in 
metal-mediated reductive coupling. 
Scheme 2.2.18  Arylacetamide Directing Effects in Alkyne-Alkyne Reductive 
Coupling 
 
 The development of this methodology was originated from our previous 
investigation concerning the reductive coupling between internal alkynes obtained from 
asymmetric propargylation reactions and acetylenic esters.
56




investigational results to the total synthesis of NFAT-68, we were surprised to find that 
previous optimal reaction conditions for the reductive coupling between alkynyl 
acetamide 1 and methyl propiolate failed to produce diene 2. Through the analysis of the 
individual steps, we learned that in comparison to the previous optimal conditions 
(Scheme 2.2.18 A): for the generation of the presumed titanacyclopropene complex, (1) 
extra two equivalents (six vs. four) of the Grignard reagent were required to obtain full 
conversion, indicating that the excess Grignard reagent was consumed to deprotonate the 
acetamide proton; (2) higher reaction temperature was required to initiate the reaction. 
Importantly, the substantial effect of the deprotonated amide on the generation of Ti-
alkyne complex has not been previously described in metal-mediated reductive coupling. 
Regarding the intermolecular carbometalation process, elevated coupling temperature 
was required to reach complete consumption of int-1, producing 2 as a single 
regioisomer. Collectively, the presence of an acetamide on the aryl ring had a pronounced 
impact on the reactivity and selectivity of the coupling reaction. Interestingly, the N-
methylated counterpart 3 (Scheme 2.2.18 B) produced diene 4 with significantly eroded 
regioselectivity under the previous optimal condition, providing circumstantial evidence 
that it is an in situ generated amidate anion that had profound effect on the selectivity of 
this coupling reaction. Enlightened by Schafer’s work on employing tight bite angle 
monoanionic N,O-chelating ligands including amidate in titanium-catalyzed reactions, we 
hypothesized that the arylamidate generated by deprotonation of the arylacetamide might 
associate to the titanium center and directed the reaction to favor the formation of (E,E)-




Table 2.2.7 Arylacetamide Directing Effect: Terminal Alkyne Scope 
 
 On the basis of this assumption, we surveyed the coupling of alkynyl acetamide 1 
with a range of terminal alkynes bearing diverse functionalities (Table 2.2.7). To our 
delight, (E,E)-diene products 8 were formed with complete regioselectivity as s single 
isomer in all cases. As illustrated in Table 2.2.7, alkyl groups (5d and 5e), aromatics (5a-
c), heterocycle (5f), silyl ether (5g), and even basic alkyl amine (5h) were all well 









Table 2.2.8 Arylacetamide Directing Effect: Internal Alkyne Scope 
 
 With the establishment of general reactivity, we next sought to probe the internal 
alkyne substrate scope, where the variation of acetamide substitution pattern and 
electronics on the aryl ring, stereochemistry, ether protecting groups, and tether length 
was explored (Table 2.2.8). In general, we were excited to find that acetamides 8 were 
afforded as single regioisomers albeit with moderate yields independent of the 
aforementioned variables. Remarkably, the stereochemistry was found to affect the 
reactivity (see Supporting Information for details) without the erosion of selectivity (8c-
d) contrary to Micalizio’s study. Compared with 6b, acetamide 6c with anti 
stereochemistry was reluctant to couple with 10a, giving only hydrolyzed intermediate. 
Importantly, while meta- and para-substituted substrates (6a-b) delivered dienes (8a-b) 
with excellent selectivity, the ortho-substituted one (Scheme 2.2.21, 24) gave no coupled 




group (6f) ortho to the acetamide did not alter the selectivity of the reaction, furnishing 
8e and 8f as the only isomers though with diminished reactivity (see Supporting 
Information for details) and yield for 8e, which may due to the metal/halogen exchange. 
More importantly, substrates (6g-i) with extended tether length bearing polypropionate-
like subunits (anti-anti-syn) also proved to be viable for the coupling with complete 
regioselectivity. Accordingly, these results have indicated that the arylacetamide may 
have strong directing effect on reductive coupling between internal alkynes 6 and 
unactivated terminal alkynes 7. 





 Encouraged by the success with acetamide, we wondered whether carbamates 
(Boc and Cbz) would display similar directing effect (Table 2.29). Gratifyingly, under 
lower reaction temperature, carbamates 11 and 12 were obtained as the exclusive 
regioisomers in moderate yields except for substrates 9k and 10k. In an analogous 
fashion, the factors of electronics on the aryl ring (9-10c and 9-10d), stereochemistry (9-
10f), ether protecting groups (9-10j), and tether length (9-10g, 9-10h, and 9-10i) was 
evaluated and appeared to have no impact on the selectivity of the coupling reaction. 
Again, resembling to acetamide, carbamates 9f and 10f did not couple with 7a with 
returned hydrolyzed intermediate in contrary to 9b and 10b bearing syn stereochemistry. 
Surprisingly, when the carbamates were para-substituted and less bulky ether group (Me) 
was present (9-10k), a decrease of selectivity was observed presumably due to the 
extenuated coordination of arylamidate to the titanium center. In contrast to acetamide, 
ortho-substituted carbamates with a methyl ether (9-10j) exhibited reactivity when 
coupled with 7b and produced 11-12j as single regioisomers. Accordingly, carbamates 
(Boc and Cbz) also displaced strong directing effect to render (E,E)-dienes 11 and 12 
with excellent levels of selectivity. 





 on the aryl ring influenced the regiochemical course of the coupling reaction 
through the in situ formation of arylamidate.
59
 To that end, control experiments were 
conducted. As depicted in Scheme 2.2.19 A and B, when the acidic proton was replaced 
with a methyl group on acetamide or carbamate, the selectivity of the reaction was lost 




operating functional group was indeed the monoanionic amidate. Additionally, removal 
of the carbonyl functionality from the amine protecting groups (Scheme 2.2.19 C and D) 
led to even lower selectivity, excluding the possibility that the transformation was 
mediated by amines. 
Scheme 2.2.19 Control Experiments (Meta Nitrogen Substitution) 
 
 Based on the above-described mechanistic observations and experiments, we 




coupling mediated by in situ generated arylamidate that also builds on our earlier work on 
this transformation. This proposal rests on the hypothesis that the arylamidate would  
Scheme 2.2.20 Proposed Reaction Mechanism 
 
associate with the titanium center through either of the binding mode established by 
Schafer and co-workers. Initial formation of the presumed complex (int-3 and int-4) is 
achieved through the following events: (1) deprotonation of the acidic proton from 
acetamide or carbamate by the Grignard reagent to generate amidate, and Ti (II) species 
formation by in situ reduction of ClTi(OiPr)3 by cC5H9MgCl; (2) association of the 
amidate to the titanium center and titanacyclopropene complex formation by activation of 
the alkyne by the Ti (II) species. Subsequent highly regioselective, intermolecular 
carbometalation (Scheme 2.2.20 A and B, transition states I and II) between metallacycle 




which upon hydrolytic quench may form their respective (E,E)-diene products 19 and 21. 
Notably, the proposed association of amidate with titanium differentiates the current 
transition states (I and II) from the previous one (III) in the following ways, which may 
account for the current unprecedented reactivity and selectivity: (1) the associations lock 
the conformation of int-6 and -7 substantially increasing the steric crowding around the 
C3-C4 bond and C1 methyl group (closer proximity of arylamide and –carbamate to it), 
compared with int-8 that has free rotation around C5; (2) the anti-stereoisomers have the 
ether (OR1) positioned closer to the titanium reacting center in comparison to the syn-
stereoisomers. Importantly, the proposition (1) explains the excellent regioselectivity as 
enhanced steric hindrance shuts down the reactivity around the other reacting sites 
(highlighted region); the proposition (2) is consistent with the observation that 6c (Table 
2.2.8) and 9-10f (Table 2.2.9) were less reactive than their syn counterparts (6b and 9-
10b), 6c and 9-10f did not couple with 7a. Additional experimental observation showed 
that the position of acetamide and carbamate on the aryl ring had great impact on the 
reactivity (Scheme 2.2.21) and selectivity (Table 2.2.9, 11-12j vs. 11-12k) of the 
coupling reaction. This observation may imply that different orientation of the acetamide 
and carbamate produce geometrically different arylamidate-associated intermediates that 








Scheme 2.2.21 Additional Experiments to Support the Proposed Arylamide and 
carbamate-Directing Effects 
 
2.4 Proposed Total Synthesis of (-)-Q-1047H-A-A and (-)-Q-1047H-R-A Based on 
Alkyne-Alkene Reductive Coupling 
 To demonstrate and expand the utility of our arylamidate-mediated reductive 
coupling methodology, we envisioned a convergent total synthesis of two prophylactic 
and therapeutic agents for nephritis natural products (-)-Q-1047H-A-A and (-)-Q-1047H-
R-A using a proposed arylamidate-mediated asymmetric alkyne-alkene reductive 
coupling between P6 and P8 (Scheme 2.2.21). This substrate-controlled asymmetric 
reductive coupling is expected to set the C4 stereochemistry, while forming C5-C6 bond. 
Literature precedents including the Micalizio group and our group have documented the 
double asymmetric alkyne-alkene coupling, where the newly formed stereocenters 
appeared to be controlled by A
1,3
-strain arising from the either coupling partner. We are 
interested in probing how the allylic C3 stereochemistry and hydroxyl protecting group 







Scheme 2.2.21 Retrosynthetic Analysis of (-)-Q-1047H-A-A and (-)-Q-1047H-R-A 
 
2.5 Conclution 
 In conclusion, full detail of a highly regioselective alkyne-alkyne reductive 
coupling mediated by in situ generated arylamidate is realized to provide access to an 
intriguing and potentially useful class of (E,E)-dienes bearing arylacetamides and 
arylcarbamates. Complete regioselectivity is achieved in all cases except for substrates 
11-12k (Table 2.2.9). Inspired by Schafer’s study on monoanionic N,O-chelating ligands 
in titanium-catalyzed reactions, we proposed that the in situ generated arylamidate would 
associate to the titanium center through either of the possible binding modes. Transition 
state modes (Scheme 2.2.20 A and B) are proposed, in consideration of the ones 




experimental observations, where factors such as acetamide and carbamate substitution 
pattern and electronics on the aryl ring, stereochemistry, ether protecting groups, and 
tether length could tremendously influence the reactivity and selectivity of the coupling 
reaction. The utility of this method was first demonstrated in our convergent synthesis of 
NFAT-68. The extension of this methodology to alkyne-alkene coupling and application 
in the total synthesis of natural products and pharmaceutically important agents are 
underway and will be reported in due course. 
2.6 Experimental Section 
2.6.1 Experimental Procedure 
 All reactions were carried out in oven or flame-dried glassware under argon 
atmosphere unless other-wise specified. Triethylamine was distilled over calcium hydride 
and stored over potassium hydroxide. Dichloromethane, tetrahydrofuran, and toluene 
were obtained from a dry solvent system (alumina) and used without further drying. 
Propionitrile was distilled over calcium hydride and stored over 4 Å molecular sieves. 
Sureseal
TM
 anhydrous MeOH and N,N-dimethylformamide (DMF) were purchased from 
Sigma Aldrich. Cyclopentylmagnesium chloride was purchased from Sigma-Aldrich, and 
was titrated by the Watson–Eastham method using 1,10-phenanthroline and sec-
butanol.
60
 Aldehydes were freshly distilled before use and stored under nitrogen at 4 
o
C. 
All other reagents were used as supplied. Unless otherwise noted, reactions were 
magnetically stirred and monitored by thin layer chromatography with Macherey Nagel 
Polygram 0.20 mm silica gel 60 Å plates. Flash chromatography was performed on 









C NMR spectra were taken in CDCl3, C6D6, and CD3OD at 400 or 500 MHz (as 
indicated), respectively. Chemical shifts are reported as major diastereomer and/or 
regioisomer in parts per million using the solvent internal standard (chloroform, 7.24 and 
77.0 ppm, benzene, 7.16 and 128.06 ppm, and methanol, 3.30 and 47.58 ppm 
respectively). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad), coupling constant, integration. 
Infrared resonance spectra were recorded on a Nexus 670 FT-IR spectrometer. Optical 
rotations were recorded on a Rudolph Autopol II digital polarimeter at 589 nm and 
reported as follows:  α  
  (concentration in g/100 mL solvent and solvent). High 
resolution mass-spectra were obtained on a Waters Q-TOF Mass Spectrometer at Boston 
University Chemical Instrumentation Center (CIC). 




To a solution of internal alkyne 1 or 6 (0.2 mmol, 1 equiv) in toluene (2.5 mL) at -78 
o
C 
was added sequentially ClTi(OiPr)3 (1.0 M in hexanes, 0.4 mL, 0.4 mmol, 2 equiv) and 
cC5H9MgCl (2.0 M in diethyl ether, 0.6 mL, 1.2 mmol, 6 equiv) in a dropwise manner. 
The resulting yellow solution turned brown while slowly warming to -40 
o
C over 45 
minutes. The reaction mixture was placed in -40 
o
C chiller and stirred for 3 hours, while 
solution turned to be black and heterogenous. It was then cooled to -78 
o
C, to which 
terminal alkyne was added in dropwise. The resulting mixture was graduately warmed to 




substrate. The reaction was quenched with saturated aqueous NH4Cl solution (3 mL). It 
was then extract with Ethyl acetate (3 x 10 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated. Purification over silica gel chromatography 
afforded coupled product 5 or 8. 
Table 1. 
 N-(3-((1S,2R,3E,5E)-1-(benzyloxy)-2,4-dimethyl-8-
phenylocta-3,5-dien-1-yl)-2,5-dimethoxyphenyl)acetamide (5a): Prepared by the 
general procedure A using acetamide 1 (76 mg), 4-phenyl-1-butyne (84 μL, 0.6 mmol, 3 
equiv),  and stirred for 3h at room temperature. The crude material was purified with 
Preparative Thin Layer Chromatography using 10% Et2O in DCM as eluent. 5a (58mg, 
57% yield, r.r.>20:1, d.r.>20:1) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.88 (d, J = 2.5 Hz, 1H), δ7.58 (s, 1H), δ7.32-7.17 (m, 
10H), δ6.74 (d, J = 2.8 Hz, 1H), δ6.01 (d, J = 15.6 Hz, 1H), δ5.54 (dt, J = 15.5, 7 Hz, 
1H), δ5.30 (d, J = 9.7 Hz, 1H), δ4.49 (d, J = 11.6 Hz, 1H), δ4.49 (d, J = 6.55 Hz, 1H), 
δ4.29 (d, J = 11.9 Hz, 1H), δ3.78 (s, 3H), δ3.61 (s, 3H), δ2.92-2.84 (m, 1H), δ2.70-2.67 
(m, 2H), δ2.40-2.36 (m, 2H), δ2.21 (s, 3H), δ1.56 (s, 3H), δ1.07 (d, J = 6.7 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.16, δ156.20, δ142.01, δ140.94, δ138.46, δ135.22, 




δ125.75, δ108.10, δ105.48, δ79.04, δ70.87, δ61.29, δ55.62, δ38.99, δ36.15, δ34.76, 




) υmax:  
 
HRMS (ESI) m/z calcd for C33H39NO4 [M+H]
+
: 514.2957, found: 514.2962. 
 
 N-(3-((1S,2R,3E,5E)-1-(benzyloxy)-2,4-dimethyl-6-
phenylhexa-3,5-dien-1-yl)-2,5-dimethoxyphenyl)acetamide (5b): Prepared by the 
general procedure A using acetamide 1 (76 mg), phenylacetylene (66 μL, 0.6 mmol, 3 
equiv), and stirred for 3h at room temperature. The crude material was purified with 
Preparative Thin Layer Chromatography using 26% Et2O in DCM as eluent. 5b (48mg, 
50% yield, r.r.>20:1, d.r.>20:1) was obtained as a pale yellow, viscous oil.  
 
1
H NMR (500 MHz, CDCl3): δ7.88 (d, J = 2.9 Hz, 1H), δ7.56 (s, 1H), δ7.39-7.17 (m, 
10), δ6.77 (d, J = 2.9 Hz, 1H), δ6.70 (d, J = 16.1 Hz, 1H), δ6.38 (d, J = 16.1 Hz, 1H), 
δ5.54 (d, J = 9.8 Hz, 1H), δ4.53 (d, J = 11.8 Hz, 1H), δ4.53 (d, J = 6.5 Hz, 1H), δ3.79 (s, 
3H), δ3.63 (s, 3H), δ2.98-2.91 (m, 1H), δ2.18 (s, 3H), δ1.68 (d, J = 1.2 Hz, 2H), δ1.12 (d, 






C NMR (125 MHz, CDCl3): δ168.18, δ156.24, δ138.38, δ138.18, δ137.90, δ136.33, 
δ134.16, δ134.01, δ133.43, δ131.77, δ128.52, δ128.30, δ127.56, δ127.49, δ126.90, δ 







HRMS (ESI) m/z calcd for C31H35NO4 [M+H]
+
: 486.2644, found: 486.2658. 
 
N-(3-((1S,2R,3E,5E)-1-(benzyloxy)-2,4-
dimethyldodeca-3,5-dien-1-yl)-2,5-dimethoxyphenyl)acetamide (5d): Prepared by the 
general procedure A using acetamide 1 (76 mg), 1-octyne (88 μL, 0.6 mmol, 3 equiv), 
and stirred for 3h at room temperature. The crude material was purified with Preparative 
Thin Layer Chromatography using 27% Ethyl acetate in Hexanes as eluent. 5d (61mg, 
62% yield, r.r.>20:1, d.r.>20:1) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.87 (d, J = 2.8 Hz, 1H), δ7.58 (s, 1H), δ7.34-7.29 (m, 
5H), δ6.74 (d, J = 2.8 Hz, 1H), δ5.95 (d, J = 15.6 Hz, 1H), δ5.49 (dt, J = 14.8, 7.2 Hz, 
1H), δ5.28 (d, J = 9.8 Hz, 1H), δ4.49 (d, J = 11.6 Hz, 1H), δ4.49 (d, J = 6.5 Hz, 1H), 




3H), δ2.05 (dt, J = 7.2 Hz, 2H), δ1.56 (s, 3H), δ1.38-1.17 (m, 8H), δ1.06 (d, J = 6.7 Hz, 
3H), δ0.88 (t, J = 6.7 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.18, δ156.17, δ140.94, δ138.47, δ134.60, δ134.30, 
δ133.22, δ132.68, δ131.71, δ128.32, δ128.26, δ127.52, δ127.42, δ108.08, δ105.44, 
δ79.03, δ70.85, δ61.28, δ55.63, δ38.96, δ32.89, δ31.75, δ29.65, δ28.96, δ24.94, δ22.62, 






HRMS (ESI) m/z calcd for C31H43NO4 [M+Na]
+
: 516.3090, found: 516.3096. 
 
 N-(3-((1S,2R,3E,5E)-1-(benzyloxy)-2,4-dimethyldeca-
3,5-dien-1-yl)-2,5-dimethoxyphenyl)acetamide (5e): Prepared by the general procedure 
A using acetamide 1 (76 mg), 1-hexyne (69 μL, 0.6 mmol, 3 equiv), and stirred for 3h at 
room temperature. The crude material was purified with Preparative Thin Layer 
Chromatography using 30% Ethyl acetate in Hexanes as eluent. 5e (56mg, 61% yield, 






H NMR (500 MHz, CDCl3): δ7.87 (d, J = 2.7 Hz, 1H), δ7.58 (s, 1H), δ7.34-7.28 (m, 
5H), δ6.74 (d, J = 2.7 Hz, 1H), δ5.95 (d, J = 15.5 Hz, 1H), δ5.49 (dt, J = 14.9, 6.8 Hz, 
1H), δ5.28 (d, J = 9.8 Hz, 1H), δ4.49 (d, J = 11.6 Hz, 1H), δ4.49 (d, J = 6.8 Hz, 1H), 
δ4.29 (d, J = 11.9 Hz, 1H), δ3.78 (s, 3H), δ3.61 (s, 3H), δ2.90-2.83 (m, 1H), δ2.21 (s, 
3H), δ2.06 (dt, J = 6.9 Hz, 2H), δ1.56 (s, 3H), δ1.38-1.27 (m, 4H), δ1.06 (d, J = 6.7 Hz, 
3H), δ0.89 (t, J = 7.0 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.18, δ156.17, δ140.93, δ138.47, δ134.64, δ134.30, 
δ133.21, δ132.66, δ131.71, δ128.26, δ128.24, δ127.52, δ127.42, δ108.06, δ105.44, 







HRMS (ESI) m/z calcd for C29H39NO4 [M+Na]
 +
: 488.2777, found: 488.2758. 
 
N-(3-((1S,2R,3E,5E)-1-(benzyloxy)-2,4-dimethyl-6-
(pyridin-3-yl)hexa-3,5-dien-1-yl)-2,5-dimethoxyphenyl)acetamide (5f): Prepared by 
the general procedure A using acetamide 1 (76 mg), 3-ethynylpyridine (62 mg, 0.6 




with Preparative Thin Layer Chromatography using 30% acetone in DCM as eluent. 5f 
(59mg, 61% yield, r.r.>20:1, d.r.>20:1) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.54-8.52 (m, 1H), δ7.85 (d, J = 2.8 Hz, 1H), δ7.62-7.59 
(m, 2H), δ7.33-7.27 (m, 5H), δ7.18 (d, J = 15.7 Hz, 1H), δ7.09-7.07 (m, 2H), δ6.75 (d, J 
= 2.9 Hz, 1H), δ6.45 (d, J = 15.8 Hz, 1H), δ5.69 (d, J = 9.9 Hz, 1H), δ4.53 (d, J = 6.7 Hz, 
1H), δ4.51 (d, J = 11.8 Hz, 1H), δ4.31 (d, J = 11.8 Hz, 1H), δ3.78 (s, 3H), δ3.63 (s, 3H), 
δ2.99-2.92 (m, 1H), δ2.18 (s, 3H), δ1.69 (d, J = 1.2 Hz, 3H), δ1.13 (d, J = 6.7 Hz, 2H); 
 
13






HRMS (ESI) m/z calcd for C30H34N2O4 [M+H]
+




dimethoxyphenyl)acetamide (5g): Prepared by the general procedure A using 
acetamide 1 (76 mg), tert-butyldimethyl(pent-4-yn-1-yloxy)silane
62
 (119 mg, 0.6 mmol, 




Preparative Thin Layer Chromatography using 30% Ethyl acetate in Hexanes as eluent. 
5g (70 mg, 60% yield, r.r.>20:1, d.r.>20:1) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.87 (d, J = 2.9 Hz, 1H), δ7.58 (s, 1H), δ7.34-7.24 (m, 
5H), δ6.74 (d, J = 2.9 Hz, 1H), δ5.97 (d, J = 15.6 Hz, 1H), δ5.49 (dt, J = 15.6, 6.9 Hz, 
1H), δ5.29 (d, J = 9.7 Hz, 1H), δ4.49 (d, J = 11.9 Hz, 1H), δ4.49 (d, J = 6.3 Hz, 1H), 
δ4.29 (d, J = 11.9 Hz, 1H), δ3.78 (s, 3H), δ3.62 (s, 3H), δ3.61 (t, J = 6.5 Hz, 2H), δ2.91-
2.84 (m, 1H), δ2.21 (s, 3H), δ2.11 (dt, J = 7.3 Hz, 2H), δ1.62-1.56 (m, 2H), δ1.56 (s, 3H), 
δ1.06 (d, J = 6.7 Hz, 3H), δ0.89 (s, 9H), δ0.04 (s, 6H); 
 
13
C NMR (125 MHz, CDCl3): δ168.17, δ156.18, δ140.95, δ138.47, δ134.98, δ134.29, 
δ133.12, δ132.85, δ131.72, δ128.26, δ127.52, δ127.42, δ108.11, δ105.48, δ79.07, δ70.87, 







HRMS (ESI) m/z calcd for C34H51NO5Si [M+Na]
 +






2,4-dimethylhepta-3,5-dien-1-yl)-2,5-dimethoxyphenyl)acetamide (5h): Prepared by 
the general procedure A using acetamide 1 (76 mg), 3-dimethylamino-1-propyne (65 μL, 
0.6 mmol, 3 equiv), and stirred for 3h at room temperature. The crude material was 
purified with Preparative Thin Layer Chromatography using 90% MeOH in DCM as 




H NMR (500 MHz, CDCl3): δ7.86 (d, J = 2.8 Hz, 1H), δ7.60 (s, 1H), δ7.32-7.26 (m, 
5H), δ6.73 (d, J = 2.8 Hz, 1H), δ6.07 (d, J = 15.7 Hz, 1H), δ5.53 (dt, J = 15.6, 6.8 Hz, 
1H), δ5.37 (d, J = 9.5 Hz, 1H), δ4.51 (d, J = 12.0 Hz, 1H), δ4.50 (d, J = 6.1 Hz, 1H), 
δ4.29 (d, J = 11.9 Hz, 1H), δ3.78 (s, 3H), δ3.61 (s, 3H), δ2.99-2.85 (m, 3H), δ2.23 (s, 
6H), δ2.21 (s, 3H), δ1.58 (s, 3H), δ1.07 (d, J = 6.7 Hz, 3H); 
 
13
C NMR (100 MHz, CDCl3): δ168.20, δ156.19, δ140.92, δ138.40, δ134.58, δ134.16, 
δ132.82, δ131.75, δ128.28, δ127.52, δ127.47, δ108.08, δ105.48, δ78.97, δ70.87, δ61.97, 









HRMS (ESI) m/z calcd for C28H38N2O4 [M+H]
+















2.1. General Procedure B for the Asymmetric Three-Component Propargylation for 
the Synthesis of Propargylic Ethers 26, 27, 28, 32 and 33 
A solution of allenylsilane (Sa)-25 (5 g, 24.7 mmol, 1 equiv), (benzyloxy)trimethylsilane 
(5.8 mL, 29.64 mmol, 1.2 equiv), and aldehyde (4.85 g, 32.11 mmol, 1.3 equiv) in 123.5 
mL propionitrile (EtCN) was stirred at room temperature for 5 minutes and cooled to -78 
o
C. Trimethylsilyl trifluoromethanesulfonate (TMSOTf) (1.8 mL, 9.88 mmol, 0.4 equiv) 
was added to above mixture dropwise. The resulting mixture was placed into -70 
o
C 
chiller and stirred for 12 hours. The reaction was quenched by adding 50 mL saturated 
NaHCO3 (aq) solution at -70 
o
C. After the mixture was warmed to room temperature, it 
was then extracted with ethyl acetate (3 x 50 mL), and the combined organic layers were 
dried over MgSO4, filtered, and concentrated. Purification over silica gel chromatography 
(CH2Cl2/Hexanes) afforded product 26, 27, 28, 32, and 33 as an oil. 
 
1-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-2-
nitrobenzene (26): Prepared by the general procedure B using 2-
nitrobenzaldehyde. The crude material was purified with silica gel column 
Chromatography using 48% DCM in Hexanes. 26 (6.11 g, 80% yield, d.r.: 5:1) was 
obtained as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.86 (d, J = 8.1 Hz, 1H), δ7.81(d, J = 7.8 Hz, 2H), δ7.62 




δ4.51 (d, J = 11.6 Hz, 1H), δ4.44 (d, J = 11.7 Hz, 1H), δ2.67-2.60 (m, 1H), δ1.63 (dd, J = 
2.4, 1.0 Hz, 3H), δ 1.27(dd, J = 6.8, 0.8 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ150.29, δ137.81, δ136.43, δ132.82, δ128.50, δ128.36, 







HRMS (ESI) m/z calcd for C19H19NO3 [M+H]
+
:310.1443, found: 310.1443. 
 
1-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-3-
nitrobenzene (27): Prepared by the general procedure B using 3-nitrobenzaldehyde. The 
crude material was purified with silica gel column Chromatography using 48% DCM in 
Hexanes. 27 (4.58 g, 60% yield, d.r.: 5:1) was obtained as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.30-8.29 (m, 1H), δ8.19-8.17, (m, 1H), δ7.73-7.69 (m, 
1H), δ7.54 (t, J = 7.9 Hz, 1H), δ7.35-7.28 (m, 5H), δ4.52 (d, J = 11.9 Hz, 1H), δ4.30 (d, J 
= 11.9 Hz, 1H), δ4.24 (d, J = 7.6 Hz, 1H), δ2.81-2.74 (m, 1H), δ1.68 (d, J = 2.4 Hz, 3H), 






C NMR (125 MHz, CDCl3): δ147.82, δ142.35, δ137.30, δ133.42, δ128.57, δ128.18, 






LCMS (ES+) m/z calcd for C19H19NO3 [M+H]
+
: 310.14, found: 310.16. 
 
1-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-4-
nitrobenzene (28): Prepared by the general procedure B using 4-nitrobenzaldehyde. The 
crude material was purified with silica gel column Chromatography using 40% DCM in 
Hexanes. 28 (4.51 g, 59% yield, d.r.: 3:1) was obtained as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.24-8.21 (m, 2H), δ7.56-7.53 (m, 2H), δ7.36-7.27 (m, 
5H), δ4.49 (d, J = 11.9 Hz, 1H), δ4.28 (d, J = 11.9 Hz, 1H), δ4.24 (d, J = 7.6 Hz, 1H), 
δ2.80-2.73 (m, 1H), δ1.67 (d, J = 2.4 Hz, 3H), δ1.24 (d, J = 6.9 Hz, 2H); 
 
13
C NMR (125 MHz, CDCl3): δ148.04, δ137.57, δ128.55, δ128.44, δ127.83, δ123.18, 









LCMS (ES+) m/z calcd for C19H19NO3 [M+H]
+
: 310.14, found: 310.16. 
 
 4-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)-1-bromo-2-
nitrobenzene (32): Prepared by the general procedure B using 4-bromo-3-
nitrobenzaldehyde. The crude material was purified with silica gel column 
Chromatography using 40% DCM in Hexanes. 32 (7.19 g, 75% yield, d.r.: 5:1) was 
obtained as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.89 (d, J = 1.8 Hz, 1H), δ7.72 (d, J = 8.2 Hz, 1H), δ7.44 
(dd, J = 8.2, 1.7 Hz, 1H), δ7.37-7.27 (m, 5H), δ4.52 (d, J = 11.9 Hz, 1H), δ4.30 (d, J = 
11.9 Hz, 1H), δ4.16 (d, J = 7.6 Hz, 1H), δ2.76-2.70 (m, 1H), δ1.70 (d, J = 2.3 Hz, 2H), 
δ1.22 (d, J = 6.9 Hz, 2H); 
 
13
C NMR (125 MHz, CDCl3): δ149.45, δ141.83, δ137.29, δ134.49, δ132.15, δ128.48, 






HRMS (ESI) m/z calcd for C19H18BrNO3 [M+H]
+






nitrobenzene (33): Prepared by the general procedure B using 4-methyl-3-
nitrobenzaldehyde. The crude material was purified with silica gel column 
Chromatography using 40% DCM in Hexanes. 33 (4.07 g, 51% yield, d.r.: 2:1) was 
obtained as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.02 (d, J = 1.3 Hz, 1H), δ7.52 (dd, J = 7.8, 1.6 Hz, 1H), 
δ7.36-7.28 (m, 5H), δ4.51 (d, J = 11.9 Hz, 1H), δ4.27 (d, J = 11.9 Hz, 1H), δ4.18 (d, J = 
7.5 Hz, 1H), δ2.79-2.72 (m, 1H), δ2.62 (s, 3H), δ1.70 (d, J = 2.3 Hz, 3H), δ1.22 (d, J = 
6.9 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ148.90, δ139.85, δ137.68, δ132.91, δ132.39, δ132.02, 







HRMS (ESI) m/z calcd for C20H21NO3 [M+H]
+
: 324.1600, found: 324.1600. 
 






Arylnitro alkyne 26, 27, 28, 32, or 33 (16.16 mmol, 1 equiv) was dissolved in 323.2 mL 
anhydrous MeOH at room temperature. Zinc powder (57.7g, 888.8 mmol, 55 equiv) and 
calcium chloride (26.9g, 242.4 mmol, 15 equiv) were added in to the above solution 
sequentially. The resulting mixture was refluxed for 1 hour. It was then cooled down to 
room temperature and MeOH was evaporated off before 100 mL saturated NaHCO3 (aq) 
solution and 100 mL Ethyl acetate were added in. The resulting biphasic mixture was 
vigorously stirred for 1 hour at room temperature before extractive isolation. The 
combined organic layers were dried over MgSO4, filtered, and concentrated. Purification 
over silica gel chromatography afforded aniline 29, 30, 31, 34, and 35. 
 
2-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)aniline (29): 
Prepared by the general procedure C using 26. The crude material was purified with 
silica gel column Chromatography using 10 % Ethyl acetate in Hexanes. 29 (4.24 g, 
15.19 mmol, 94% yield) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.35-7.27 (m, 5H), δ7.12 (ddd, J = 7.9, 7.4, 1.6 Hz, 1H), 
δ7.09 (dd, J = 7.6, 1.6 Hz, 1H), δ4.54 (d, J = 11.8 Hz, 1H), δ4.31 (d, J = 11.8 Hz, 1H), 
δ4.22 (d, J = 9.0 Hz, 1H), δ3.09 (dqq, J = 9.0, 6.7, 2.3 Hz, 1H), δ1.65 (d, J = 2.4 Hz, 3H), 






C NMR (125 MHz, CDCl3): δ144.58, δ138.08, δ130.43, δ128.54, δ128.30, δ127.92, 







LCMS (ES+) m/z calcd for C19H21NO [M+H]
+
: 280.17, found: 280.18. 
 
3-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)aniline (30): 
Prepared by the general procedure C using 27. The crude material was purified with 
silica gel column Chromatography using 23 % Ethyl acetate in Hexanes. 30 (4.42 g, 
15.84 mmol, 98% yield) was obtained as a pale yellow, viscous oil.  
 
1
H NMR (500 MHz, CDCl3): δ7.38-7.27 (m, 5H), δ7.15 (t, J = 7.7 Hz, 1H), δ6.79-6.76 
(m, 2H), δ6.68 (ddd, J = 7.9, 2.4, 0.9 Hz, 1H), δ4.54 (d, J = 12.0 Hz, 1H), δ4.28 (d, J = 
12.0 Hz, 1H), δ4.11 (d, J = 7.1 Hz, 1H), δ2.78-2.72 (m, 1H), δ1.71 (d, J = 2.4 Hz, 3H), 
δ1.21 (d, J = 6.9 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ145.98, δ141.51, δ138.56, δ128.78, δ128.25, δ127.76, 










HRMS (ESI) m/z calcd for C19H21NO [M+H]
+
: 280.1701, found: 280.1696. 
 
4-((1S,2R)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)aniline (31): 
Prepared by the general procedure C using 28. The crude material was purified with 
silica gel column Chromatography using 22 % Ethyl acetate in Hexanes. 31 (4.11 g, 
14.71 mmol, 91% yield) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.38-7.25 (m, 5H), δ7.19-7.16 (m, 2H), δ6.73 (d, J = 7.8 
Hz, 1H), δ4.49 (d, J = 12.1 Hz, 1H), δ4.23 (d, J = 12.1 Hz, 1H), δ4.06 (d, J = 7.3 Hz, 
1H), δ2.78-2.71 (m, 1H), δ1.70 (d, J = 2.4 Hz, 1H), δ1.19 (d, J = 6.9 Hz, 1H); 
 
13
C NMR (125 MHz, CDCl3): δ138.60, δ128.84, δ128.22, δ127.78, δ127.37, δ115.07, 






LCMS (ESI) m/z calcd for C19H21NO [M+H]
+






bromoaniline (34): Prepared by the general procedure C using 32. The crude material 
was purified with silica gel column Chromatography using 22 % Ethyl acetate in 
Hexanes.  (4.40 g, 12.28 mmol, 76% yield) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.38 (d, J = 8.1 Hz, 1H), δ7.35-7.28 (m, 5H), δ6.80 (s, 
1H), δ6.62 (d, J = 8.0 Hz, 1H), δ4.51 (d, J = 12.0 Hz, 1H), δ4.25 (d, J = 12.0 Hz, 1H), 




methylaniline (35): Prepared by the general procedure C using 33. The crude material 
was purified with silica gel column Chromatography using 16 % Ethyl acetate in 
Hexanes.  (3.79 g, 12.93 mmol, 80% yield) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.38-7.27 (m, 5H), δ7.04 (d, J = 7.5 Hz, 1H), δ6.73 (s, 
1H), δ6.69 (d, J = 15.1 Hz, 1H), δ4.54 (d, J = 12.1 Hz, 1H), δ4.27 (d, J = 12.1 Hz, 1H), 
δ4.10 (d, J = 7.0 Hz, 1H), δ3.66 (brs, 2H), δ2.78-2.72 (m, 1H), δ2.19 (s, 3H), δ1.72 (d, J 






C NMR (125 MHz, CDCl3): δ144.11, δ139.00, δ138.63, δ129.97, δ128.23, δ127.76, 







HRMS (ESI) m/z calcd for C20H23NO [M+H]
+
: 294.1858, found: 294.1854. 
 
General Procedure D for the Synthesis of 21a, 6a, 6b, 6e, and 6f by N-Acylation 
Alkynyl aniline 29, 30, 31, 34, or 35 (14.32 mmol, 1 equiv) was dissolved in 71.6 mL 
dichloromethane (DCM) at room temperature. Acetic anhydride (2.7 mL, 28.64 mmol, 2 
equiv), triethyl amine (6 mL, 42.96 mmol, 3 equiv) (dropwise), and 4-
dimethylaminopyridine (DMAP) (525 mg, 4.3 mmol, 30% equiv) was added in 
sequentially. The resulting mixture was stirred at room temperature for 12 hours before it 
was quenched with 10 mL saturated NH4Cl(aq) solution. It was then extracted with Ethyl 
acetate (50 mL x 3). The combined organic layers were dried over MgSO4, filtered, and 
concentrated. Purification over silica gel chromatography afforded acetamide 21a, 6a, 6b, 






yl)phenyl)acetamide (21a): Prepared by the general procedure D using 29. The crude 
material was purified with silica gel column Chromatography using 23 % Ethyl acetate in 
Hexanes. 21a (4.14 g, 12.89 mmol, 90% yield) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ9.03 (s, 1H), δ8.26 (d, J = 8.4 Hz, 1H), δ7.37-7.28 (m, 
5H), δ7.14 (d, J = 7.3 Hz, 1H), δ7.09-7.05 (m, 2H), δ4.52 (d, J = 11.4 Hz, 1H), δ4.37 (d, 
J = 11.4 Hz, 1H), δ4.27 (d, J = 8.2 Hz, 1H), δ2.95-2.87 (m, 1H), δ2.00 (s, 3H), δ1.65 (d, J 
= 2.1 Hz, 3H), δ1.28 (d, J = 6.8 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.21, δ137.05, δ130.02, δ128.68, δ128.49, δ128.15, 







HRMS (ESI) m/z calcd for C21H23NO2 [M+Na]
+






yl)phenyl)acetamide (6b): Prepared by the general procedure D using 30. The crude 
material was purified with silica gel column Chromatography using 40 % Ethyl acetate in 
Hexanes. 6b (4.42 g, 13.75 mmol, 96% yield) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.59 (d, J = 8.0 Hz, 1H), δ7.39 (s, 1H), δ7.35-7.27 (m, 
5H), δ7.19 (s, 1H), δ7.12 (d, J = 7.7 Hz, 1H), δ4.51 (d, J = 12.0 Hz, 1H), δ4.27 (d, J = 
12.0 Hz, 1H), δ4.16 (d, J = 7.2 Hz, 1H), δ2.79-2.72 (m, 1H), δ2.18 (s, 3H), δ1.69 (d, J = 
2.4 Hz, 3H), δ1.21 (d, J = 6.9 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.40, δ141.24, δ138.30, δ137.80, δ128.58, δ128.28, 
δ127.74, δ127.50, δ123.78, δ119.36, δ118.77, δ83.90, δ80.64, δ77.96, δ70.73, δ33.67, 






HRMS (ESI) m/z calcd for C21H23NO2 [M+Na]
+






yl)phenyl)acetamide (6a): Prepared by the general procedure D using 31. The crude 
material was purified with silica gel column Chromatography using 50 % Ethyl acetate in 
Hexanes. 6a (4.37 g, 13.60 mmol, 95% yield) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.49 (d, J = 8.4 Hz, 1H), δ7.34-7.27 (m, 5H), δ7.17 (brs, 
1H), δ4.49 (d, J = 12.0 Hz, 1H), δ4.24 (d, J = 12.0 Hz, 1H), δ4.12 (d, J = 7.3 Hz, 1H), 
δ2.75 (dddq, J = 9.3, 6.9, 4.5, 2.3 Hz, 1H), δ2.19 (s, 3H), δ1.68 (d, J = 2.4 Hz, 3H), δ1.20 
(d, J = 6.9 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.44, δ138.29, δ137.44, δ136.08, δ128.37, δ128.29, 







HRMS (ESI) m/z calcd for C21H23NO2 [M+H]
+






bromophenyl)acetamide (6e): Prepared by the general procedure D using 34. The crude 
material was purified with silica gel column Chromatography using 34 % Ethyl acetate in 
Hexanes. 6e (2.69 g, 6.73 mmol, 47% yield) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.36 (s, 1H), δ7.60 (s, 1H), δ7.52 (d, J = 8.3 Hz, 1H), 
δ7.34-7.27 (m, 5H), δ7.07 (dd, J = 8.2, 1.8 Hz, 2H), δ4.51 (d, J = 12.0 Hz, 1H), δ4.26 (d, 
J = 11.9 Hz, 1H), δ4.15 (d, J = 7.3 Hz, 1H), δ2.79-2.72 (m, 1H), δ2.24 (s, 3H), δ1.70 (d, J 
= 2.4 Hz, 3H), δ1.20 (d, J = 6.9 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ167.96, δ141.08, δ140.53, δ138.11, δ135.21, δ131.69, 
δ128.29, δ127.82, δ127.54, δ124.10, δ121.55, δ112.14, δ83.58, δ80.28, δ78.34, δ70.83, 












methylphenyl)acetamide (6f): Prepared by the general procedure D using 35. The crude 
material was purified with silica gel column Chromatography using 37 % Ethyl acetate in 
Hexanes. 6f (2.45 g, 7.30 mmol, 51% yield) was obtained as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.74 (s, 1H), δ7.34-7.25 (m, 5H), δ7.19-7.13 (m, 2H), 
δ7.06 (brs, 1H), δ4.53 (d, J = 12.1 Hz, 1H), δ4.26 (d, J = 12.0 Hz, 1H), δ4.17 (d, J = 6.9 
Hz, 1H), δ2.80-2.72 (m, 1H), δ2.27 (s, 3H), δ2.19 (s, 3H), δ1.20 (d, J = 6.8 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.19, δ138.84, δ138.43, δ135.27, δ130.15, δ128.96, 
δ128.25, δ127.79, δ127.41, δ124.53, δ123.07, δ83.69, δ80.75, δ77.91, δ70.61, δ33.70, 






HRMS (ESI) m/z calcd for C22H25NO2 [M+Na]
+
: 358.1783, found: 358.1770. 
 





General Procedure E for Enantioselective Cross Aldol Reaction Catalyzed by D- or 
L-Proline for the Synthesis of Anti-β-Hydroxyl Aldehyde 36 and Related
64
 
Nitrobenzaldehyde (10g, 66.2 mmol, 1 equiv) and D- or L-proline (1.52g, 13.2 mmol, 0.2 
equiv) were dissolved in 662 mL anhydrous N,N-dimethylformamide (DMF) at room 
temperature. Freshly distilled propionaldehyde (6.2 mL, 86.06 mmol, 1.3 equiv) was 
added into the above mixture, which was subsequently placed into -4 
o
C and stirred for 
6h. The reaction was quenched by adding 200 mL DI water and warmed to room 
temperature. DMF was removed by washing the mixture with 5% LiCl (50g LiCl and 1 
liter DI water) solution. Accordingly, 500 mL 5% LiCl solution and 700 ethyl acetate 
were added into the quenched reaction mixture. After extractive workup, the aqueous 
layer was back extracted with 250 mL Ethyl acetate twice. The combined organic layer 




MgSO4, filtered, and concentrated. The afforded anti-β-hydroxyl aldehyde was unstable 
on silica gel column or stored overnight, and was used immediately in the next reaction. 
 
36 (dr: 10:1) was synthesized according to general procedure E using 2-nitrobenzaldhyde 
and D-proline. It was used without purification. 
 
1
H NMR (400 MHz, CDCl3): δ9.80 (s, 1H), δ8.23 (d, J = 8.7 Hz, 1H), δ7.54 (d, J = 8.4 
Hz, 1H), δ4.96 (d, J = 7.8 Hz, 1H), δ2.80-2.73 (m, 1H), δ0.99 (d, J = 7.5 Hz, 3H). 
 
General procedure F for Synthesis of Anti-β-Hydroxyl Dimethyl Acetal 37 and 
Related 
To a solution of anti-β-hydroxyl aldehyde (10g, 47.8 mmol, 1 equiv, treated as 75% pure 
from previous step) in 240 mL anhydrous MeOH at room temperature was added 
trimethyl orthoformate (11 mL, 95.6 mmol, 2 equiv) and p-toluenesulfonic acid 
monohydrate (700mg, 3.83 mmol, 0.08 equiv) sequentially. The resulting solution was 
stirred at room temperature for 6 hours before it was quenched with saturated NaHCO3 
(aq). It was then extracted with Ethyl acetate (400 mL x 3). The combined organic layers 
were dried over MgSO4, filtered, and concentrated. Purification over silica gel 






(37): Prepared by general procedure F using 36. The crude material was purified with 
silica gel column Chromatography using 30% Ethyl acetate in hexanes. 37 (12.17g, 47.66 
mmol, 72% over two steps, dr: 10:1) was afforded as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.23 (t, J = 1.9 Hz, 1H), δ8.14 (ddd, J = 8.2, 2.3, 1.0 Hz, 
1H), δ7.67 (d, J = 7.7 Hz, 1H), δ7.51 (t, J = 7.9 Hz, 1H), δ4.72 (dd, J = 8.5, 1.6 Hz, 1H), 
δ4.41 (d, J = 1.8 Hz, 1H), δ4.34 (d, J = 5.5 Hz, 1H), δ3.51 (s, 3H), δ3.43 (s, 3H), δ2.17-
2.10 (m, 1H), δ1.55 (s, 3H), δ0.69 (d, J = 7.0 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ148.27, δ145.16, δ133.26, δ129.10, δ122.56, δ122.06, 






LCMS (ESI) m/z calcd for C12H17NO5 [M+H]
+
: 256.11, found: 256.16. 
 
General procedure G for the Hydroxyl Protection of Anti-β-Hydroxyl Dimethyl 
Acetal 37 and Related as Benzyl Ether
65
 
To a solution of anti-β-hydroxyl dimethyl acetal (10g, 39.17 mmol, 1 equiv) in a solvent 




mmol, 3 equiv) at room temperature. Tetrabutylammonium iodide (2.89g, 7.82 mmol, 0.2 
equiv) was added into above mixture and stirred for 5 minutes, followed by silver (I) 
oxide (27g, 116.5 mmol, 3 equiv). The reaction mixture was stirred at room temperature 
for 4 hours. It was quenched by filtering through a pad of Celite. 500 mL 5% LiCl (aq) 
solution and 700 mL Ethyl acetate were added in before extractive workup. The aqueous 
layer was back extracted with 250 mL Ethyl acetate for three times. The combined 
organic layers were washed with 5% LiCl (aq) solution (250 mL x 4), dried over MgSO4, 
filtered, and concentrated. Purification over silica gel chromatography afforded the 
benzyl protected dimethyl acetal. 
 
 1-((1S,2R)-1-(benzyloxy)-3,3-dimethoxy-2-methylpropyl)-3-
nitrobenzene (38): Prepared by general procedure G using 37. The crude material was 
purified with silica gel column Chromatography using 12.8% Ethyl acetate in hexanes. 38 
(11.1 g, 32.12 mmol, 82% yield) was afforded as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.22-8.21 (m, 1H), δ8.18-8.16 (m, 1H), δ7.67 (d, J = 7.6 
Hz, 1H), δ7.54 (t, J = 7.9 Hz, 1H), δ7.36-7.27 (m, 5H), δ4.48 (d, J = 7.9 Hz, 1H), δ4.40 
(d, J = 11.6 Hz, 1H), δ4.37 (d, J = 4.7 Hz, 1H), δ4.26 (d, J = 11.7 Hz, 1H), δ3.40 (s, 3H), 






C NMR (125 MHz, CDCl3): δ148.37, δ142.74, δ137.77, δ133.86, δ129.20, δ128.42, 






LCMS (ESI) m/z calcd for C19H23NO5 [M+Na]
+
: 368.16, found: 368.17. 
 
General procedure H for Hydroxyl Protection of Anti-β-Hydroxyl Dimethyl Acetal 
37 and Related as Methyl Ether 
Sodium hydride (3.1g, 78 mmol, 60% dispersed in mineral oil, 2 equiv) was washed with 
Hexanes (~4 mL) twice and suspended in 480 mL THF. Iodomethane (9.7 mL, 156 
mmol, 4 equiv) was added into above solution and cooled to 0 
o
C. Anti-β-hydroxyl 
dimethyl acetal (10g, 39 mmol, 1 equiv) in 20 mL THF was added into above solution 
slowly. The resulting mixture was slowly warmed to room temperature and stirred for 4 
hours. After the completion of the reaction, it was then quenched with 100 mL saturated 
NH4Cl aqueous solution. The mixture was then partitioned between 480 mL THF and 
500 mL DI water, and extracted with Ethyl acetate (300 mL x 3). The combined organic 
layers were dried over MgSO4, filtered, and concentrated. Purification over silica gel 






(39): Prepared by general procedure H using 37. The crude material was purified with 
silica gel column Chromatography using 14% Ethyl acetate in hexanes. 39 (7.56 g, 28.08 
mmol, 72% yield) was afforded as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.16-8.14 (m, 1H), δ7.62 (d, J = 7.6 Hz, 1H), δ7.53 (td, J 
= 7.6, 1.8 Hz, 1H), δ4.30 (d, J = 5.0 Hz, 1H), δ4.26 (d, J = 7.7 Hz, 1H), δ3.45 (s, 3H), 
δ3.42 (s, 3H), δ3.20 (s, 3H), δ2.25-2.18 (m, 1H), δ0.68 (d, J = 7.0 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ148.31, δ142.48, δ133.77, δ129.09, δ122.68, δ122.54, 






HRMS (ESI) m/z calcd for C13H19NO5 [M+Na]
+
: 292.1161, found: 292.1150. 
 
General procedure I for the Synthesis of Aldehyde from Dimethyl Acetal 
To a solution of dimethyl acetal (25 mmol, 1 equiv) in 250 mL acetone (reagent grade 
from Sigma Aldrich) at room temperature was added in DI water (13.8 mL, 750 mmol, 
30 equiv) followed by p-toluenesulfonic acid monohydrate (951 mg, 5 mmol, 0.2 equiv). 




hours), after which it was quenched with saturated NaHCO3 (aq) solution. Acetone was 
evaporated in vacuo before the mixture was then partitioned between 500 mL DI water 
and 500 mL Ethyl acetate. The aqueous layer was extracted with Ethyl acetate (200 mL x 
3). The combined organic layers were dried over MgSO4, filtered, and concentrated. 
Purification over silica gel chromatography afforded aldehyde. 
 
 (2R,3S)-3-(benzyloxy)-2-methyl-3-(3-nitrophenyl)propanal (40): 
Prepared by general procedure H using 38. The crude material was purified with silica 
gel column Chromatography using 17% Ethyl acetate in hexanes. 40 (5.31 g, 17.75 
mmol, 71% yield) was afforded as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ9.80 (d, J = 2.5 Hz, 1H), δ8.24-8.21 (m, 2H), δ7.69 (d, J = 
7.6 Hz, 1H), δ7.60 (dd, J = 8.7, 7.7 Hz, 1H), δ7.36-7.30 (m, 2H), δ7.23 (d, J = 7.0 Hz, 
2H), δ4.61 (d, J = 8.8 Hz, 1H), δ4.46 (d, J = 11.7 Hz, 1H), δ4.27 (d, J = 11.7 Hz, 1H), 
δ2.85-2.78 (m, 1H), δ0.86 (d, J = 7.2 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ202.71, δ148.54, δ141.48, δ136.93, δ133.43, δ129.81, 









LCMS (ESI) m/z calcd for C17H17NO4 [M+Na]
+
: 322.12, found: 322.13. 
 
(2R,3S)-3-methoxy-2-methyl-3-(3-nitrophenyl)propanal (41): 
Prepared by general procedure I using 39. The crude material was purified with silica gel 
column Chromatography using 17% Ethyl acetate in hexanes. 41 (3.91 g, 17.5 mmol, 
70% yield) was afforded as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ9.81 (d, J = 2.5 Hz, 1H), δ8.22-8.19 (m, 2H), δ7.66 (d, J = 
7.7 Hz, 1H), δ7.59 (t, J = 7.8 Hz, 1H), δ4.43 (d, J = 8.7 Hz, 1H), δ3.23 (s, 3H), δ2.78-
2.72 (m, 1H), δ0.88 (d, J = 7.2 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ202.75, δ148.51, δ141.39, δ133.32, δ129.73, δ123.38, 






HRMS (ESI) m/z calcd for C11H13NO4 [M+Na]
+
: 246.0742, found: 246.0746. 
 
General procedure J for Seyferth-Gilbert Homologation for the Synthesis of 







Potassium tert-butoxide (5.68 g, 50.6 mmol, 2.2 equiv) was suspended in 220 mL THF 




 (6.90 g, 46 mmol, 2 equiv) in 
4 mL THF was added into above solution dropwise and stirred for 20 minutes, followed 
by the dropwise addition of aldehyde (23 mmol, 1 equiv) in 6 mL THF. The resulting 
mixture was stirred at -78 
o
C for 10 minutes, before it was quenched with 250 mL 
saturated NH4Cl (aq) solution. 500 mL added into the quenched mixture and the organic 
layer was collected. The aqueous layer was extracted with Ethyl acetate (200 mL x3). 
The combined organic layers were dried over MgSO4, filtered, and concentrated. 
Purification over silica gel chromatography afforded aldehyde as a pale yellow oil. 
 
 1-((1S,2S)-1-(benzyloxy)-2-methylbut-3-yn-1-yl)-3-nitrobenzene 
(42): Prepared by general procedure J using 40. The crude material was purified with 
silica gel column Chromatography using 11% Ethyl acetate in hexanes. 42 (3.46 g, 11.73 
mmol, 51% yield) was afforded as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.25 (s, 1H), δ8.19 (d, J = 8.1 Hz, 1H), δ7.74 (d, J = 7.6 
Hz, 1H), δ7.55 (t, J = 7.9 Hz, 1H), δ7.36-7.29 (m, 5H), δ4.59 (d, J = 12.1 Hz, 1H), δ4.46 
(d, J = 5.3 Hz, 1H), δ4.34 (d, J = 12.0 Hz, 1H), δ2.92-2.87 (m, 1H), δ2.14 (d, J = 2.4 Hz, 






C NMR (125 MHz, CDCl3): δ148.20, δ141.49, δ137.38, δ133.57, δ129.10, δ128.44, 






HRMS (ESI) m/z calcd for C18H17NO3 [M+H]
+
: 296.1287, found: 296.1273. 
 
1-((1S,2S)-1-methoxy-2-methylbut-3-yn-1-yl)-3-nitrobenzene (43): 
Prepared by general procedure J using 41. The crude material was purified with silica gel 
column Chromatography using 8.7% Ethyl acetate in hexanes. 43 (4.54 g, 20.7 mmol, 
90% yield) was afforded as a white solid. 
 
1
H NMR (500 MHz, CDCl3): δ8.24-8.22 (m, 1H), δ8.19-8.17 (m, 1H), δ7.71 (d, J = 7.6 
Hz, 1H), δ7.55 (t, J = 7.9 Hz, 1H), δ4.26 (d, J = 5.3 Hz, 1H), δ3.32 (s, 3H), δ2.89-2.82 
(m, 1H), δ2.14 (d, J = 2.5 Hz, 1H), δ1.14 (d, J = 7.1 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ148.17, δ141.41, δ133.38, δ129.08, δ122.98, δ122.36, 









LCMS (ESI) m/z calcd for C12H13NO3 [M+Na]
+
: 242.079, found: 242.084. 
 
General Procedure K for Methylation of Terminal Alkyne 
To a solution of terminal alkyne (10 mmol, 1 equiv) in 200 mL THF at -78 
o
C was added 
in lithium bis(trimethylsilyl)amide solution (20 mL, 20 mmol, 2 equiv, 1M in THF) 
dropwise. The resulting reaction mixture was stirred at -78 
o
C for 1 hour (check HNMR 
for completion of deprotonation). Iodomethane (6.2 mL, 100 mmol, 10 equiv) was added 
into the above mixture dropwise, which was slowly warmed to room temperature over 5 
hours. The reaction was quenched with 200 mL saturated NH4Cl (aq) solution. 200 mL 
DI water added into the mixture for extractive isolation. The aqueous layer was extracted 
with Ethyl acetate (100 mL x3). The combined organic layers were dried over MgSO4, 




nitrobenzene (44): Prepared by general procedure K using 42. The crude material was 
purified with silica gel column Chromatography using 6.3% Ethyl acetate in hexanes. 44 
(2.94 g, 9.5 mmol, 95% yield) was afforded as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.27 (s, 1H), δ8.18 (ddd, J = 8.2, 2.2, 1.0 Hz, 1H), δ7.71 




1H), δ4.42 (d, J = 5.2 Hz, 1H), δ4.33 (d, J = 12.2 Hz, 1H), δ2.88-2.81 (m, 1H), δ1.79 (d, 
J = 2.4 Hz, 3H), δ1.06 (d, J = 7.0 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ148.09, δ141.88, δ137.61, δ133.57, δ128.89, δ128.41, 






HRMS (ESI) m/z calcd for C19H19NO3 [M+H]
+
: 310.1443, found: 310.1458. 
 
3-((1S,2S)-1-(benzyloxy)-2-methylpent-3-yn-1-yl)aniline (46): 
Prepared by general procedure C using 44 (2.94g, 9.5 mmol). The crude material was 
purified with silica gel column Chromatography using 21% Ethyl acetate in hexanes. 46 
(2.36g, 8.46 mmol, 89% yield) was afforded as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ 
 
 N-(3-((1S,2S)-1-(benzyloxy)-2-methylpent-3-yn-1-




mmol). The crude material was purified with silica gel column Chromatography using 
38%  




H NMR (500 MHz, CDCl3): δ 
 
13






HRMS (ESI) m/z calcd for C21H23NO2  
 
1-((1S,2S)-1-methoxy-2-methylpent-3-yn-1-yl)-3-nitrobenzene 
(45): Prepared by general procedure K using 43. The crude material was purified with 
silica gel column Chromatography using 7.3% Ethyl acetate in hexanes. 45 (2.31 g, 9.9 
mmol, 99% yield) was afforded as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.24 (s, 1H), δ8.17-8.15 (m, 1H), δ7.68 (d, J = 7.7 Hz, 
1H), δ7.53 (t, J = 7.9 Hz, 1H), δ4.23 (d, J = 5.0 Hz, 1H), δ3.31 (s, 3H), δ2.83-2.76 (m, 






C NMR (125 MHz, CDCl3): δ148.05, δ141.84, δ133.34, δ128.85, δ122.74, δ122.50, 






LCMS (ESI) m/z calcd for C13H15NO3 [M+Na]
+
: 256.0950, found: 256.0976. 
 
3-((1S,2S)-1-methoxy-2-methylpent-3-yn-1-yl)aniline (47): 
Prepared by general procedure C using 45 (2.31 g, 9.9 mmol). The crude material was 
purified with silica gel column Chromatography using 22% Ethyl acetate in hexanes. 47 
(1.79g, 8.81 mmol, 89% yield) was afforded as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ 
 
N-(3-((1S,2S)-1-methoxy-2-methylpent-3-yn-1-
yl)phenyl)acetamide (6d): Prepared by general procedure D using 47 (1.79g ,8.81 








H NMR (500 MHz, CDCl3): δ7.54 (d, J = 8.2 Hz, 1H), δ7.37 (s, 1H), δ7.31-7.27 (m, 
2H), δ7.07 (d, J = 7.6 Hz, 1H), δ4.01 (d, J = 6.5 Hz, 1H), δ3.25 (s, 3H), δ2.77-2.69 (m, 
1H), δ2.18 (s, 3H), δ1.80 (d, J = 2.2 Hz, 3H), δ1.01 (d, J = 7.0 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.58, δ140.67, δ138.05, δ128.70, δ123.33, δ119.37, 






HRMS (ESI) m/z calcd for C15H19NO2 [M+Na]
+
: 268.1313, found: 268.1317. 
 
Supplementary Scheme S3. Synthesis of 6g, 6h, and 6i (Anti, Anti, Syn- and Anti, 






 (1R,2S)-3,3-dimethoxy-2-methyl-1-(2-nitrophenyl)propan-1-ol (50): 
Prepared by general procedure E and F using 2-nitrobenzaldhyde (10g, 66.2 mmol). The 
crude material was purified with silica gel column Chromatography using 28% Ethyl 
acetate in hexanes. 50 (9.13 g, 35.75 mmol, 54% yield over two steps, dr>20:1) was 
afforded as yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ7.81 (dd, J = 8.2, 1.2 Hz, 1H), δ7.72 (dd, J = 7.9, 1.4 Hz, 




7.8, 2.9 Hz, 1H), δ4.35 (d, J = 5.5 Hz, 1H), δ4.31 (d, J = 2.9 Hz, 1H), δ3.46 (s, 3H), 
δ3.41 (s, 3H), δ2.29-2.21 (m, 1H), δ0.79 (d, J = 7.1 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ149.06, δ137.63, δ132.77, δ129.19, δ128.14, δ123.97, 






LCMS (ESI) m/z calcd for C12H17NO5 [M+H]
+





 Prepared by general procedure E and F using 4-nitrobenzaldhyde (10g, 66.2 
mmol). The crude material was purified with silica gel column Chromatography using 
31% Ethyl acetate in hexanes. 51 (12.17 g, 47.66 mmol, 72% yield over two steps, 
dr>20:1) was afforded as yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.22-8.19 (m, 2H), δ7.53-7.50 (m, 2H), δ4.72 (dd, J = 8.3, 
2.0 Hz, 1H), δ4.37 (d, J = 2.0 Hz, 1H), δ4.31 (d, J = 5.4 Hz, 1H), δ3.50 (s, 3H), δ3.42 (s, 






C NMR (125 MHz, CDCl3): δ150.36, δ147.43, δ127.81, δ123.40, δ108.62, δ75.54, 
δ56.13, δ53.91, δ42.62, δ12.20. 
 
1-nitro-2-((1R,2S)-1,3,3-trimethoxy-2-methylpropyl)benzene (52): 
Prepared by general procedure H using 50 (9.13 g, 35.75 mmol). The crude material was 
purified with silica gel column Chromatography using 17% Ethyl acetate in hexanes. 52 
(6.74 g, 25.03 mmol, 70% yield) was afforded as a pale yellow crystal. 
 
1
H NMR (500 MHz, CDCl3): δ 
 
13






HRMS (ESI) m/z calcd for C13H19NO5  
 
1-nitro-4-((1R,2S)-1,3,3-trimethoxy-2-methylpropyl)benzene 




material was purified with silica gel column Chromatography using 18% Ethyl acetate in 
hexanes. 53 (10.14, 37.65 mmol, 79% yield) was afforded as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.21 (d, J = 8.7 Hz, 2H), δ7.46 (d, J = 8.7 Hz, 2H), δ4.30 
(d, J = 5.0 Hz, 1H), δ4.25 (d, J = 7.7 Hz, 1H), δ3.44 (s, 3H), δ3.41 (s, 3H), δ3.19 (s, 3H), 
δ2.23-2.17 (m, 1H), δ0.67 (d, J = 7.0 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ147.83, δ128.48, δ123.38, δ105.68, δ83.67, δ56.88, 






LCMS (ESI) m/z calcd for C13H19NO5 [M+H]
+
: 270.13, found: 270.16; 
 
(2S,3R)-3-methoxy-2-methyl-3-(2-nitrophenyl)propanal (54): Prepared by 
general procedure I using 52 (6.74 g, 25.03 mmol) (12 hours reaction time).  The crude 
material was purified with silica gel column Chromatography using 17% Ethyl acetate in 






H NMR (500 MHz, CDCl3): δ9.76 (d, J = 2.6 Hz, 1H), δ7.99-7.97 (m, 1H), δ7.72-7.67 
(m, 2H), δ7.50 (ddd, J = 8.5, 6.2, 2.6 Hz, 1H), δ5.06 (d, J = 6.5 Hz, 1H), δ3.23 (s, 3H), 
δ2.75 (dq, J = 7.1, 2.6 Hz, 1H), δ1.08 (d, J = 7.2 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ202.45, δ135.08, δ133.41, δ128.87, δ128.52, δ124.51, 






LCMS (ESI) m/z calcd for C11H13NO4 [M+Na]
+
: 246.07, found: 246.07. 
 
(2S,3R)-3-methoxy-2-methyl-3-(4-nitrophenyl)propanal (55): 
Prepared by general procedure I using 53 (10.14, 37.65 mmol) (12 hours reaction time). 
The crude material was purified with silica gel column Chromatography using 18% Ethyl 
acetate in hexanes. 55 (4.69 g, 21.03 mmol, 84% yield, dr: 10:1) was afforded as a pale 
yellow oil.  
 
1
H NMR (500 MHz, CDCl3): δ9.80 (d, J = 2.5 Hz, 1H), δ8.27-8.24 (m, 2H), δ7.51-7.48 
(m, 2H), δ4.43 (d, J = 8.5 Hz, 1H), δ3.22 (s, 3H), δ2.73 (dqd, J = 8.5, 7.2, 2.5 Hz, 1H), 













LCMS (ESI) m/z calcd for C11H13NO4 [M+H]
+
: 224.09, found: 224.11. 
 
1-((1R,2R,3R,4S)-3-(benzyloxy)-1-methoxy-2,4-dimethylhept-5-
yn-1-yl)-2-nitrobenzene (56): Prepared by general procedure B using 54 (4.69 g, 21.03 
mmol, 1.05 equiv), Ra-25 (4.05g, 20.03 mmol, 1 equiv),  (benzyloxy)trimethylsilane (4.1 
mL, 21.03 mmol, 1.05 equiv), and TMSOTf (1.5 mL, 8 mmol, 0.4 equiv). The reaction 
was stirred at – 60 
o
C for 12 hours. The crude material (dr: 2:1, double 
stereodifferentiation, “mismatched”) was purified with silica gel column 
Chromatography using 61% DCM in Hexanes. 56 (3.21g, 8.41 mmol, 42% major isomer 
yield) was afforded as a pale yellow oil.  
 
1
H NMR (500 MHz, CDCl3): δ7.71 (dd, J = 8.1, 1.2 Hz, 1H), δ7.67 (dd, J = 7.9, 1.4 Hz, 
1H), δ7.62-7.58 (m, 1H), δ7.42-7.39 (m, 1H), δ7.35-7.27 (m, 5H), δ5.23 (d, J = 10.1 Hz, 
1H), δ4.65 (d, J = 11.4 Hz, 1H), δ4.54 (d, J = 11.4 Hz, 1H), δ3.70 (dd, J = 9.6, 2.0 Hz, 
1H), δ3.20 (s, 3H), δ2.71-2.65 (m, 1H), δ2.3 (dqd, J = 9.3, 7.3, 1.9 Hz, 1H), δ1.87 (d, J = 






C NMR (125 MHz, CDCl3): δ151.04, δ138.78, δ136.77, δ132.46, δ128.62, δ128.19, 
δ128.08, δ127.82, δ127.37, δ123.01, δ82.78, δ81.66, δ79.27, δ77.79, δ72.75, δ56.72, 






HRMS (ESI) m/z calcd for C23H27NO4 [M+Na]
+
: 404.1838, found: 404.1840. 
 
1-((1S,2S,3R,4S)-3-(benzyloxy)-1-methoxy-2,4-
dimethylhept-5-yn-1-yl)-3-nitrobenzene (58): Prepared by general procedure B using 
41 (4.69 g, 21.03 mmol, 1.05 equiv), Ra-25 (4.05g, 20.03 mmol, 1 equiv),  
(benzyloxy)trimethylsilane (4.1 mL, 21.03 mmol, 1.05 equiv), and TMSOTf (1.5 mL, 8 
mmol, 0.4 equiv). The reaction was stirred at – 60 
o
C for 12 hours. The crude material 
(dr> 20:1, double stereodifferentiation, “matched”) was purified with silica gel column 
Chromatography using 10% ethyl acetate in Hexanes. 58 was (6.34 g, 16.61 mmol, 79% 
yield) was afforded as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.17-8.13 (m, 2H), δ7.63 (d, J = 7.6 Hz, 1H), δ7.55-7.52 
(m, 1H), δ7.42-7.30 (m, 5H), δ4.77 (d, J = 11.6 Hz, 1H), δ4.64 (d, J = 11.6 Hz, 1H), 




1H), δ2.39-2.33 (m, 1H), δ1.80 (d, J = 2.4 Hz, 3H), δ1.31 (d, J = 6.8 Hz, 3H), δ0.66 (d, J 
= 7.0 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ148.42, δ144.03, δ139.01, δ133.94, δ129.24, δ128.41, 
δ127.54, δ127.34, δ122.79, δ122.67, δ84.94, δ81.78, δ80.77, δ77.76, δ74.89, δ56.32, 






HRMS (ESI) m/z calcd for C23H27NO4 [M+H]
+
: 382.2018, found: 382.2029. 
 
1-((1R,2R,3R,4S)-3-(benzyloxy)-1-methoxy-2,4-
dimethylhept-5-yn-1-yl)-4-nitrobenzene (57): Prepared by general procedure B using 
55 (4.69 g, 21.03 mmol, 1.05 equiv), Ra-25 (4.05g, 20.03 mmol, 1 equiv),  
(benzyloxy)trimethylsilane (4.1 mL, 21.03 mmol, 1.05 equiv), and TMSOTf (1.5 mL, 8 
mmol, 0.4 equiv). The reaction was stirred at – 60 
o
C for 12 hours. The crude material 
(dr: 3:1, double stereodifferentiation, “mismatched”) was purified with silica gel column 
Chromatography using 61% DCM in Hexanes. 57 (3.21 g, 8.41 mmol, 42 % major 






H NMR (500 MHz, CDCl3): δ8.20-8.17 (m, 2H), δ7.43-7.41 (m, 2H), δ7.35-7.28 (m, 
5H), δ4.70 (d, J = 11.5 Hz, 1H), δ4.64 (d, J = 8.3 Hz, 1H), δ4.60 (d, J = 11.5 Hz, 1H), 
δ3.51 (dd, J = 7.8, 3.8 Hz, 1H), δ3.18 (s, 3H), δ2.76-2.69 (m, 1H), δ2.32 (ddq, J = 11.1, 




C NMR (125 MHz, CDCl3): δ148.99, δ147.40, δ138.62, δ128.45, δ128.33, δ127.70, 
δ127.55, δ123.36, δ84.22, δ82.93, δ82.34, δ77.50, δ72.81, δ56.85, δ42.37, δ28.13, 






HRMS (ESI) m/z calcd for C23H27NO4 [M+H]
+
: 382.2018, found: 382.2005. 
 
2-((1R,2R,3R,4S)-3-(benzyloxy)-1-methoxy-2,4-dimethylhept-5-
yn-1-yl)aniline (59): Prepared by general procedure C using 56 (3.21g, 8.41 mmol). The 
crude material was purified with silica gel column Chromatography using 10% ethyl 







H NMR (500 MHz, CDCl3): δ7.38-7.28 (m, 5H), δ7.08 (td, J = 7.6, 1.6 Hz, 1H), δ6.94 
(dd, J = 7.5, 1.4 Hz, 1H), δ6.67 (td, J = 7.4, 0.7 Hz, 1H), δ6.62 (dd, J = 8.8, 0.8 Hz, 1H), 
δ4.66 (d, J = 11.4 Hz, 1H), δ4.57 (d, J = 11.4 Hz, 1H), δ4.54 (d, J = 10.1 Hz, 1H), δ4.31 
(brs, 2H), δ3.62 (dd, J = 9.5, 1.9 Hz, 1H), δ3.24 (s, 3H), δ2.85-2.71 (m, 2H), δ1.86 (d, J = 
2.4 Hz, 3H), δ1.28 (d, J = 6.7 Hz, 3H), δ0.76 (d, J = 7.2 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ145.46, δ138.86, δ130.58, δ128.30, δ128.26, δ127.86, 
δ127.44, δ123.71, δ117.30, δ116.11, δ86.88, δ83.71, δ82.49, δ73.05, δ56.39, δ38.41, 






HRMS (ESI) m/z calcd for C23H29NO2 [M+H]
+
: 352.2277, found: 352.2277. 
 
3-((1S,2S,3R,4S)-3-(benzyloxy)-1-methoxy-2,4-dimethylhept-
5-yn-1-yl)aniline (61): Prepared by general procedure C using 58 (6.34 g, 16.61 mmol). 
The crude material was purified with silica gel column Chromatography using 20% ethyl 







H NMR (500 MHz, CDCl3): δ7.42-7.28 (m, 5H), δ7.12 (t, J = 7.6 Hz, 1H), δ6.68 (d, J = 
7.5 Hz, 1H), δ6.64-6.61 (m, 2H), δ4.73 (d, J = 11.5 Hz, 1H), δ4.66 (d, J = 11.6 Hz, 1H), 
δ3.91 (d, J = 9.5 Hz, 1H), δ3.83 (d, J = 10.1 Hz, 1H), δ3.65 (brs, 2H), δ3.08 (s, 3H), 
δ2.68-2.60 (m, 1H), δ2.38-2.32 (m, 1H), δ1.79 (d, J = 2.3 Hz, 3H), δ1.29 (d, J = 6.8 Hz, 
3H), δ0.66 (d, J = 7.0 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ146.30, δ142.63, δ139.28, δ128.98, δ128.32, δ127.39, 
δ118.68, δ114.52, δ114.26, δ85.62, δ82.07, δ81.07, δ77.38, δ74.88, δ55.90, δ42.45, 






HRMS (ESI) m/z calcd for C23H29NO2 [M+H]
+
: 352.2277, found: 352.2277. 
 
4-((1R,2R,3R,4S)-3-(benzyloxy)-1-methoxy-2,4-
dimethylhept-5-yn-1-yl)aniline (60): Prepared by general procedure C using 57 (3.21 g, 
8.41 mmol). The crude material was purified with silica gel column Chromatography 
using 24% ethyl acetate in hexanes. 60 (2.63 g, 7.49 mmol, 89%) was afforded as a pale 






H NMR (500 MHz, CDCl3): δ7.40-7.26 (m, 5H), δ7.07-7.04 (m, 2H), δ6.68-6.65 (m, 
2H), δ4.69 (d, J = 11.5 Hz, 1H), δ4.64 (d, J = 11.5 Hz, 1H), δ4.40 (d, J = 8.7 Hz, 1H), 
δ3.64 (brs, 2H), δ3.58 (dd, J = 7.7, 3.9 Hz, 1H), δ3.14 (s, 3H), δ2.73-2.66 (m, 1H), δ2.30 
(ddq, J = 14.4, 7.2, 3.9 Hz, 1H), δ1.83 (d, J = 2.4 Hz, 3H), δ1.25 (d, J = 6.8 Hz, 3H), 
δ0.72 (d, J = 7.2 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ145.71, δ139.07, δ130.83, δ128.79, δ128.26, δ127.71, 
δ127.34, δ114.80, δ84.81, δ82.98, δ82.76, δ77.01, δ72.54, δ56.10, δ42.39, δ27.82, 






HRMS (ESI) m/z calcd for C23H29NO2 [M+H]
+
: 352.2277, found: 352.2281. 
 
N-(2-((1R,2R,3R,4S)-3-(benzyloxy)-1-methoxy-2,4-
dimethylhept-5-yn-1-yl)phenyl)acetamide (6i): Prepared by general procedure D using 
59 (2.22 g, 6.31 mmol) and 0.5 equiv of DMAP (386 mg). The crude material was 
purified with silica gel column chromatography using 21% ethyl acetate in hexanes. 6i 






H NMR (500 MHz, CDCl3): δ9.24 (brs, 1H), δ8.26 (d, J = 8.1 Hz, 1H), δ7.46-7.28 (m, 
6H), δ7.04-7.01 (m, 2H), δ4.63 (s, 2H), δ4.54 (d, J = 10.0 Hz, 1H), δ3.49 (dd, J = 9.7, 1.5 
Hz, 1H), δ3.28 (s, 3H), δ2.94-2.87 (m, 1H), δ2.73-2.66 (m, 1H), δ2.13 (s, 3H), δ1.83 (d, J 
= 2.4 Hz, 3H), δ1.29 (d, J = 6.8 Hz, 3H), δ0.70 (d, J = 7.2 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.13, δ138.53, δ137.02, δ130.38, δ128.53, δ128.38, 
δ127.65, δ127.61, δ123.08, δ121.75, δ87.58, δ85.35, δ82.28, δ77.42, δ74.21, δ56.89, 






HRMS (ESI) m/z calcd for C25H31NO3 [M+H]
+
: 394.2382, found: 394.2384. 
 
N-(3-((1S,2S,3R,4S)-3-(benzyloxy)-1-methoxy-2,4-
dimethylhept-5-yn-1-yl)phenyl)acetamide (6h): Prepared by general procedure D 
using 61 (4.55 g, 12.96 mmol). The crude material was purified with silica gel column 
Chromatography using 41% ethyl acetate in hexanes. 6h (4.13 g, 10.50 mmol, 81% yield) 
was afforded as a brown solid. 
 
1
H NMR (500 MHz, CDCl3): δ7.60 (d, J = 8.0 Hz, 1H), δ7.41-7.28 (m, 7H), δ7.21 (brs, 




δ3.95-3.82 (m, 2H), δ3.07 (s, 3H), δ2.67-2.61 (m, 1H), δ2.37-2.31 (m, 1H), δ2.18 (s, 3H), 
δ1.79 (d, J = 2.4 Hz, 3H), δ1.29 (d, J = 6.8 Hz, 3H), δ0.65 (d, J = 7.0 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.18, δ142.48, δ139.17, δ137.88, δ128.98, δ128.35, 
δ127.41, δ123.77, δ119.24, δ118.92, δ85.45, δ81.93, δ81.04, δ77.46, δ74.87, δ56.00, 






HRMS (ESI) m/z calcd for C25H31NO3 [M+H]
+
: 394.2382, found: 394.2361. 
 
N-(4-((1R,2R,3R,4S)-3-(benzyloxy)-1-methoxy-2,4-
dimethylhept-5-yn-1-yl)phenyl)acetamide (6g): Prepared by general procedure D 
using 60 (2.63 g, 7.49 mmol). The crude material was purified with silica gel column 
chromatography using 19% ethyl acetate in DCM. 6g (2.27 g, 5.77 mmol, 77% yield) 
was afforded as a brown solid. 
 
1
H NMR (500 MHz, CDCl3): δ7.48-7.46 (m, 2H), δ7.39-7.26 (m, 5H), δ7.23-7.19 (m, 
3H), δ4.69 (d, J = 11.5 Hz, 1H), δ4.63 (d, J = 11.5 Hz, 1H), δ4.48 (d, J = 8.6 Hz, 1H), 




7.3, 3.7 Hz, 1H), δ2.18 (d, J = 4.0 Hz, 3H), δ1.83 (d, J = 2.4 Hz, 3H), δ1.25 (d, J = 6.8 
Hz, 3H), δ0.70 (d, J = 7.2 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.24, δ138.93, δ137.12, δ136.94, δ128.34, δ128.27, 
δ127.70, δ127.39, δ119.53, δ84.61, δ82.91, δ82.63, δ77.15, δ72.58, δ56.35, δ42.37, 






HRMS (ESI) m/z calcd for C25H31NO3 [M+Na]
+
: 416.2202, found: 416.2195. 
 
Relative and Absolute Stereochemistry Confirmation of 8c and 8d Obtained from 
Enantioselective Cross Aldol Reaction 





β-hydroxyl aldehyde 36 was reduced to diol 62 using sodium borohydride , which was 
under acid-catalyzed ketalization to form acetonide 63. Three-bond coupling constant 
between H1 and H2 is 10.35 Hz, indicating the anti relationship between C1 methyl and 
C2 oxygen. 
 
 (4S,5S)-2,2,5-trimethyl-4-(3-nitrophenyl)-1,3-dioxane (63): 63 was 
afforded as a pale yellow, viscous oil. 
 
1
H NMR (500 MHz, CDCl3): δ8.25 (s, 1H), δ8.17 (d, J = 7.2 Hz, 1H), δ7.71 (d, J = 7.6 
Hz, 1H), δ7.53 (t, J = 8.0 Hz, 1H), δ4.54 (d, J = 10.3 Hz, 1H), δ3.85 (dd, J = 11.8, 5.0 
Hz, 1H), δ3.71 (dd, J = 23, 11.5 Hz, 1H), δ1.92(ddq, J = 17.8, 11.9, 6.5 Hz, 1H), δ1.56 (s, 
3H), δ1.50 (s, 3H), δ0.65 (d, J = 6.7 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ148.23, δ142.64, δ133.56, δ129.27, δ122.94, δ122.42, 






HRMS (ESI) m/z calcd for C13H17NO4 [M+H]
+





Confirmation of Absolute Chemistry 
 
The absolute stereochemistry of the secondary alcohol in 8c and 8d was determined by 
converting the alcohol to Mosher’s esters 64 and ent-64. Using Hoye’s protocol, the 
absolute stereochemistry of the secondary alcohol was determined to be R. If the cross 
aldol reaction is catalyzed by D-proline, the absolute stereochemistry of the secondary 
alcohol should be S. 
 
(1R,2S)-3,3-dimethoxy-2-methyl-1-(2-nitrophenyl)propyl (S)-3,3,3-






H NMR (500 MHz, CDCl3): δ7.96 (dd, J = 8.0, 1.5 Hz, 1H), δ7.51-7.33 (m, 6H), δ7.28 
(dd, J = 7.7, 1.5 Hz, 1H), δ6.55 (d, J = 7.7 Hz, 1H), δ4.35 (d, J = 4.5 Hz, 1H), δ3.46 (d, J 




C NMR (125 MHz, CDCl3): δ165.42, δ148.89, δ133.89, δ132.93, δ131.62, δ129.67, 







HRMS (ESI) m/z calcd for C22H24F3NO7 [M+Na]
+
: 494.1403, found: 494.1390. 
 
(1R,2S)-3,3-dimethoxy-2-methyl-1-(2-nitrophenyl)propyl (R)-3,3,3-




H NMR (500 MHz, CDCl3): δ7.96 (dd, J = 8.1, 1.2 Hz, 1H), δ7.58 (td, J = 7.6, 1.2 Hz, 




Hz, 1H), δ3.42 (d, J = 1.0 Hz, 3H), δ3.31 (s, 3H), δ3.23 (s, 3H), δ2.48-2.41 (m, 1H), 
δ0.85 (d, J = 7.1 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ165.50, δ149.16, δ133.52, δ132.80, δ131.78, δ129.67, 







HRMS (ESI) m/z calcd for C22H24F3NO7 [M+Na]
+
: 494.1403, found: 494.1411; 
 
Relative Stereochemistry Confirmation of 8g, 8h, and 8i 
 
Alkyne-Alkyne Reductive Coupling between 6 and 7 to Generate 8 Prepared by 
General Procedure A 
 N-(4-((1S,2R,3E,5E,7S)-1-(benzyloxy)-8-((tert-
butyldimethylsilyl)oxy)-2,4,7-trimethylocta-3,5-dien-1-yl)phenyl)acetamide (8a): 
Prepared by general procedure A using 6a and 7a
68
 (1.1 equiv) and stirred for 3h. The 
crude material was purified with Preparative Thin Layer Chromatography using 30% 
ethyl acetate in Hexanes. 8a (49 mg, 0.094 mmol, 47% yield) was afforded as a pale 






H NMR (400 MHz, CDCl3): δ7.46-7.18 (m, 10H), δ5.94 (d, J = 15.8 Hz, 1H), δ5.36 (dd, 
J = 15.8, 7.4 Hz, 1H), δ5.17 (d, J = 9.9 Hz, 1H), δ4.44 (d, J = 11.9 Hz, 1H), δ4.22 (d, J = 
11.9 Hz, 1H), δ4.09 (d, J = 6.9 Hz, 1H), δ3.47 (dd, J = 9.7, 6.0 Hz, 1H), δ3.36 (dd, J = 
9.7, 7.3 Hz, 1H), δ2.89-2.79 (m, 1H), δ2.37-2.27 (m, 1H), δ2.18 (s, 3H), δ1.48 (s, 3H), 
δ1.06 (d, J = 6.6 Hz, 3H), δ0.98 (d, J = 6.7 Hz, 3H), δ0.88 (s, 9H), δ0.01 (s, 6H); 
 
13






HRMS (ESI) m/z calcd for C32H47NO3Si [M+H]
+




Prepared by general procedure A using 6b and 7a (1.1 equiv) and stirred for 3h. The 
crude material was purified with Preparative Thin Layer Chromatography using 30% 
ethyl acetate in Hexanes. 8a (50 mg, 0.096 mmol, 48% yield) was afforded as a pale 






H NMR (500 MHz, CDCl3): δ7.57 (d, J = 7.6 Hz, 1H), δ7.35-7.27 (m, 7H), δ7.17 (s, 
1H), δ7.03 (d, J = 7.4 Hz, 1H), δ5.97 (d, J = 15.8 Hz, 1H), δ5.37 (dd, J = 15.7, 7.4 Hz, 
1H), δ5.22 (d, J = 9.5 Hz, 1H), δ4.48 (d, J = 12.0 Hz, 1H), δ4.25 (d, J = 12.0 Hz, 1H), 
δ4.14 (d, J = 6.5 Hz, 1H), δ3.48 (dd, J = 9.7, 5.9 Hz, 1H), δ3.37 (dd, J = 9.7, 7.3 Hz, 1H), 
δ2.84 (dq, J = 9.5, 6.6 Hz, 1H), δ2.34-2.29 (m, 1H), δ2.17 (s, 3H), δ1.50 (s, 3H), δ1.06 
(d, J = 6.6 Hz, 3H), δ0.99 (d, J = 6.8 Hz, 3H), δ0.88 (s, 9H), δ0.02 (d, J = 1.2 Hz, 6H); 
 
13
C NMR (125 MHz, CDCl3): δ168.14, δ142.02, δ138.66, δ137.69, δ134.36, δ133.46, 
δ132.90, δ130.16, δ128.72, δ128.24, δ127.50, δ127.35, δ123.38, δ118.85, δ118.40, 







HRMS (ESI) m/z calcd for C32H47NO3Si [M+H]
+
: 522.3403, found: 522.3395. 
 
N-(3-((1S,2S,3E,5E)-1-(benzyloxy)-2,4-dimethylnona-
3,5-dien-1-yl)phenyl)acetamide (8c): Prepared by general procedure A using 6c and 7c 
(1.1 equiv) and stirred for 3h. The crude material was purified with Preparative Thin 
Layer Chromatography using 11% diethyl ether in DCM. 8c (48 mg, 0.124 mmol, 62% 






H NMR (500 MHz, CDCl3): δ7.62 (d, J = 8.3 Hz, 1H), δ7.33-7.25 (m, 8H), δ7.03 (d, J = 
7.6 Hz, 1H), δ6.06 (d, J = 15.6 Hz, 1H), δ5.54 (td, J = 15.6, 7.0 Hz, 1H), δ5.25 (d, J = 9.5 
Hz, 1H), δ4.48 (d, J = 12.2 Hz, 1H), δ4.22 (d, J = 12.2 Hz, 1H), δ4.13 (d, J = 6.3 Hz, 
1H), δ2.85 (dq, J = 9.5, 6.8 Hz, 1H), δ2.17 (s, 3H), δ2.07 (dt, J = 7.1 Hz, 2H), δ1.59 (s, 
3H), δ1.46-1.39 (m, 2H), δ0.92 (t, J = 7.4 Hz, 3H), δ0.87 (d, J = 6.8 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.28, δ141.89, δ138.72, δ137.83, δ134.99, δ133.98, 
δ132.65, δ128.76, δ128.19, δ127.75, δ127.56, δ127.32, δ123.62, δ119.03, δ118.55, 






HRMS (ESI) m/z calcd for C26H33NO2 [M+Na]
+
: 414.2409, found: 414.2396. 
 
N-(3-((1S,2S,3E,5E)-1-methoxy-2,4-dimethylnona-3,5-
dien-1-yl)phenyl)acetamide (8d): Prepared by general procedure A using 6d and 7c (1.1 
equiv) and stirred for 3h. The crude material was purified with Preparative Thin Layer 
Chromatography using 16% diethyl ether in DCM. 8d (34 mg, 0.108 mmol, 54% yield) 






H NMR (500 MHz, CDCl3): δ7.62 (d, J = 8.1 Hz, 1H), δ7.35 (brs, 1H), δ7.30-7.26 (m, 
2H), δ6.99 (d, J = 7.3 Hz, 1H), δ6.06 (d, J = 15.6 Hz, 1H), δ5.53 (td, J = 19.4, 8.7 Hz, 
1H), δ5.26 (d, J = 9.3 Hz, 1H), δ3.94 (d, J = 6.7 Hz, 1H), δ3.18 (s, 3H), δ2.85-2.76 (m, 
1H), δ2.16 (s, 3H), δ2.05 (dt, J = 7.3 Hz, 2H), δ1.58 (s, 3H), δ1.43-1.38 (m, 2H), δ0.90 (t, 
J = 7.4 Hz, 3H), δ0.84 (d, J = 6.8 Hz, 3H); 
 
13
C NMR (125 MHz, CDCl3): δ168.21, δ141.69, δ137.91, δ134.86, δ133.96, δ132.55, 
δ128.72, δ127.87, δ123.56, δ118.94, δ118.26, δ88.30, δ57.02, δ39.45, δ34.98, δ24.63, 






HRMS (ESI) m/z calcd for C20H29NO2 [M+Na]
+




(8e): Prepared by general procedure A using 6e and 7b
69
 (1.3 equiv) and stirred for 1h. 
The crude material was purified with Preparative Thin Layer Chromatography using 20% 
ethyl acetate in Hexanes. 8e (23 mg, 0.04 mmol, 20% yield) was afforded as a pale 






H NMR (500 MHz, CDCl3): δ8.28 (s, 1H), δ7.57 (s, 1H), δ7.47 (d, J = 8.3 Hz, 1H), 
δ7.35-7.28 (m, 5H), δ6.95 (d, J = 7.0 Hz, 1H), δ5.97 (d, J = 15.6 Hz, 1H), δ5.46 (td, J = 
15.6, 7 Hz, 1H), δ5.17 (d, J = 9.8 Hz, 1H), δ4.46 (d, J = 11.8 Hz, 1H), δ4.24 (d, J = 11.8 
Hz, 1H), δ4.11 (d, J = 6.9 Hz, 1H), δ3.61 (t, J = 6.9 Hz, 2H), δ2.89-2.82 (m, 1H), δ2.28-
2.24 (m, 5H), δ1.56 (s, 3H), δ1.06 (d, J = 6.6 Hz, 3H), δ0.88 (s, 9H), δ0.03 (s, 6H); 
 
13
C NMR (125 MHz, CDCl3): δ168.04, δ141.92, δ138.45, δ136.58, δ135.26, δ133.48, 
δ132.61, δ131.73, δ128.26, δ127.63, δ127.41, δ123.97, δ123.88, δ121.12, δ84.77, δ70.83, 






HRMS (ESI) m/z calcd for C31H44BrNO3Si [M+Na]
+
: 608.2172, found: 608.2176. 
 
N-(5-((1S,2R,3E,5E)-1-(benzyloxy)-8-hydroxy-2,4-
dimethylocta-3,5-dien-1-yl)-2-methylphenyl)acetamide (8f): Prepared by general 
procedure A using 6f and 7b (1.1 equiv) and stirred for 3h. The crude material was 
subject to TBS deprotection using TBAF (1M in THF, Sigma Aldrich). It was then 
purified with Preparative Thin Layer Chromatography using 70% ethyl acetate in DCM. 






H NMR (500 MHz, CDCl3): δ7.56 (s, 1H), δ7.34-7.27 (m, 5H), δ7.15 (d, J = 7.8 Hz, 
1H), δ7.08 (d, J = 7.7 Hz, 1H), δ6.96 (brs, 1H), δ6.06 (d, J = 15.7 Hz, 1H), δ5.41 (dt, J = 
15.2, 7.2 Hz, 1H), δ5.21 (d, J = 9.6 Hz, 1H), δ4.48 (d, J = 11.9 Hz, 1H), δ4.23 (d, J = 
11.9 Hz, 1H), δ4.08 (d, J = 7.0 Hz, 1H), δ3.69-3.60 (m, 2H), δ2.84 (dq, J = 9.6, 6.6 Hz, 




C NMR (125 MHz, CDCl3): δ139.53, δ138.73, δ138.03, δ135.03, δ133.44, δ133.38, 
δ130.18, δ128.23, δ127.59, δ127.32, δ124.05, δ123.42, δ123.12, δ84.94, δ70.65, δ61.90, 






HRMS (ESI) m/z calcd for C26H33NO3 [M+Na]
+




yl)phenyl)acetamide (8g): Prepared by general procedure A using 6g and 7a (2 equiv) 
and stirred for 8 hours. The crude material was purified with Preparative Thin Layer 
Chromatography using 15% diethyl ether in DCM. 8g (58 mg, 0.098 mmol, 49% yield) 






H NMR (500 MHz, CDCl3): δ7.44 (d, J = 8.4 Hz, 2H), δ7.38-7.27 (m, 5H), δ7.20 (brs, 
1H), δ7.15 (d, J = 8.4 Hz, 2H), δ6.09 (d, J = 15.7 Hz, 1H), δ5.53 (dd, J = 15.7, 7.4 Hz, 
1H), δ5.35 (d, J = 10.1 Hz, 1H), δ4.62 (d, J = 11.4 Hz, 1H), δ4.54 (d, J = 11.4 Hz, 1H), 
δ3.98 (d, J = 9.4 Hz, 1H), δ3.62 (dd, J = 8.1, 3.5 Hz, 1H), δ3.53 (dd, J = 9.7, 6.2 Hz, 1H), 
δ3.43 (dd, J = 9.7, 7.1 Hz, 1H), δ3.07 (s, 3H), δ2.91-2.83 (m, 1H), δ2.42-2.36 (m, 1H), 
δ2.26-2.19 (m, 1H), δ2.17 (s, 3H), δ1.77 (s, 3H), δ1.08 (d, J = 6.6 Hz, 3H), δ1.03 (d, J = 
6.7 Hz, 3H), δ0.89 (s, 9H), δ0.63 (d, J = 7.1 Hz, 3H), δ0.04 (d, J = 2.5 Hz, 6H); 
 
13
C NMR (125 MHz, CDCl3): δ168.16, δ139.17, δ137.20, δ137.15, δ135.00, δ134.46, 
δ131.65, δ130.49, δ128.31, δ128.24, δ127.61, δ127.29, δ119.50, δ84.98, δ83.64, δ72.79, 







HRMS (ESI) m/z calcd for C36H55NO4Si [M+Na]
+
















Convergent Synthesis of Novel Muramyl Dipeptide Analogues: Inhibition of 








 Two major classes of pattern recognition receptors (PRRs) include membrane-
bound Toll-like receptors (TLRs) and soluble, cytosolic nucleotide-binding 
oligomerization domain (NOD) like receptors (NLRs).
70
 Where TLRs help to sense 
extracellular pathogens, NLRs provide surveillance of the cytosol. Mammals have two 
closely related NOD family members, NOD1 and NOD2, both of which contain caspase 
recruitment domains (CARDs), a central NACHT domain, and C-terminal Leu-rich 
repeats (LRRs).
71-74
 Studies have linked NOD2 mutations to severe inflammatory 
diseases, suggesting that NOD2 might play a pathophysiological role in inflammatory 
disorders. However it is important to note that chronic stimulation of NOD2 was reported 
to mediate tolerance to bacterial products.
75,76
 The mechanism(s) behind this tolerance 
remain poorly understood. Following breakdown of bacterial cell walls, muramyl 
dipeptide (MDP) is formed and detected by NOD2. Upon detection of low doses of MDP, 
NOD2 binds to the kinase receptor-interacting protein 2 (RIP2) via CARD-CARD 
homophilic interactions—a necessary step for downstream signaling to proceed.
77-79
 
Signaling to RIP2 leads to NFκB transcriptional activity through the inhibitor of κB (IκB) 
kinase complex, as well as other cascades involving mitogen-activated protein (MAP) 
kinases that result in the production of pro-inflammatory cytokines and chemokines such 
as interleukin-6 (IL-6), TNF-α, IL-12, and IL-8.
80
 In contrast, a higher dose of MDP has 
been found to dampen the inflammatory response.
81,82
 Studies on NOD2 mutations 
suggest that NOD2 might mediate tolerance to bacterial products, but the precise 






 The effects of MDP are biphasic: at 10 µg/ml (MDP-low), MDP activates the 
inflammatory process, while a dose of 100 µg/ml or higher (MDP-high) dampens the 
process by inhibiting the NFkB-mediated cytokine response.
84,85
 No signs of cytotoxicity 
or apoptosis were observed in vitro at high MDP doses. While the pro-inflammatory 
effects of low doses of MDP are well documented, the mechanisms behind the anti-
inflammatory effects of high doses of MDP remain unclear. Understanding the dual 
actions of MDP on NOD2 may reveal an important signaling pathway that may be 
therapeutically important in chronic inflammatory conditions. 
 The realization that MDP and its derivatives exhibit potent anti-inflammatory 
effects has resulted in active research programs in both academia
86
 and industries. 
Mifamurtide, an analog of MDP originally developed by Novartis and commercialized by 
Takeda, was approved in the United States and Europe for the treatment of osteosarcoma. 
In reviewing studies aimed at identifying pro-inflammatory cytokine inhibitors, we 
learned that conformationally biased (bicyclic systems) MDP derivatives serve as new 
lead compounds accessed through an efficient convergent synthesis. A literature search 
revealed that existing methods did not describe the preparation of conformationally 
biased, bicyclic analogs,
87-90
 which are the first examples of this therapeutic class. In 
addition, few reports
91-94
 have fully characterized synthetic intermediates and final 
products, while also allowing for their preparation in quantities that would be sufficient 
for biological evaluation.
95
 Our work enabled the production of stereochemically pure 




sequence, requiring a single purification step and features an efficient, seven-step route to 
the associated dipeptides.  
 With this chemical strategy in place, we looked for the signal transduction 
pathway associated with the biochemical effects of MDP-high on inflammation. Based on 
previous studies showing that A20 functions as an anti-inflammatory protein
96
 and as a 
key negative regulator of NFκB,
97
 we proposed a role of A20 in MDP anti-inflammatory 
function. 
 Four enantiomerically enriched analogs of MDP were synthesized and among 
them, analog 4 exhibited the most potent activity. A new signaling pathway mediated by 
MDP-high or analog 4 after P.g stimulation was hereto advocated. 
 In this chapter, aside from describing our work, a synthetic effort toward MDP 
analogues that selectively functionalized the 2-postion from the Grimes group at the 





3.2 Synthesis of Muramyl Dipeptide Analogues by Grimes and Coworkers 
 The Grimes group is interested in understanding how peptidoglycan 
modifications, strategies that pathogenic bacteria utilizes to evade an innate immune 
response, alter the innate immune response. It is known that peptidoglycan derivatives 
activate this response via the intracellular innate immune receptor, Nod2. To further 
study the interaction of N-substituted MDPs and Nod2, they developed a synthetic route 
that (1) allowed general exploration of function via acylation at the carbohydrate 2-
position and (2) utilized an azide, a sterically unobstrusive acid- and base-stable 
protecting group, to mask the amine in the synthetic approach.
95
 





 Their synthesis commenced with the commercially available starting material 
glucosamine hydrochloride, which was converted to G2 in a five-step-sequence involving 




anomeric position (Scheme 3.2.1). They discovered that the coupling reactions of a 
dipeptide fragment to modularly protected muramic acid derivatives were low yielding, 
so they chose to perform the amide coupling sequentially. Global deprotection with Pd/C 
and H2 exposed the 2-amino functionality and produced G5, an N-deacetylated naturally 
occurring MDP. The final acetylation of the 2-amino position delivered N-acetyl-MDP 
target G6 and the N-glycolyl- MDP target G7 in ten linear steps from glucosamine 
hydrochloride with overall yields of 33% and 28%, respectively.  
3.3 Scalable Synthesis of Enantiomerically Pure Muramyl Dipeptide Analogues 
for Inhibition of Porphyromonas Gingivalis-Induced Pro-inflammatory Effects by 
the Panek Laboratory (in Collaboration with and Funded by Professor Salomon 
Amar) 
3.3.1 MDP Effects on P.g.-Induced TNF-α, A20, and Other Factors. 
 
Figure 3.3.1 ELISA analysis of TNF-α expression. 
The precultured primary macrophages from wild-type (WT) mice were untreated or 
treated with 10, 100, and 1000 μg/mL of MDP as the control, or treated with P.g. alone as 
a positive control, or cotreated with P.g. plus 10, 100, or 1000 μg/mL of MDP for 3 h. 
The media from each test group were used to detect TNF-α via an ELISA kit 




 Our previous data indicated that LPS-induced TNF-α in macrophages was 
increased by concurrent treatment with MDP-low treatment but, surprisingly, was 
decreased by MDP-high treatment.
98
 To further confirm this, a dose course of MDP was 
performed. As shown in Figure 3.3.1, MDP-low upregulated P.g.-induced TNF-α by 29% 
but MDP-high significantly decreased P.g.-induced TNF-α secretion by 16-38% in 
macrophages. Furthermore, to see whether a higher dose of MDP had an immediate toxic 
effect on cell survival, a toxicity test was performed. As shown in Figure 3.3.2, neither 
the  
 
Figure 3.3.2. Toxicity test. 
WT mouse macrophages were treated with different quantities of MDP for 0, 2, 4, 8, 12, 
16, 18, and 24 h. Cells from each time point were collected by trypsin. Cells were stained 
by Trypan blue, and their survival rate was calculated. The survival rate by 0 μg/mL of 
MDP for 24 h was assigned a value of 100% as the baseline, to which the actual values of 
the others was compared. Data are represented as mean ± SE *p ≤ 0.05. 
 
low- nor high-dose MDP treatments significantly affected macrophage survival, even 
when a much higher dose (1000 μg/ mL) of MDP was used. Meanwhile, we also found 
that a high dose of MDP in macrophages did not affect NOD2 or RIP2 transcription 
(Figure 3.3.3 A-D). However, this treatment significantly induced A20 with a 5.6-fold 




(Figure 3.3.3 E). This phenomenon was further confirmed by Western blot analysis 
(Figure 3.3.4). Interestingly, we also found that this treatment up-regulated the activator 
protein 1 (AP1) production but not MyD88, NFκB (Figure 3.3.4 A), p53, or p21 (Figure 
3.3.4 B) compared to the control. 
 
Figure 3.3.3. RT-PCR analysis of MDP-mediated gene expression. 
WT mouse macrophages were untreated as the negative control, P.g alone as the positive 
control, or co-treated with P.g plus MDP-low treatment, or MDP-high treatment for 3 h. 
Total mRNA from each test group were assessed by RT-PCR with the primers of NOD2, 
RIP2, or A20 and normalized with GAPDH. The intensity of mRNA levels of NOD2, or 
RIP2 from the P.g alone treatment (A-D) were assigned to a base value (100%). For A20, 
the intensity of mRNA levels after MDP-low treatment (E) was assigned to a base value 
(100%). The others were calculated relative to this base value. Triplicate assays were 






Figure 3.3.4 Western blot analysis. 
WT mouse macrophages were untreated or treated with a SC peptide as the negative 
control, MDP-low treatment, or MDP-high treatment for 3 h. The total protein from each 
test group was assessed by Western blot with antibodies (Abs) acting against AP1, A20, 
MyD88, NFkB, or Actin as the control. The intensity of protein levels by treatment of a 
SC peptide was assigned a value of 100% as the baseline, to which the actual value of 
others was compared (A). WT mouse macrophages were treated with either different 
doses of MDP (0, 10, 100, 1,000 µg/ml), or co-treated with P.g plus different doses of 
MDP (0, 10, 100, 1,000 µg/ml) for 3 h. The total protein from each test group was 
assessed by Western blot with Abs against p21, p53, or Actin as the control (B). 
Triplicate assays are presented. 
3.3.2 Activation of A20 via AP1 Protein/DNA Interaction. 
 Because MDP-high treatment in cells induced both A20 and AP1, we hypothesize 
that they are associated in the response to MDP. Through further analysis of the A20 
DNA sequence, we found that the promoter region of A20 contains an AP1 binding site. 
 
Figure 3.3.5. Chromatin Immunoprecipitation (ChIP) assay. 
Diagram of the A20 promoter region sequences, with the location of the AP1 binding site 
and PCR primers of A20 (A). DNA fragments of A20 or GAPDH as controls were 
amplified by PCR, with Input or IPs after the transfection of a full length AP1 cDNA in 
RAW264.7 cells (B). The assays were performed in triplicate and a representative 
experiment is presented. 
 
(Figure 3.3.5 A). To determine whether AP1 interacts with A20, a ChIP analysis assay 
using RAW 264.7 cells was performed. As shown in Figure 3.3.5 B, a PCR amplification 




MDP-low compared to the control (transfected with AP1 cDNA). To determine the 
region of the A20 promoter important for AP1 binding activity, RAW 264.7 cells were 
cotransfected with A20 promoter DNA and different concentrations of AP1 cDNA, after 
which the protein from each test group was assessed via a luciferase assay. As shown in 
 
Figure 3.3.6. Promoter assay. 
RAW264.7 cells were transfected with pcDN3 (lane 1), 0.2 µg of the A20 promoter DNA 
alone (lane 2) as the control, co-transfected with the A20 promoter DNA (0.2 µg) plus 
different quantities of the full length AP1 cDNA (0.1 µg in lane 3, 0.25 µg in lane 4, 0.5 
µg in lane 5). Proteins extracted from each group were measured by luciferase assay (A) 
and by Western blot (B), with antibodies acting against AP1 or Actin as the control. 
Triplicate assays are presented. 
 
Figure 3.3.6, A20 promoter activity increased dose-dependently with increasing AP1 
cDNA concentration, indicating that AP1 is an important factor for up-regulating A20 via 
protein/DNA interactions. As it is well-known that activation of A20 restricts NOD2,
99,100
 
we therefore propose a new signaling pathway mediated by high doses of MDP treatment 
in response to P.g. (Figure 3.3.7). Specifically, we suggest that through this pathway, 
when cells are treated with a high dose of MDP, MDP is transferred into the cytoplasm 




activates A20 and restricts NOD2 ubiquitination, consequently inhibiting TNF-α 
secretion that would otherwise have been induced in response to P.g. We speculate that 
the signal transduction pathway identified for MDP-high would be the same as the one 
activated by analogue 4. 
 
Figure 3.3.7. MDP-high-induced signaling pathway in response to P.g. 
MDP will be transferred into the cell’s’ cytoplasm and will activate JNKs, which will up-
regulate AP1. AP1 will activate A20 and restrict NOD2 ubiquitin, consequently 
inhibiting TNF-α secretion in response to P.g. 
3.3.3 Synthesis of Novel MDP Analogues 
 Since the discovery of the key role of MDP in NOD2-mediated innate immune 
responses to bacterial invasions in certain inflammatory diseases, research on the 
mechanism of actions and signaling pathways have been flourishing.
101-106
 More recently, 
we have shown that treatment with a higher concentration of MDP could have anti-
inflammatory effects through regulating NOD2, mitigating atherosclerosis and bone loss. 
In a related study, the Kobayashi group
107




aminosaccharide compound (DFK1012) which could inhibit the production of pro-
inflammatory cytokines upon stimulation of the immune receptor proteins, TLR and/or 
NLR. DFK1012 has also proved to have no cytotoxicity, thus exhibiting promising anti-
inflammatory effects. Since then, there have surprisingly been no further reports on the 
SAR of MDP pertaining to its anti-inflammatory effects. This underdeveloped, yet 
promising field prompted us to study the SAR of selected MDP analogues by employing 
a convergent synthesis strategy delineating the signaling pathway to analogues, and the 
eventual identification of a lead compound. In that context, we targeted four novel 
analogues (Figure 3.3.8) because of their synthetic accessibility. 





 The underlying principles that guided us to design an early stage probe into the 
SAR were that the analogues (1) needed to be synthetically accessible, (2) must bear the 
features of both MDP and DFK1012, and (3) yet be differentiated from each other in 
subtle substitutions in the carbohydrate fragments. As such, we selected to independently 
modify the dipeptide and carbohydrate fragments before merging the two. In that regard, 
two variables were considered: the stereocenter on the lactic acid moiety and the rigidity 
of the N-acetylmuramic acidfragment by incorporation of the cyclic ketal on the C4 and 
C6 hydroxyl groups, with the expectation that a conformationally biased carbohydrate 
fragment may provide guidance for further structural optimization. As in Figure 3.3.8, 
analogue 3 is devoid of the methyl-bearing stereocenter on the lactic acid subunit, while 
analogue 6 contains the natural stereochemistry of the lactic acid moiety. Similarly, 
analogue 5 was produced with the cyclic ketal and, last, analogue 4 merged the two 
variables, the (4R)-stereocenter of the lactic acid group and the bicyclic ketal. 
 In our initial efforts toward the synthesis of MDP analogues, progress was 
hampered by low yielding reactions.
108,109
 More importantly, these methods did not allow 
for the preparation of the dipeptide fragment from simple, inexpensive, and/or 
commercially available materials. In that context, the Grimes group described a synthetic 
approach leading to MDP-like agents that cleverly employed the functional group 
interconversion strategy of an azide to N-acylated variants at the C2-position and 
subsequently studied their effects on NOD2 signaling and stability. The limitations of 
their synthesis include the production of mixtures of α/β-anomers of the carbohydrate 




Scheme 3.3.1. Retrosynthetic Analysis of MDP Analogues 
 
 In our synthetic approach, we established a reliable, scalable, and divergent 
solution-phase synthesis of diastereomerically and enantiomerically pure MDP analogues 
in order to allow for the preparation of MDP analogues in useful quantities for evaluating 
P.g.-induced pro-inflammatory cytokine inhibitors. The present work marks the first 
reliable preparation of this dipeptide structural type with complete spectroscopic 
characterization of all intermediates and final products (see Supporting Information for 
details). In addition, the synthesis of carbohydrate fragments produced N-acetyl 
glucosamine scaffolds as single α-anomers.
110
 Retrosynthetically, analogues 6 and 3 
could be derived respectively through removal of the ketal of 4 and 5 (Scheme 3.3.1). 




acids 7a and 7b and dipeptide 8, which were synthesized respectively from commercially 
available N-acetyl-D-glucosamine and D-glutamic acid. 




 The synthesis of the carboxylic acids 7a and 7b commenced with the introduction 
of the benzyl ether at the anomeric position of N-acetyl-D-glucosamine (Scheme 3.3.2). 
Originally, we adopted a two-step sequence similar to that reported by Hecker et al., 
wherein the N-acetyl amino sugar 10 was produced by using intermediate 9 without 
purification. However, in our hands, we opted to purify 9 by recrystallizing it in hot 
ethanol before moving on to the next steps and obtained 9 as a single α- anomer.
111
 Thus, 
9 was produced by heating N-acetyl-D-glucosamine in benzyl alcohol at 95 °C in the 
presence of anhydrous hydrochloric acid (1.0 equiv, 4 N solution in 1,4- dioxane) in 
tetrahydrofuran (THF) as the promoter. The orientation of the benzyl ether was assigned 




axial−equatorial orientation) for the anomeric proton. The stereochemical assignment was 
further confirmed by heteronuclear single quantum coherence (HSQC) and heteronuclear 
multiple bond correlation (HMBC) nuclear magnetic resonancespectroscopic experiments 
(see Supporting Informationfor details). Protection of 9 with 2,2-dimethoxypropane and a 
catalytic amount of p-toluenesulfonic acid monohydrate (p-TsOH) in acetone afforded 
acetonide 10 with 100% conversion, which was then used without further purification. O-
Alkylation of 10 with (S)-2-chloropropanoic acid and bromoacetic acid using sodium 
hydride (3 and 4 equiv, respectively) as a base in THF cleanly produced alkylation 
products 7a and 7b, respectively. The production of 7a as a single diastereomer was 
confirmed by comparing optical rotation of 7a to the literature value (    
  = +118 (c 1.0, 
CHCl3), literature     
  = +117 (c 1.0, CHCl3). Notably, this three-step sequence required 
only one single purification step employing a conventional chromatography on SiO2 
(silica gel). Accordingly, we established a facile and scalable route that allowed for the 
preparation of the functionalized glucosamines 7a and 7b in multigram quantities (>20 g) 
with an overall yield of 43% (see Supporting Information for details). 
 The preparation of dipeptide 17 was guided by a desire to establish a reproducible 
route suitable for multi-gram production of the diastereomerically and enantiomerically 
pure material (Scheme 3.3.3). A disconnection at the peptide bond revealed that the 
dipeptide could be constructed by peptide coupling between the trifluoroacetic acid 
(TFA) salt of isoglutamine benzyl ester 16 and Boc-L-alanine. Despite the fact that amino 
acid 16 is a substructure of the proposed MDP analogs, existing routes do not permit a 




regard, our synthesis commenced with a modified three-step sequence originally reported 
by Ressler. Commercially available D-glutamic acid was protected as benzyl carbamate 
11, according to a published report by Abell,
112
 wherein the pH was carefully maintained 
in the range of 8 to 10 by using a combination of sodium carbonate and sodium 
bicarbonate in a solution of acetone and water (1:10). This crucial pH range minimized 
the decomposition of benzylchloroformate in an aqueous solution and prevented 
racemization of the derived carbamate. In our hands, the largest scale of this reaction in 
one pot was 10 grams with an excellent yield of 92%. It was postulated that the α-
carboxylic acid of the bis-carboxylic acid 11 would exhibit a greater acidity than the γ-
carboxylic acid, as evidenced by a smaller chemical shift of the α-carbon in the 
13
C-
NMR. Based on this assumption, a regioselective amidation of 11 was achieved by 
selectively converting the α-carboxylic acid into a mixed anhydride using 
isobutylchloroformate and triethylamine. Isoglutamine 13 was obtained as a hydrochloric 
acid salt by hydrogenolysis of the carboxybenzyl (Cbz) protecting group of 12 and 
subsequent recrystallization with concentrated hydrochloric acid. Isoglutamine benzyl 
ester 15 was generated in good yield through benzylation of amide 14, which was 
produced by protection of the isoglutamine hydrochloric acid salt 13 with Boc anhydride. 
This optimized route enabled the preparation of multi-gram quantities (>20 grams) of 15 
in four steps, requiring only one silica gel chromatography operation. Subsequent 
removal of the tert-butyloxycarbonyl (Boc) protecting group of 15 using TFA (13 equiv.) 
afforded 16, setting the stage for the peptide coupling between 16 and Boc-L-alanine. 
Optimization of coupling conditions
114-117 




dimethylaminopropyl)carbodiimide (EDCI), 1-hydroxy-7-azabenzotriazole (HOAt), and 
2,2,6,6-tetramethylpiperidine (TMP) in dichloromethane as optimal. Final deprotection of 
17 afforded the primary amine used for the coupling of 8 and protected N-acetyl 
glucosamine 7a and 7b. 




 With 8, 7a, and 7b in hand, our attention turned to the fragment coupling between 
8 and carbohydrate 7a and 7b (Scheme 3.3.4). Gratifyingly, by employing the conditions 
of EDCI, HOAt, and TMP in dichloromethane, 4 and 5 were formed cleanly after twelve 















3.3.4 Analysis of MDP Analogues 
 MDP was shown earlier to express activity inhibiting the synthesis of TNF-α. 
Therefore, we were interested in MDP-like compounds with improved anti-inflammatory 
potency (more typically nonspecific ester hydrolysis). Four MDP derivatives (3-6) were 
synthesized (Figure 3.3.8 B) and further analyzed (Figures 3.3.9-11). As shown in 
Figures 3.3.9 and 3.3.10, among the four derivatives, only 4 was similar to MDP, in that 
it gradually reduced TNF-α as a result of an increased concentration and induced 
AP1/A20 gene expression. We also found that a high dose of analogue 4 in macrophages 
reduced the transcription of RIP2, NOD2, and NFκB to an even greater extent than MDP 




indeed an improved compound in comparison to MDP. To confirm our in vitro 
observations, in vivo P.g-induced endotoxic shock was performed.
119
 As shown in Figure 
3.3.12, P.g-injection-only induced septic shock, while death was precipitated with 
additional treatment of MDP-low. However, injecting mice with MDP-high or analogue 4 
significantly reduced endotoxic shock and further prevented death. 
 
Figure 3.3.9. ELISA analysis of individual MDP or its derivative-mediated TNF-α 
gene expression. 
WT mouse macrophages were untreated or treated with P.g alone or the different MDP 
derivatives alone as the controls or co-treated with P.g plus 10, 100, 200 µg/ml of MDP 
or analogs 3-6 for 3 h. The media from each test group were used to detect TNF-α via an 
ELISA kit. Data are represented as Mean ±S.E. *≤0.05. 
 
 
Figure 3.3.10. ELISA analysis of TNF-α production in response to P.g and/or MDP, 




WT mouse macrophages were untreated or treated with P.g, MDP, analogue 3, or 
analogue 4 as controls, or co-treated with P.g plus 10, 100, 200 µg/ml of MDP, analogue 
3, or analogue 4 for 3 h. The supernatants from each group were assessed by ELISA to 
detect the levels of TNF-α protein (A). The regulatory proteins from each group were 
detected by Western blot (B) using antibodies against AP1, A20, NFkB, or Actin as the 
control. Data were represented as Mean ± S.E. *p<0.05. 
 
 
Figure 3.3.11. RT-PCR analysis of individual MDP or derivative-mediated gene 
expression. 
WT mouse macrophages were untreated or treated with P.g.alone, or MDP, analogue 3, 
or analogue 4 alone as the controls or cotreated with P.g. plus 10, 100, and 200 μg/mL of 
MDP, analogue 3, or analogue 4 for 3 h. The total RNAs from each group were assessed 
by RT-PCR with the primers of NFkB (A), RIP2 (B), or NOD2 (C). GAPDH was used as 




Figure 3.3.12. Analysis of endotoxic shock. 
WT mice were ip injected with 2 mg/kg (50 μg) of MDP-low (A) or the derivative 
analogue 4 (B), 8 mg/kg (200 μg) of MDP-high (A) or analogue 4 (B), or DMSO alone as 




× 108 cells/mouse). Mice were then monitored, and their status was recorded. The p-
value for the test groups (n = 3) was calculated by the Wald’s test in a discrete time 
hazard model using version 9.2 of SAS software gene for normalization. Data are 
represented as mean ± SE *p < 0.05. 
 
3.4 Conclusion 
 Inflammatory and immune responses appear to be important mediators linking 
infection and systemic conditions, such as atherogenesis, possibly requiring residence of 
the pathogen in the vessel wall. Interestingly, the majority of pathogens associated with 
atherogenesis share four important characteristics: they are involved in common 
infections,
120
 they are all intracellular pathogens,
121
 they establish long-term persistent 
infections,
122 
and they induce long-lasting increases in specific antibody production.
123
 
Specific cytosolic recognition molecules (e.g., NOD2) activated by MDP appear to be 
involved in this process, such that the infection itself is appropriate to drive the activation 
of signaling pathways. We evaluated the role of NOD2 in two chronic inflammatory 
diseases: atherosclerosis and alveolar bone loss. P.g.-challenged ApoE−/− mice injected 
with high doses of MDP displayed a reduction of serumcholesterol and inflammatory 
cytokines, alveolar bone loss, andatherosclerotic lesions, compared to the P.g. challenged 
ApoE−/− mice injected with saline. In the present study,we present evidence highlighting 
a high dose MDP-dependent signaling pathway which activates JNKs, induces AP1, 
upregulates A20 expression, restricts NOD2, inhibits NFκB, and consequently reduces 
P.g.-induced TNF-α production in mouse macrophages. Furthermore, using the power of 
modern synthetic chemistry, we have described an efficient, highly convergent synthesis 




functionalized carbohydrate portion with the dipeptide fragment. The conformationally 
biased analogue 4 was found to further improve MDP function and inhibition of P.g.-
induced proinflammatory activities. A novel signaling pathway leading to TNF-α 
expression that is influenced by exposing macrophages to both P.g. and a high dose of 
MDP or analogue 4 is heretofor advocated. MDP-high and its optimized analogue 4 both 
reduced P.g-induced septic shock and death, a clear indication of their potent anti-
inflammatory effect. We propose that the rigid bicyclic ring system present on analogue 4 
is responsible for the enhanced reduction of TNF-α production and immunity to septic 
shock and death. The present work paves the way for further MDP optimization to 
improve its efficacy and safety. 
3.5 Experimental Section 
3.5.1 Experimental Procedure 
 
 A. Chemistry. All reactions were carried out in oven or flame-dried glassware 
under argon atmosphere unless otherwise specified. Triethylamine and 2,2,6,6-
tetramethylpiperidine were distilled over calcium hydride and stored over potassium 
hydroxide. Dichloromethane and tetrahydrofuran were obtained from a dry solvent 
system (alumina) and used without further drying. All other reagents were used as 
supplied. Unless otherwise noted, reactions were magnetically stirred and monitored by 
thin layer chromatography with Macherey Nagel Polygram 0.20 mm silica gel 60 Å 
plates. Flash chromatography was performed on Sorbent Technologies 32-63 μm 60 Å 








C NMR spectra were taken in CDCl3, DMSO-d6, and 
MeOH-d4 at 400 or 500 MHz (as indicated), respectively. Chemical shifts are reported in 
parts per million using the solvent internal standard (chloroform, 7.24 and 77.0 ppm, 
DMSO, 2.5 and 40.0 ppm, and MeOH, 3.31 and 49.0 ppm, respectively). Data are 
reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, br = broad), coupling constant, integration. Infrared resonance 
spectra were recorded on a Nexus 670 FT-IR spectrometer. Optical rotations were 
recorded on a Rudolph Autopol II digital polarimeter at 589 nm and reported as follows: 
    
   (concentration in g/100 mL solvent and solvent). High resolution mass spectra were 
obtained on a Waters QTOF mass spectrometer at the Boston University Chemical 
Instrumentation Center. The purity of all compounds were determined to be >95% by 
UPLC-MS. 
N-((2S,3R,4R,5S,6R)-2-(benzyloxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-3-yl)acetamide (9): N-acetyl-D-glucosamine (20 g, 9.04 mmol, 1.0 equiv) was 
suspended in 152 mL benzyl alcohol under argon at room temperature. Hydrogen 
chloride solution (4M in anhydrous 1,4-dioxane, 2.5 mL, 9.94 mmol, 1.1 equiv) was 
added drop-wise via a syringe. The mixture was heated at 95 
o
C for 4 h. After the 
reaction was complete, it was cooled down to room temperature, and then poured into 1L 
cold ether with vigorous stirring. The resulting brown cake was filtered, collected, and 
washed with cold ether. Purification by recrystallization from ethanol afforded 9 as a 
white solid as a single α-anomer (18g, 64% yield).     





H NMR (500 MHz, DMSO-d6): δ7.80 (d, J = 8.5Hz, 1H), 7.36-7.25 (m, 5H), 5.00 (d, J 
= 6Hz, 1H), 4.71 (d, J = 6Hz, 1H), 4.68 (d, J = 3.5Hz, 1H, anomeric), 4.65 (d, J = 
12.5Hz, 1H), 4.52 (t, J = 5.7Hz, 1H), 4.40 (d, J = 12.5 Hz, 1H), 3.68-3.62 (m, 2H), 3.53-
3.42 (m, 3H), 3.16-3.11 (m, 1H), 1.81 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6): δ169.90, 138.37, 128.62, 127.95, 127.86, 96.33, 73.56, 
71.34, 71.02, 68.13, 61.30, 54.20, 23.00; 
IR (neat/cm
-1
) υmax : 3288, 2908, 1637, 1549, 1124, 1039 
HRMS (ESI) m/z calcd for C8H15NO6 [M+H]
 +
 312.1447, found 312.1443; 
UPLC TR 0.72 min. 
N-((4aR,6S,7R,8R,8aS)-6-(benzyloxy)-8-hydroxy-2,2-dimethylhexahydropyrano[3,2-
d][1,3]dioxin-7-yl)acetamide (10): 9(18g, 57.8 mmol, 1 equiv) was suspended in 288mL 
acetone under argon. 2,2-dimethoxypropane (72 mL,578.2 mmol, 10 equiv) was added 
in, followed by p-toluenesulfonic acid monohydrate (p-TSA·H2O) (1.09g, 5.76 mmol, 0.1 
equiv). The mixture was stirred at room temperature for 12 h. The reaction was quenched 
and neutralized with saturated sodium bicarbonate solution. The aqueous layer was 
extracted with dichloromethane (3 x 500mL), and the combined organic layers were dried 
over MgSO4, filtered, and concentrated to obtain pure 10 (20g, 100% yield).  α  
  = +86.4 
(c 1.0, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.40-7.30 (m, 5H), 5.86 (d, J = 8.5Hz, 1H), 4.88 (d, J = 
3.5Hz, 1H, anomeric), 4.71 (d, J = 12.0Hz, 1H), 4.45 (d, J = 12.0Hz, 1H), 4.17 (dt, J = 





C NMR (125 MHz, CDCl3): δ171.41, 136.79, 128.65, 128.27, 128.07, 99.87, 97.16, 
74.70, 70.95, 69.83, 63.66, 62.20, 54.08, 29.07, 23.25, 19.08; 
IR (neat/cm
-1
) υmax : 3319, 1656, 1546, 1372, 1267, 1199, 1122, 1073; 
HRMS (ESI) m/z calcd for C18H25NO6 [M+Na]
 + 
374.1580, found 374.1589; 
UPLC TR 1.09 min. 
(R)-2-(((4aR,6S,7R,8R,8aS)-7-acetamido-6-(benzyloxy)-2,2-
dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)oxy)propanoic acid (7a): Sodium 
hydride (1.5g, 60% dispersion in mineral oil, 37.5 mmol, 3 equiv) was washed with 
hexanes (3 mL) three time to remove mineral oil, and was suspended in 42 mL THF 
under argon. 10 (4.4g, 12.5 mmol, 1 equiv) was added into the above solution slowly, 
followed by (S)-2-chloropropanoic acid (1.3 mL, 15.0 mmol, 1.2 equiv) drop-wise. The 
resulting mixture was stirred vigorously at room temperature until there was no gas 
evolution. Then it was heated at 50 
o
C for 18 h (max speed of stirring). The reaction 
mixture was cooled down to room temperature, quenched with 40mL DI water, and 
acidified with phosphoric acid to pH=3. It was then extracted with dichloromethane (3 x 
300 mL), and the combined organic layers were dried over MgSO4, filtered, and 
concentrated. Purification over silica gel chromatography (50% EtOAc/CH2Cl2, then 4% 
MeOH/CH2Cl2) afforded product 7a as a fluffy, white solid (4.5g, 85% yield).  α  
  = 
+118.4 (c 1.0, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.45 (d, J = 5.2Hz, 1H), 7.35-7.28 (m, 5H), 5.26 (d, J = 




7.1Hz, 1H),  3.94-3.90 (m, 1H), 3.82-3.65 (m, 5H), 2.00 (s, 3H), 1.51 (s, 3H), 1.42 (d, J = 
7.1Hz, 3H), 1.40 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ177.07, 172.49, 137.21, 128.39, 127.89, 127.87, 99.57, 
96.78, 75.77, 75.38, 75.24, 70.11, 63.77, 62.43, 54.56, 29.16, 22.60, 19.24, 18.73; 
IR (neat/cm
-1
) υmax : 3298, 2992, 2942, 2880, 1716, 1621, 1565, 1455, 1383, 1267, 1237, 
1202, 1175, 1149, 1123, 1076, 1046; 
HRMS (ESI) m/z calcd for C21H29NO8 [M+Na]
 + 
446.1791, found 446.1794; 
UPLC TR 1.30 min. 
2-(((4aR,6S,7R,8R,8aS)-7-acetamido-6-(benzyloxy)-2,2-
dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)oxy)acetic acid (7b): Sodium 
hydride (2.19g, 60% dispersion in mineral oil, 45.6 mmol, 4 equiv) was washed with 
hexanes (4 mL) three time to remove mineral oil, and was suspended in 60 mL THF 
under argon. 10 (4.0g, 11.4 mmol, 1 equiv) was added into the above solution slowly, 
followed by bromoacetic acid (2.225g, 16.0 mmol, 1.4 equiv) dropwise. The resulting 
mixture was stirred vigorously at room temperature until no gas evolution. Then it was 
heated at 50 
o
C for 18 h (max speed of stirring). The reaction mixture was cooled down to 
room temperature, quenched with 100mL DI water, and acidified with phosphoric acid to 
pH=3. It was then extracted with dichloromethane (3 x 300 mL), and the combined 
organic layers were dried over MgSO4, filtered, and concentrated. Purification over silica 
gel chromatography (3.7% MeOH/CH2Cl2) afforded product 7b as a fluffy, white solid 
(3.9g, 84% yield).  α  





H NMR (500 MHz, CDCl3): δ7.36-7.28 (m, 5H), 7.24 (d, J = 6.3Hz, 1H), 5.16 (d, J = 
3.8Hz, 1H, anomeric), 4.67 (d, J = 11.9Hz, 1H), 4.47 (d, J = 11.9Hz, 1H), 4.31 (ABq, J 
= 17.6Hz, 2H), 4.01 (ddd, J = 10.2, 6.6, 3.8 Hz, 1H), 3.82-3.65 (m, 5H), 2.00 (s, 3H), 
1.51 (s, 3H), 1.41 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ174.26, 172.53, 137.18, 128.42, 127.91, 127.84, 99.68, 
96.74, 76.06, 75.58, 70.04, 68.32, 63.72, 62.30, 54.39, 29.11, 22.57, 19.18; 
IR (neat/cm
-1
) υmax : 3309, 2995, 2932, 2882, 1719, 1621, 1560, 1433, 1383, 1267, 1233, 
1201, 1174, 1146, 1119, 1074, 1042; 
HRMS (ESI) m/z calcd for C21H29NO8 [M+Na]
 + 
432.1634, found 432.1628; 
UPLC TR 1.19 min. 
((Benzyloxy)carbonyl)-D-glutamic acid (11): Glutamic acid (10g, 68 mmol, 1 equiv) 
was dissolved in 100 mL DI water at 0 
o
C (without Argon protection). Sodium carbonate 
(21.6g, 204 mmol, 3 equiv) and sodium bicarbonate (5.8g, 68 mmol, 1 equiv) were added 
sequentially. 10mL acetone was added into the above mixture, followed by benzyl 
chloroformate (20 mL, 150 mmol, 2.2 equiv). The resulting mixture was stirred for 36 h, 
gradually warming to room temperature. It was quenched by acidifying to pH=3 with 
20% hydrochloric acid and extracted with EtOAc (3 x 500 mL). The combined organic 
layers were dried over MgSO4, filtered, and concentrated. Purification over silica gel 
chromatography (5% MeOH/CH2Cl2) afforded product 11 as a white solid (17.5g, 92% 
yield).     
  = +7.2 (c 1.0, MeOH); 
1
H NMR (500 MHz, DMSO-d6): δ12.37 (br, 2H), 7.37-7.28 (m, 5H), 5.02 (s, 2H), 3.98 





C NMR (100 MHz, DMSO-d6): δ174.19, 174.06, 156.62, 137.40, 128.79, 128.26, 
128.15, 65.87, 53.48, 30.52, 26.52; 
IR (neat/cm
-1
) υmax : 3466, 3332, 3199, 1723, 1666, 1644, 1541, 1410, 1267, 1172, 1051; 
HRMS (ESI) m/z calcd for C13H15NO6 [M+Na]
 + 
304.0797, found 304.0789; 
UPLC TR 0.82 min. 
(R)-5-amino-4-(((benzyloxy)carbonyl)amino)-5-oxopentanoic acid (12): 11 (15g, 53.3 
mmol, 1 equiv) was dissolved in 100mL THF under argon at room temperature. Freshly 
distilled triethylamine (16.4mL, 117.3 mmol, 2.2 equiv) was added dropwise into the 
above solution, and stirred for 15 min before moved to a -30 
o
C chiller. At -30 
o
C, 
isobutylchloroformate (8 mL, 64 mmol, 1.0 equiv) was added in dropwise, forming a 
heterogeneous mixture. It was stirred at -30 
o
C for 1h. Ammonia (266mL, 0.5M in THF, 
133 mmol, 2.5 equiv) was added in slowly through the inner surface of the reaction flask. 
The reaction mixture was stirred at -30 
o
C for 48 h before it was quenched by 200 mL DI 
water. The mixture was acidified to pH=3 by phosphoric acid. The resulting mixture was 
partitioned between 500 mL water and 500 mL ethyl acetate. The aqueous layer was 
extracted with EtOAc (3 x 500 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated. The crude material was used without purification. 
Pure product 12 was obtained by preparative thin layer chromatography (TLC) 
purification in 10% MeOH/CH2Cl2 for characterization (60% yield).  α  






H NMR (500 MHz, DMSO-d6): δ12.07 (br, 1H), 7.35-7.29 (m, 5H), 7.00 (s, 1H), 5.00 
(s, 2H), 3.92 (td, J = 8.8, 5.2Hz, 1H), 2.23 (t, J = 15.7Hz, 2H), 1.91-1.84 (m, 1H), 1.74-
1.67 (m, 1H); 
13
C NMR (100 MHz, DMSO-d6): δ174.32, 173.87, 156.38, 137.47, 128.76, 128.21, 
128.11, 65.85, 54.31, 30.72, 27.63; 
IR (neat/cm
-1
) υmax : 3465, 3331, 3202, 1723, 1666, 1647, 1609, 1541, 1410, 1352,  1267, 
1172, 1052; 
HRMS (ESI) m/z calcd for C13H16N2O5 [M+Na]
 + 
303.0957, found 303.0963; 
UPLC TR 0.82 min. 
(R)-1-amino-4-carboxy-1-oxobutan-2-aminium chloride (13): 12 (12g, 42.8 mmol, 1 
equiv) was dissolved in a mixture of 75 mL methanol and 75 mL acetic acid at room 
temperature. Pd/C (10 wt. % loading, 10g, 80 w%) was added in. The internal 
atmosphere was exchanged with hydrogen gas by bubbling through hydrogen gas for 5 
min. The reaction was stirred under an atmosphere of hydrogen gas (1 atm, balloon) for 
12h. The reaction mixture was then filtered through a pad of celite and washed with dry 
methanol. The solvents were removed in vacuo. The remaining acetic acid was 
azeotropically removed with ethyl acetate in vacuo (it is important to make sure that all 
of the acetic acid was removed). The crude oil was recrystallized by dissolving it in 
methanol and adding concentrated hydrochloric acid to it. The mother liquor was 
recrystallized twice until no more solids formed. 13 was obtained as a fluffy, white solid 




(R)-5-amino-4-((tert-butoxycarbonyl)amino)-5-oxopentanoic acid (14): A solution of 
13 (7.5g, 51.0 mmol, 1 equiv) in 44 mL DI water was cooled to 0 
o
C (without Argon 
protection). Sodium carbonate (10.9g, 102.8 mmol, 2 equiv) was slowly added in to the 
mixture. The resulting solution was stirred for 10 min until it was clear. 36 mL of 1,4-
dioxane was added in, followed by Di-tert-butyl dicarbonate (Boc2O) (13.4g, 61.4 mmol, 
1.2 equiv). The mixture was stirred at room temperature for 12h. It was quenched by 
phosphoric acid and the pH was adjusted to 3. The mixture was partitioned between 500 
mL ethyl acetate and 500 mL DI water. The aqueous layer was extracted with EtOAc (3 x 
500 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated. The crude material was used without purification. 
Benzyl (R)-5-amino-4-((tert-butoxycarbonyl)amino)-5-oxopentanoate (15): Crude 14 
(12.6g, 51.2 mmol, 1 equiv) was dissolved in 200 mL dry DMF under argon. Sodium 
bicarbonate (12.9g, 153.6 mmol, 3 equiv) was added in one portion, followed by benzyl 
bromide (12 mL, 102.4 mmol, 2 equiv). The mixture was heated at 60 
o
C for 18 h. The 
reaction mixture was cooled down to room temperature, and neutralized by phosphoric 
acid. The resulting mixture was partitioned between 800 mL ethyl acetate and 500 mL DI 
water. The aqueous layer was extracted with EtOAc (3 x 100 mL). The combined organic 
layers were washed with 5% LiCl solution (8 x 200 mL) to remove most DMF. Then the 
organic layer was dried over MgSO4, filtered, and concentrated. Purification over silica 
gel chromatography (gradient, 3% to 4%, MeOH/CH2Cl2) afforded product 15 as a white 
solid (6.8g, 44% yield over two steps).  α  





H NMR (500 MHz, CDCl3): δ7.39-7.30 (m, 5H), 6.30 (br, 1H), 5.65 (br, 1H), 5.33 (br, 
1H), 5.13 (s, 2H), 4.21 (br, 1H), 2.57 (td, J = 16.9, 7.4Hz, 1H), 2.46 (td, J = 16.9, 7.0Hz, 
1H), 2.20-2.13 (m, 1H), 1.97-1.90 (m, 1H), 1.43 (s, 9H); 
13
C NMR (125 MHz, CDCl3): δ174.45, 173.00, 155.82, 135.74, 128.53, 128.23, 128.17, 
79.96, 66.46, 53.24, 30.40, 28.31, 27.89; 
IR (neat/cm
-1
) υmax : 3384, 3348, 3184, 2978, 1727, 1682, 1519, 1450, 1391, 1366, 1278, 
1250, 1165; 
HRMS (ESI) m/z calcd for C17H24N2O5 [M+Na]
 + 
359.1583, found 359.1582; 
UPLC TR 1.30 min. 
(R)-1-amino-5-(benzyloxy)-1,5-dioxopentan-2-aminium 2,2,2-trifluoroacetate (16):  
A solution of 15 (500mg, 1.5 mmol, 1 equiv) in 13 mL dry CH2Cl2 under argon was 
added in TFA (1.5 mL, 19.6 mmol, 13 equiv) drop-wise. The resulting solution was 
stirred at room temperature for 4h. The solvent was removed in vacuo. The crude product 
16 was used without purification. 
Benzyl (R)-5-amino-4-((S)-2-((tert-butoxycarbonyl)amino)propanamido)-5-
oxopentanoate (17): 16 (525mg, 1.5 mmol, 1 equiv)  was taken up in dry 
dichloromethane and Boc-L-alanine (227mg, 1.2 mmol, 0.8 equiv) was added under 
argon. The resulting mixture was cooled down to 0 
o
C. TMP (1.3 mL, 7.5 mmol, 5 equiv) 
was added dropwise into the above mixture. It was stirred for 5 min before HOAt 
(306mg, 2.25 mmol, 1.5 equiv) and EDCI (349 mg, 2.25 mmol, 1.5 equiv) were added. 
The reaction mixture was stirred for 18 h, gradually warming to room temperature. The 




mixture was partitioned between 100mL DI water and 100 mL dichloromethane. The 
aqueous layer was extracted with dichloromethane (3 x 100mL). The combined organic 
layers were dried over MgSO4, filtered, and concentrated. Purification over silica gel 
chromatography (4% MeOH/CH2Cl2) afforded product 17 (403mg, 66% over two steps) 
as a fluffy, white solid.  α  
  = +1.4 (c 1.0, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.38-7.30 (m, 5H), 7.26 (br, 1H), 6.80 (br, 1H), 5.75 (br, 
1H), 5.19 (d, J =3.1, 1H), 5.12 (ABq, J = 12.3 Hz, 2H), 4.48 (dd, J = 10, 7.5Hz, 1H), 
4.07, (dq, J = 7.1, 3.1Hz, 1H), 2.57 (dt, J = 16.9, 7.3Hz, 1H), 2.46 (dt, J = 17.0, 6.8 Hz, 
1H), 2.26-2.19, (m, 1H), 2.05-1.98 (m, 1H), 1.41 (s, 9H), 1.32 (d, J = 7.1Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ173.50, 173.42, 173.32, 155.84, 135.62, 128.57, 128.32, 
128.25, 80.38, 66.64, 52.27, 50.64, 30.58, 28.26, 26.77, 17.75; 
IR (neat/cm
-1
) υmax : 3303, 2980, 2936, 1665, 1520, 1455, 1367, 1249, 1164, 1069, 1022; 
HRMS (ESI) m/z calcd for C20H29N3O6 [M+Na]
 + 
430.1954, found 430.1951; 
UPLC TR 1.25 min. 
(S)-1-(((R)-1-amino-5-(benzyloxy)-1,5-dioxopentan-2-yl)amino)-1-oxopropan-2-
aminium 2,2,2-trifluoroacetate (8): A solution of 17 (400mg, 0.98 mmol, 1 equiv) in 21 
mL dry dichloromethane was added TFA (2.2 mL, 28.8 mmol, 29 equiv) dropwise under 
argon. The reaction mixture was stirred at room temperature for 1 h. The solvent was 
removed in vacuo. The remaining TFA was azeotropically removed with ethyl acetate in 






5-amino-5-oxopentanoate (4): A solution of 8 (249mg, 0.59 mmol, 1 equiv) in 6 mL 
dichloromethane was added 7a (200mg, 0.47 mmol, 0.8 equiv) under argon at 0 
o
C. To 
the above solution, tetramethylpiperidine (TMP) (0.7 mL, 4.13 mmol, 7 equiv) was added 
dropwise. The resulting solution was stirred for 5 min. HOAt (120mg, 0.89 mmol, 1.5 
equiv), followed by EDCI (138 mg, 0.89 mmol, 1.5 equiv) was added sequentially. The 
reaction mixture was stirred for 18 h, gradually warming to room temperature. The 
reaction was quenched by neutralizing it with saturated ammonia chloride solution. The 
mixture was partitioned between 100mL DI water and 100 mL dichloromethane. The 
aqueous layer was extracted with dichloromethane (3 x 100mL). The combined organic 
layers were dried over MgSO4, filtered, and concentrated. Purification over silica gel 
chromatography (5% MeOH/CH2Cl2) afforded product 4 (188mg, 56% over two steps) as 
a fluffy, white solid.  α  
  = +83.8 (c 1.0, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.39-7.30 (m, 10H), 7.15 (d, J = 6.2Hz, 1H), 6.94 (s, 1H), 
6.18 (d, J = 9.15Hz, 1H), 5.51 (s, 1H), 5.09 (s, 2H), 4.86 (d, J = 3.9Hz, 1H, anomeric), 
4.68 (ABq, J = 11.9Hz, 1H), 4.48-4.44 (m, 1H), 4.45 (ABq, J = 11.8Hz), 4.23 (td, J = 
9.6, 3.9Hz, 1H), 4.18-4.12 (m, 1H), 3.97 (q, J = 6.75Hz, 1H), 3.84-3.63 (m, 4H), 3.49 
(dd, J = 9Hz, 1H), 2.57 (dt, J = 16.8, 7.3 Hz, 1H), 2.46 (dt, J = 17.2, 6.5 Hz, 1H), 2.24-
2.18 (m, 1H), 2.07-2.00 (m, 1H), 1.92 (s, 3H), 1.50 (s, 3H), 1.40 (d, mix, 3H), 1.39, (s, 
3H), 1.35 (d, J = 6.7, 3H); 
13
C NMR (100 MHz, CDCl3): δ174.36, 173.93, 173.31, 172.10, 170.61, 136.57, 135.47, 
128.73, 128.62, 128.45, 128.35, 128.29, 128.06, 99.63, 97.35, 79.20, 78.39, 74.09, 69.96, 






) υmax : 3390, 3302, 3055, 2988, 2938, 1736, 1651, 1545, 1455, 1384, 1266, 
1203, 1170, 1123, 1077, 1041; 
HRMS (ESI) m/z calcd for C36H48N4O11 [M+Na]
 + 
735.3217, found 735.3197; 
UPLC TR 1.44 min. 
Benzyl (R)-4-((S)-2-(2-(((4aR,6S,7R,8R,8aS)-7-acetamido-6-(benzyloxy)-2,2-
dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)oxy)acetamido)propanamido)-5-
amino-5-oxopentanoate (5): A solution of 8 (249mg, 0.59 mmol, 1 equiv) in 6 mL 
dichloromethane was added 7b (192mg, 0.47 mmol, 0.8 equiv) under argon at 0 
o
C. To 
the above solution, TMP (0.7 mL, 4.13 mmol, 7 equiv) was added dropwise. The 
resulting solution was stirred for 5 min. HOAt (120mg, 0.89 mmol, 1.5 equiv), followed 
by EDCI (138 mg, 0.89 mmol, 1.5 equiv) was added sequentially. The reaction mixture 
was stirred for 18 h, gradually warming to room temperature. The reaction was quenched 
by neutralizing it with saturated ammonia chloride solution. The mixture was partitioned 
between 100mL DI water and 100 mL dichloromethane. The aqueous layer was extracted 
with dichloromethane (3 x 100mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated. Purification over silica gel chromatography (5% 
MeOH/CH2Cl2) afforded product 5 (187mg, 56% over two steps) as a fluffy, white solid. 
 α  
  = +59.8 (c 0.95, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ7.39-7.29 (m, 10H), 6.93 (s, 1H), 6.12 (d, J = 9.3Hz, 1H), 
5.66 (s, 1H), 5.10 (s, 2H), 4.84 (d, J =4.0Hz, 1H, anomeric), 4.70 (ABq, J =11.8Hz, 1H), 
4.46 (ABq, J =11.8Hz, 1H), 4.45-4.41 (m, 1H), 4.34 (ABq, J =15.8Hz, 1H), 4.33-4.28 




= 9.2Hz, 1H), 2.53 (dt, J = 16.7, 7.3Hz, 1H), 2.43 (dt, J = 17.0, 6.8Hz, 1H), 1.93 (s, 3H), 
1.49 (3, 3H), 1.39 (s, 3H), 1.37 (d, J = 7.1Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ173.58, 173.52, 172.46, 170.77, 170.70, 136.51, 135.59, 
128.74, 128.59, 128.44, 128.32, 128.27, 128.18, 99.78, 97.25, 79.47, 74.22, 70.71, 69.98, 
66.60, 63.56, 62.19, 52.60, 52.39, 49.24, 30.70, 29.15, 26.29, 23.54, 19.18, 17.32. 
IR (neat/cm
-1
) υmax : 3307, 2943, 1737, 1660, 1533, 1456, 1377, 1267, 1202, 1173, 1128, 
1076, 1046; 
HRMS (ESI) m/z calcd for C35H46N4O11 [M+Na]
 + 
721.3061, found 721.3080; 
UPLC TR 1.40 min. 
Benzyl (R)-4-((S)-2-((R)-2-(((2S,3R,4R,5S,6R)-3-acetamido-2-(benzyloxy)-5-hydroxy-
6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)oxy)propanamido)propanamido)-5-
amino-5-oxopentanoate (6): A solution of 4(100mg, 0.14 mmol, 1 equiv) in 6 mL dry 
dichloromethane was added 0.65 mL TFA under argon at 0
o
C. The reaction mixture was 
stirred at 0 
o
C for 1 h. The reaction was quenched by neutralizing it with saturated 
aqueous sodium bicarbonate. The mixture was partitioned between 50mL DI water and 
50 mL ethyl acetate. The aqueous layer was extracted with ethyl acetate (3 x 50mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated. Purification 
over silica gel chromatography (8% MeOH/CH2Cl2) afforded product 6 (69mg, 73%) as a 
white solid.  α  
  = +46.4 (c 0.75, CH2Cl2); 
1
H NMR (500 MHz, CD3OD): δ7.38-7.25 (m, 10H), 5.11 (s, 2H), 4.87 (d, J = 3.6Hz, 1H, 
anomeric), 4.72 (ABq, J = 12.0Hz, 1H), 4.50 (ABq, J = 12.0Hz, 1H), 4.36 (dd, J = 9.5, 




1H), 3.81 (dd, J = 11.8, 2.1Hz, 1H), 3.73-3.62 (m, 3H), 3.51-3.48 (m, 1H), 2.44 (t, J = 
7.6Hz, 2H), 2.25-2.18 (m, 1H), 1.93-1.86 (m, 1H), 1.89 (s, 3H), 1.36 (d, J = 7.0Hz, 6H). 
13
C NMR (100 MHz, CD3OD): δ174.85, 174.73, 173.78, 172.68, 172.00, 137.38, 136.10, 
128.11, 127.98, 127.80, 127.77, 127.48, 96.03, 79.40, 76.83, 72.74, 69.93, 68.77, 66.00, 
61.12, 53.36, 52.15, 49.37, 29.96, 26.57, 21.41, 18.20, 16.35; 
IR (neat/cm
-1
) υmax : 3373, 2933, 1655, 1545, 1456, 1204, 1136, 1026. 
HRMS (ESI) m/z calcd for C32H42N4O11 [M+Na]
 + 
681.2748, found 681.2764; 
UPLC TR 1.11 min. 
Benzyl (R)-4-((S)-2-(2-(((2S,3R,4R,5S,6R)-3-acetamido-2-(benzyloxy)-5-hydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-4-yl)oxy)acetamido)propanamido)-5-amino-
5-oxopentanoate (3): A solution of 5 (98mg, 0.14 mmol, 1 equiv) in 6 mL dry 
dichloromethane was added 0.65 mL TFA under argon at 0
o
C. The reaction mixture was 
stirred at 0 
o
C for 1 h. The reaction was quenched by neutralizing it with saturated 
aqueous sodium bicarbonate. The mixture was partitioned between 50 mL DI water and 
50 mL ethyl acetate. The aqueous layer was extracted with ethyl acetate (3 x 50 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated. Purification 
over silica gel chromatography (8% MeOH/CH2Cl2) afforded product 3 (58mg, 63%) as a 
white solid.  α  
  = +62.2 (c 0.55, MeOH); 
1
H NMR (500 MHz, CD3OD): δ7.40-7.27 (m, 10H), 5.11 (s, 2H), 4.83 (d, J = 3.7Hz, 1H, 
anomeric), 4.74 (ABq, J = 11.9Hz, 1H), 4.51 (ABq, J = 11.9Hz, 1H), 4.37 (dd, J = 9.6, 




3.6Hz, 1H), 3.82 (d, J = 9.9Hz, 1H), 3.74-3.57 (m, 4H), 2.45 (t, J = 7.5Hz, 2H), 2.26-2.19 
(m, 1H), 1.94 (s, 3H), 1.94-1.87 (m, 1H), 1.37 (d, J = 7.2Hz, 3H); 
13
C NMR (100 MHz, CD3OD): δ174.73, 173.85, 172.74, 172.04, 172.00, 137.35, 136.10, 
128.11, 128.04, 128.00, 127.79, 127.77, 127.53, 96.22, 81.70, 72.76, 70.92, 70.12, 68.88, 
66.03, 60.98, 53.18, 52.21, 49.12, 30.03, 26.51, 21.26, 16.31; 
IR (neat/cm
-1
) υmax : 3306, 2925, 1733, 1654, 1543, 1455, 1385, 1333, 1259, 1158, 1126, 
1039; 
HRMS (ESI) m/z calcd for C33H44N4O11 [M+H]
 + 
673.3085, found 673.4091; 
UPLC TR 1.11 min. 
(B) Biological Methods and Materials. Animals and cells. 8 to 10 week-old WT 
(C57BL/6) mice from The Jackson Laboratory were maintained under strict specific 
pathogen-free conditions. RAW264.7 cells (TIB 71, ATCC) and mouse primary 
peritoneal macrophages were cultured in a RPMI 1640 media (Cat#: 11875-093, Life 
Technologies, NY) with 10% FBS at 37ºC in a 5% CO2 atmosphere. Cells were treated 
with LPS, MDP or others as described below.  
All mice protocols used in this study were approved by the Boston University Animal 
Care and Use Committee. All mice were obtained and used in compliance with 
institutional regulations and related federal, state, and local laws. 
DNA constructs. A full-length mouse AP1 cDNA (Locus: AK135023, aa 1~335, Open 
Biosystems) was used as a template; the primer pairs 5’-atgactgcaaagatggaaac-3’ and 5’-
tcaaaacgtttgcaactgct-3’ were used to amplify the full-length AP1 cDNA fragments by 
PCR. The DNA fragment was then sub-cloned into pcDNA3HA
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mouse genomic DNA (isolated by our lab) served as a template DNA, and primer pairs 
(5’- cagggaaagatgtccatatg-3’ & 5’-gtcctcgacaaggcctgaag-3’) were used to amplify A20 
promoter DNA fragments (-1051~ -1 of A20, Locus: JN960089) by PCR. The DNA 
fragments were then sub-cloned into a pGL3-basic vector (Promega). 
Luciferase assay. A commercial kit was used (Cat# E1500, Promega) and the assay was 
performed according to the protocols provided by the manufacturer. 
Real-time PCR. The total mRNA purified from each test group was subjected to RT-PCR 
using RT-PCR kits (iScript & iQ SYBR Green, Bio-Rad) and the following primers: 
NOD2 (5’- gtgacatgtgctcacagg-3’ & 5’-agcagccagtctaagatgct-3’), RIP2 (5’-
atgaacggggacgccatctg-3’& 5’-acgagaccgtgccagaggcg-3’), A20 (5’-gctgaacaacttcttcctca-
3’& 5’-atcccattggtaggtttgaa-3’), or NFkB (5’-atggcagacgatgatcccta-3’& 5’-
gtatttctggtgaatataat-3’). The PCR products were then normalized to GAPDH mRNA 
levels following the manufacturer’s protocols. 
In vivo assay for LPS and/or MDP. The 8 to 10 week-old WT mice were i.p. injected 
with DMSO alone as the negative control, P.g alone (1x10
8
/kg) as the positive control, or 
co-treated with P.g (1x10
8
/kg) and 2 mg/kg (50µg) of MDP-low or 8 mg/kg (200µg) of 
MDP-high (50ug or 200ug/mouse) among the test group subjects. All animals were 
continuously monitored for endotoxic response for 2 h after injection (n = 3 per group). 
The data were analyzed and then graphed (see Figure 3.3.12). 
ELISA. Using an Invitrogen kit (Cat#: KMC30110), the conditioned media from mouse 
primary peritoneal macrophages were subjected to ELISA for the detection of TNF-α 




immunoreactivities were quantified by using a microplate reader (Model 680, Bio-Rad). 
Data were analyzed and then graphed. 
Chromatin immunoprecipitation (ChIP). The assay was performed using a commercial 
kit (Cat#: 53009, ChIP-IT Express Enzymatic, Active Motif), with some modifications. 
RAW264.7 cells were treated with MDP-high or MDP-low concentrations for 3 hrs or 
transfected with 1 µg of the AP1 DNA overnight. 10 µg nuclear extracts as described,
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as input from the cross-linked cells, were immunoprecipitated (IP) with 1 µg of the AP1 
antibody or 1 µg of normal mouse IgG as the control at 4ºC for 4 hrs. DNA from each 
experimental group (Input or immunoprecipitated) was isolated by elution, reverse cross-
linking and proteinase K treatment, according to the kit manufacturer’s instructions. The 
DNA was then used as a template to perform PCR with A20 primers (5’-
aaactatttgctgccttgta-3’& 5’-cactgaagaccaccaccatt-3’) for amplification of a 100 bp DNA 
fragment of the A20 promoter or GAPDH primers (Invitrogen) as the control. 
Western blotting. Cells were harvested and proteins from the whole cell and from the 
nuclei were fractionally purified. Nuclear proteins were purified by scraping treated and 
untreated cells. Pellets were held on ice for 15 min and in the presence of 25 µL 1% 
Nonidet P-40. They were re-suspended in 400 µL of cold buffer A (10 mM Hepes, pH 
7.9/10 mM, KCl/0.1 mM, EDTA/0.1 mM, EGTA/1 mM, DTT/0.5 mM, 
phenylmethylsulfonyl fluoride/1 µg/ml, pepstatin A/10 µg/ml, leupeptin/10 µg/ml, 
aprotinin). Samples were vortexed and centrifuged for 1 min at 10,000 × g, and the 
pellets were again suspended with 100 µL of buffer B (20 mM Hepes, pH 7.9/400 mM, 




µg/ml, pepstatin A/10 µg/ml, leupeptin/10 µg/ml, aprotinin). After shaking the samples 
on a rocker platform for 15 min at 4°C, they were centrifuged at 4°C for another 15 min 
at 10,000 × g. Cell lysates from whole cells or nuclei (60 µg total proteins per lane) were 
applied to SDS polyacrylamide gels, and the proteins were detected by Western blot 
using antibodies directed against AP1 (sc-14027), A20 (sc- -372), p21 
(sc-6246), p53 (sc-17846), NOD2 (sc-30199), MyD88 (sc-8196), GAPDH (sc-365062), 
or actin (sc-1615) (Santa Cruz Biotechnology). The Ub antibody (sc-271289, Santa Cruz 
Biotechnology) was used for detection of mouse ubiquitin and polyubiquitin. 
Trypan blue exclusion method. To determine cell survival rates after toxicity tests, the 
Trypan blue exclusion method (Triangle Research Laboratories) was used. (Link: http:// 
triangleresearchlabs.net/wp-content/uploads/2012/06/Trypan-Blue-Cell-Counting-
Protocol.pdf). 
MDP. MDP was purchase from INVIVOGEN (tlrl-mdp, San Diego, CA) and was diluted 
to either a high concentration (100 µg/ml) or a low concentration (10 µg/ml). 
Statistical analysis. All experiments were performed in triplicate and statistical analyses 
were conducted with the SAS software package. All data were normally distributed. For 
multiple mean comparisons, we conducted analysis of variance (ANOVA) tests, while 
using the Student's t-test for single mean comparisons. For time-course studies, we used a 
two-way repeated measure ANOVA. P-values less than 0.05 were considered significant. 
Abbreviations used 
Pattern recognition receptors (PRRs), Toll-like receptors (TLRs), nucleotide-binding 




domains (CARDs), Leu-rich repeats (LRRs), muramyl dipeptide (MDP), receptor-
interacting protein 2 (RIP2), inhibitor of κB (IκB), mitogen-activated protein (MAP), 
interleukin-6 (IL-6), 10 µg/ml of MDP (MDP-low), 100 µg/ml or higher of MDP (MPD-
high), Jun N-terminal kinases (JNKs), dichloromethane (CH2Cl2), dimethylformamide 
(DMF), tetrahydrofuran (THF), p-toluenesulfonic acid monohydrate (p-TsOH), 
trifluoroacetic acid (TFA), carboxybenzyl (Cbz), tert-butyloxycarbonyl (Boc), 
Heteronuclear Single Quantum Coherence (HSQC), Heteronuclear Multiple Bond 
Correlation (HMBC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), 1-
hydroxy-7-azabenzotriazole (HOAt), 2,2,6,6-tetramethylpiperidine (TMP), thin layer 







































































 Periodontal disease caused by bacterial accumulations or dental plaque on the 
teeth is highly prevalent in the United States.
126-128
 Gingivitis which is the most popular 
and mild form of periodontal disease affects 70%-80% of adults in the United States. The 
more advanced form is periodontitis with affected US adult population over 47%.
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While gingivitis is characterized by inflammation of the gums, redness, swelling, and 
frequent bleeding, periodontitis is more severe and leads to tissue damage and alveolar 
bone loss. Studies in the past 10 years have also indicated correlations between 
periodontal disease and various systemic disorders and disease, including cardiovascular 
disease, diabetes mellitus, preterm low birth weight, and osteoporosis. The source of 
periodontal disease comes from approximately 500 different bacterial entities and various 
human viruses.
130-133
 Among them, three microaerophilic species (Actinobacillus 
actinomycetemcomitans, Campylobacter rectus, and Eikenella corrodens) and seven 
anaerobic species (Porphyromonas gingivalis, Bacteroides forsythus, Treponema 
denticola, Prevotella intermedia, Fusobacterium nucleatum, Eubacteria, and spirochetes) 
are frequently identified periodontal pathogens. 
 The difficulty with treatment of periodontal disease has been the fact that there 
are no effective, orally available small molecule drugs. Conventional periodontal therapy 
comprises oral hygiene instruction and scaling and root planning. However, systemic or 
local risk factors such as deep pockets or furcations of multirooted teeth may complicate 
the treatment.
134
 To control the inflammation associated with periodontal disease, many 
anti-TNF-α drugs have been used as additive therapies.
135,136




therapies outweigh potential benefits. Additionally, all current TNF-α blockers are 
protein therapeutics, which must be administered parenterally and cost significantly 
higher than small molecule drug formulations. Therefore, there is a pressing need for the 
development of effective small molecule therapeutics for the definitive treatment of 
periodontal diseases.  
 
Figure 4.1.1. The major components of kava. The relative abundance of the major 
constituents is shown in parentheses. 
 In line with our continued interest in identifying a novel class of oral TNF-α 
modulators, we recently discovered that Kava, a natural product extract from the Piper 
methysticum plant, and its several analogues exhibited significant TNF-α reduction in 
vitro and in vivo.
137
 Moreover, our recent study of kava on a conventional oral gavage 




loss and inflammation in P. gingivalis-induced periodontitis. The major chemical 
components of kava are seven lactones (Figure 4.1.1 A) and three chalcones (Figure 4.1.1 
B).
138
 Although previous studies
 
have demonstrated kava, a mixture of the ten major 
compounds, as a potent agent on TNF-α reduction, limitations including hepatic, 
neurologic, and dermatological toxicity, solubility and stability in vivo and cell 
permeability
139
 present opportunity for further medicinal chemistry optimization. 
4.2 Synthesis of Novel Kava Analogues by the Panek Laboratory 
 A widely used and well-established method for early-stage discovery chemistry to 
optimize potent compounds to achieve drug-like properties is the structure–activity-
relationship (SAR) study. In this study, the correlations between the structural features of 
designed analogues and biological properties and/or activities of targets are presented. 
These correlations often provide useful information for specific interactions between the 
substructures of compounds and biological systems. More importantly, efforts are 
directed to identify sites of the molecules that can tolerate modifications without losing 
significant activities while displaying a range of potencies. Through the chemical 
modifications of these sites, compounds are modified in order to improve potency and 
pharmaceutical properties. Our previous efforts on the initial SAR study generated a set 
of kavain analogues. Interestingly, among them, one ring-opened analogue which bears 
an α,β-unsaturated ester surprisingly showed ≥ 50% suppression of TNF-α secretion. 
Additionally, medicinal chemistry
140-142 
efforts have pointed out the effect of the methyl 
group (and 4,4-dimethyl substitution in compounds 13-15) in improving potency in drug 




designed analogues to explore the above factors, preliminary structure-activity-
relationship (SAR) study, evaluation of these analogues, and identification of a potent 
compound kava-241.
143
 In that regard, we sought to enhance the hydrolytic stability of 
the second generation of kava analogues by replacing the lactone with an α,β-unsaturated 
ketone (Scheme 4.2.1). The structural variations allowed the rapid production of six 
cyclohexanones substituted with a benzoate or benzamide at the C6-position of the cyclic 
enone (Schemes 4.2.1 and 4.2.2), and through these structural modifications we have 
gained enhanced bioactivity. 
Scheme 4.2.1 Synthesis of Compounds 13-15 
 
 The synthetic approach towards compounds 13 and 14 is based on the O-
acylation
144
 19 of the highly enolizable cyclic 1,3-diketones. Accordingly, treatment of 
1,2-dichloroethane solution of commercially available 1,3-cyclohexanedione with various 




derivatives 13 and 14 (Scheme 4.2.1). They were further transformed to β-ketoesters 
through C-acylation of in situ-generated lithium enolate using Mander’s reagent
145
 (ethyl 
cyanoformate). Thus, compound 14 was treated with lithium bis(trimethylsilyl)amide 
solution (LHMDS) to generate lithium enolates. The subsequent nucleophilic attack (C-
acylation) of the enolate with ethyl cyanoformate was facilitated by additive 1,3-
dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), cleanly providing compound 
15 (Scheme 4.2.1) without trace of O-acylation products. 
Scheme 4.2.2 Synthesis of Vinyl Amides 17-19 
 
 Encouraged by the initial screening results showing that electron-donating groups 
on the aryl ring provides a beneficial role in TNF-α reduction and the assumption that 
amide would be more stable in vivo, we synthesized three enamides (17-19) utilizing 
Buchwald’s copper-mediated coupling
146-150 
between vinyl iodide 16 and commercially 
available benzamides. Treatment of commercially available 5,5-dimethylcyclohexane-1, 




afforded vinyl iodide 16, which subsequently participated in a copper-mediated cross-
coupling reaction (Scheme 4.2.2). Thus, 16 and the benzamides were successfully 
coupled in the presence of substoicometric amounts of CuI, N, N-dimethylglycine, and 
Cs2CO3 to produce three enamides 17-19 respectfully. Unfortunately the series of vinyl 
amides proved to be inactive in the initial TNF-α production assay, which of course 
requires further evaluation. 
4.3 Biological Evaluation 
 Given that kava was found to be anti-inflammatory, we selected our screening 
strategy involving a cell-based assay wherein control experiments cells were exposed to 
P. gingivalis and responded by producing a potent pro-inflammatory cytokine TNF-α. 
The analogs in schemes 4.2.1 and 4.2.2 were screened using our cell-based assay with 
two optimal concentrations of the given compound at concentration depicted in Figure 
4.3.1 using parent Kava as a positive control. Briefly, bone-marrow macrophages were 
harvested as previously described
151
 and cultured during 7 days in RPMI medium 
supplemented with L929 and 10 000 U/liter penicillin, 100 mg/liter streptomycin and 
10% fetal bovine serum in a humidified atmosphere (5% CO2) at 37°C. According to 
experimental design, cells were infected by P.gingivalis (MOI=20) and/or treated with 50 
to 200 μg.ml
-1
 of synthesized Kava compound. As shown in Figure 2, compound 15 at 
concentration of 100 μg/mL significantly reduced P. gingivalis stimulated TNF-α to the 




Figure 4.3.1. Mouse macrophages were collected from wild type mice and recovered in 
the RPIM-1640 medium with 10% FBS for 5 days, and exposed with P. gingivalis (MOI: 
20 P. gingivalis cells for 1 macrophage cell) with or without Kava compounds (at 
concentrations indicated above) for 4h. The supernatants from each test group were 
collected and TNF-α levels were subsequently assayed by ELISA (Invitrogen), following 
the manufacturer’s instructions. Data were analyzed and then graphed where *** p＜
0.0005; **p＜0.01; *p＜0.05. 
 
4.4 Conclusion 
 In summary, we have synthesized a new class of kava analogues (13-15) bearing 
an α,β-unsaturated cyclohexanone substituted with a benzoate at the C6-position. These 
analogues were then evaluated for their effect on periodontal destruction in a collagen 
antibody primed oral gavage model of periodontitis. Among these derivatives, compound 
15 was found to significantly reduce P. gingivalis induced TNF-α production. 
Unfortunately the corresponding vinyl amide analogs were devoid of activity in the initial 
screening. Nevertheless, our preliminary results suggest they (13-15) are promising leads 
as potential therapeutic agents of periodontal diseases in the future. However, future 
studies will focus on determining the most effective dosing regimen and expanding the 





4.5 Experimental Section 
4.5.1 Experimetal Procedure 
 
 All reactions were carried out in oven or flame-dried glassware under argon 
atmosphere unless otherwise specified. Tetrahydrofuran was obtained from a dry solvent 
system (alumina) and used without further drying. 1,2-dichloroethane was purchased as 
Sure/Seal™ bottle from Sigma Aldrich. 1,4-dioxane was freshly distilled with calcium 
hydride before use. All other reagents were used as supplied. Unless otherwise noted, 
reactions were magnetically stirred and monitored by thin layer chromatography with 
Macherey Nagel Polygram 0.20 mm silica gel 60 Å plates. Flash chromatography was 
performed on Sorbent Technologies 32-63 μm 60 Å silica gel. Yields referred to 





C NMR spectra were taken in CDCl3 at 400 or 500 MHz (as indicated), 
respectively. Chemical shifts are reported in parts per million using the solvent internal 
standard (chloroform, 7.24 and 77.0 ppm). Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), 
coupling constant, integration. High resolution mass-spectra were obtained on a Waters 
Q-TOF Mass Spectrometer at Boston University Chemical Instrumentation Center (CIC). 
O-acylation of cyclic 1,3-diketone (11) 
General procedure for acylation between cyclic 1,3-diketone 11 and benzoyl chloride 12: 
To a solution of cyclic 1,3-diketone 11 (35.65 mmol, 1 equiv) in 1,2-dichloroethane 




and pyridine (35.65 mmol, 1 equiv) sequentially. The resulting solution was stirred at 
room temperature for 12 hours. The reaction was quenched with saturated aqueous 
NH4Cl solution. It was then extracted with ethyl acetate (3 x 200 mL), and the combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. Purification 
over silica gel chromatography (EtOAc/Hexanes) afforded product 13-15 respectively. 
5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-difluorobenzoate (13): 
Prepared by the general procedure using 11 and 3,4-difluorobenzoyl chloride, benzoate 
13 (9.29 g, 33.15 mmol, 93% yield) was obtained as a pale yellow solid. 
1
H NMR (500 MHz, CDCl3): δ7.90-7.85 (m, 2H), δ7.30-7.25 (m, 1H), δ6.03 (s, 1H), 
δ2.53 (s, 2H), δ2.32 (s, 2H), δ1.14 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ199.23, δ167.96, δ161.39, δ155.30, δ153.25, δ151.20, 
δ149.20, δ127.34, δ125.64, δ119.54, δ117.80, δ117.00, δ50.80, δ42.16, δ33.29, δ28.17; 
LCMS (ES+) m/z calcd for C15H14F2O3 [M+H]
+
: 281.09, found: 281.19. 
 5,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate (14): Prepared by the 
general procedure using 11 and benzoyl chloride, benzoate 14 (8.27 g, 33.87 mmol, 95% 
yield) was obtained as a white solid. 
1
H NMR (500 MHz, CDCl3): δ8.09-8.06 (m, 2H), δ7.65-7.62 (m, 1H), δ7.51-7.47 (m, 





C NMR (125 MHz, CDCl3): δ199.45, δ168.54, δ163.33, δ134.10, δ130.19, δ128.70, 
δ116.85, δ50.87, δ42.29, δ33.29, δ28.21; 
HRMS (ESI) m/z calcd for C15H16O3 [M+Na]
+
: 267.0997, found: 267.0999. 
C-acylation of benzoate 15 
 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 
benzoate (15): To a solution of benzoate 14 (0.357 mmol, 1 equiv) in THF (1.8 mL) was 
added LHMDS (0.375 mmol, 1.05 equiv, 1M in THF) dropwise at -78 
o
C. It was then 
stirred at -78 
o
C for 30 min. To this reaction mixture, ethyl cyanoformate (35 μL, 0.357 
mmol, 1 equiv) and DMPU (60 μL, 0.536 mmol, 1.5 equiv) were added sequentially. The 
resulting mixture was stirred at -78 
o
C for 1 hour. The reaction was quenched with 
saturated aqueous NH4Cl solution. The mixture was warmed to r.t. before extractive 
isolation with ethyl acetate (3 x 5 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated. Purification over silica gel chromatography (26% 
EtOAc/Hexanes) afforded β-ketoester 15 (90 mg, 0.286 mmol, 80% yield) was obtained 
as a colorless, viscous oil. 
1
H NMR (500 MHz, CDCl3): δ8.09-8.07 (m, 2H), δ7.66-7.62 (m, 1H), δ7.51-7.48 (m, 
2H), δ6.14 (s, 1H), δ4.21 (q, J = 7.1 Hz, 2H), δ3.24 (s, 1H), δ2.90 (dd, J = 18.0, 1.5 Hz, 
1H), δ2.49 (d, J = 18.0 Hz, 1H), δ1.29 (t, J = 7.1 Hz, 3H), δ1.23 (s, 3H), δ1.22 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ194.33, δ169.03, δ168.35, δ163.17, δ134.16, δ130.22, 




HRMS (ESI) m/z calcd for C18H20O5 [M+H]
+
: 317.1389, found: 317.1389. 
Cross-coupling between vinyl iodide 16 and benzamide 
General procedure for amide coupling between vinyl iodide 16
1
 and benzamide: Vinyl 
iodide 16 (500 mg, 2.0 mmol, 1 equiv) was added into a seal tube and it was then 
backfilled with argon. Benzamide (2.4 mmol, 1.2 equiv), CuI (37.5 mg, 0.2 mmol, 0.1 
equiv), N,N-dimethylglycine (40 mg, 0.4 mmol, 0.2 equiv), and cesium carbonate (1.3 g, 
4 mmol, 2 equiv) were added into the tube sequentially. The tube was backfilled with 
argon three times before freshly distilled 1,4-dioxane (4 mL) was added in. The 
heterogeneous mixture was vigorously stirred at 60 
o
C for 12 hours. The reaction mixture 
was cooled to room temperature, diluted with 20 mL ethyl acetate, and filtered through a 
plug of silica gel eluting with ethyl acetate. The filtrate was concentrated and purified 
over silica gel chromatography (EtOAc/Hexanes) afforded product 17-19 respectively. 
 N-(5,5-dimethyl-3-oxocyclohex-1-en-1-yl)benzamide (17): Prepared by 
the general procedure using benzamide, enamide 17 was (341 mg, 1.4 mmol, 70% yield) 
obtained as a white solid. 
1
H NMR (500 MHz, CDCl3): δ7.81-7.79 (m, 3H), δ7.58-7.55 (m, 1H), δ7.49-7.46 (m, 
2H), δ6.71 (s, 1H), δ2.56 (s, 2H), δ2.24 (s, 2H), δ1.11 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ199.88, δ166.17, δ153.58, δ133.84, δ132.59, δ128.89, 
δ127.26, δ111.37, δ50.51, δ42.59, δ32.94, δ28.29; 
HRMS (ESI) m/z calcd for C15H17NO2 [M+Na]
+





(18): Prepared by the general procedure using p-toluamide, enamide 18 was (401 mg, 
1.56 mmol, 78% yield) obtained as a white solid. 
1
H NMR (500 MHz, CDCl3): δ7.71-7.68 (s, 2H), δ7.65 (br, 1H), δ7.28-7.26 (m, 2H), 
δ6.69 (s, 1H), δ2.56 (s, 2H), δ2.41 (s, 3H), δ2.25 (s, 2H), δ1.11 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ199.72, δ165.93, δ153.47, δ143.39, δ130.96, δ129.58, 
δ127.23, δ111.21, δ50.53, δ42.66, δ32.94, δ28.30, δ21.56; 
HRMS (ESI) m/z calcd for C16H19NO2 [M+H]
+
: 258.1494, found: 258.1505. 
 N-(5,5-dimethyl-3-oxocyclohex-1-en-1-yl)-4-methoxybenzamide 
(19): Prepared by the general procedure using 4-methoxybenzamide, enamide 19 was 
(355 mg, 1.3 mmol, 65% yield) obtained as a white solid. 
1
H NMR (500 MHz, CDCl3): δ7.86 (br, 1H), δ7.80-7.77 (m, 2H), δ6.95-6.92 (m, 2H), 
δ6.68 (s, 1H), δ3.85 (s, 3H), δ2.57 (s, 2H), δ2.23 (s, 2H), δ1.10 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ199.89, δ165.60, δ163.05, δ154.04, δ129.34, δ125.95, 
δ114.05, δ110.97, δ55.52, δ50.52, δ42.60, δ32.93, δ28.29; 
HRMS (ESI) m/z calcd for C16H19NO3 [M+H]
+
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